Document

0000898770-18-000019.txt : 20180503 0000898770-18-000019.hdr.sgml : 20180503 20180503114210 ACCESSION NUMBER: 0000898770-18-000019 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 54 CONFORMED PERIOD OF REPORT: 20180331 FILED AS OF DATE: 20180503 DATE AS OF CHANGE: 20180503 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SHARPS COMPLIANCE CORP CENTRAL INDEX KEY: 0000898770 STANDARD INDUSTRIAL CLASSIFICATION: HAZARDOUS WASTE MANAGEMENT [4955] IRS NUMBER: 742657168 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-34269 FILM NUMBER: 18802522 BUSINESS ADDRESS: STREET 1: 9220 KIRBY DRIVE STREET 2: STE 500 CITY: HOUSTON STATE: TX ZIP: 77054 BUSINESS PHONE: 713-432-0300 MAIL ADDRESS: STREET 1: 9220 KIRBY DRIVE STREET 2: STE 500 CITY: HOUSTON STATE: TX ZIP: 77054 FORMER COMPANY: FORMER CONFORMED NAME: US MEDICAL SYSTEMS INC DATE OF NAME CHANGE: 19970128 FORMER COMPANY: FORMER CONFORMED NAME: MEDICAL POLYMERS TECHNOLOGIES INC DATE OF NAME CHANGE: 19930916 10-Q 1 q3fy1810q.htm 10-Q Q3 FY18 Document

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

___________________

FORM 10-Q


ý	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018


¨	TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to .

Commission File Number: 001-34269

_______________________

SHARPS COMPLIANCE CORP.

(Exact name of registrant as specified in its charter)



Delaware	74-2657168
(State or other jurisdiction of	(I.R.S. Employer Identification No.)
incorporation or organization)



9220 Kirby Drive, Suite 500, Houston, Texas	77054
(Address of principal executive offices)	(Zip Code)

(713) 432-0300

(Registrant’s telephone number, including area code)

Indicate by check mark if the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ý No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes ý No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Securities Exchange Act of 1934.




Large Accelerated Filer o	Accelerated Filer o	Non-accelerated Filer o (Do not check if a smaller reporting company)	Emerging growth company o	Smaller reporting company ý

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12(b)-2 of the Exchange Act). Yes o No ý

As of May 1, 2018, there were 16,082,021 outstanding shares of the Registrant's common stock, par value $0.01 per share.



SHARPS COMPLIANCE CORP. AND SUBSIDIARIES


PART I	FINANCIAL INFORMATION	PAGE

Item 1.	Condensed Consolidated Financial Statements	3

	Condensed Consolidated Balance Sheets as of March 31, 2018 and June 30, 2017	3

	Condensed Consolidated Statements of Operations for the three months ended March 31, 2018 and 2017	4

	Condensed Consolidated Statements of Operations for the nine months ended March 31, 2018 and 2017	5

	Condensed Consolidated Statements of Stockholders’ Equity for the nine months ended March 31, 2018 and year ended June 30, 2017	6

	Condensed Consolidated Statements of Cash Flows for the nine months ended March 31, 2018 and 2017	7

	Notes to Condensed Consolidated Financial Statements	8

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	15

Item 4.	Controls and Procedures	22

Part II	OTHER INFORMATION	22

Item 1.	Legal Proceedings	22

Item 1A.	Risk Factors	22

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds.	22

Item 6.	Exhibits	23

	SIGNATURES	23

PART I – FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

SHARPS COMPLIANCE CORP. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

(In thousands, except share and par value)



	March 31,			June 30,
	2018			2017

ASSETS
CURRENT ASSETS
Cash and cash equivalents	$	5,499		$	4,675
Accounts receivable, net of allowance for doubtful accounts of $95 and $78, respectively	6,103			7,553
Inventory, net	4,163			4,098
Prepaid and other current assets	761			694
TOTAL CURRENT ASSETS	16,526			17,020

PROPERTY, PLANT AND EQUIPMENT, net	6,538			6,543

OTHER ASSETS	159			120

GOODWILL	6,735			6,735

INTANGIBLE ASSETS, net	3,648			4,046

TOTAL ASSETS	$	33,606		$	34,464

LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES
Accounts payable	$	1,836		$	1,710
Accrued liabilities	1,618			1,800
Current maturities of long-term debt	558			601
Deferred revenue	2,107			2,421
TOTAL CURRENT LIABILITIES	6,119			6,532

LONG-TERM DEFERRED REVENUE, net of current portion	475			478

OTHER LONG-TERM LIABILITIES	199			165

LONG-TERM DEBT, net of current portion	1,594			2,002

TOTAL LIABILITIES	8,387			9,177

COMMITMENTS AND CONTINGENCIES

STOCKHOLDERS' EQUITY
Common stock, $0.01 par value per share; 20,000,000 shares authorized; 16,377,636 and 16,304,027 shares issued, respectively, and 16,082,021 and 16,008,412 shares outstanding, respectively.	164			163
Treasury stock, at cost, 295,615 shares repurchased	(1,554		)	(1,554		)
Additional paid-in capital	28,520			28,063
Accumulated deficit	(1,911		)	(1,385		)
TOTAL STOCKHOLDERS' EQUITY	25,219			25,287

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$	33,606		$	34,464

The accompanying notes are an integral part of these condensed consolidated financial statements.

SHARPS COMPLIANCE CORP. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

(In thousands, except per-share data)



	Three-Months Ended March 31,
	2018			2017

REVENUES	$	9,427		$	8,588
Cost of revenues	7,131			6,236
GROSS PROFIT	2,296			2,352

Selling, general and administrative	2,800			2,790
Depreciation and amortization	203			200

OPERATING LOSS	(707		)	(638		)

OTHER INCOME (EXPENSE)
Interest income	5			4
Interest expense	(23		)	(34		)
TOTAL OTHER EXPENSE	(18		)	(30		)

LOSS BEFORE INCOME TAXES	(725		)	(668		)

INCOME TAX EXPENSE	32			—

NET LOSS	$	(757	)	$	(668	)

NET LOSS PER COMMON SHARE - Basic and Diluted	$	(0.05	)	$	(0.04	)

WEIGHTED AVERAGE SHARES USED IN COMPUTING LOSS PER COMMON SHARE:
Basic and diluted	16,082			15,994

The accompanying notes are an integral part of these condensed consolidated financial statements.

SHARPS COMPLIANCE CORP. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

(In thousands, except per-share data)



	Nine-Months Ended March 31,
	2018			2017

REVENUES	$	30,229		$	27,826
Cost of revenues	21,774			19,620
GROSS PROFIT	8,455			8,206

Selling, general and administrative	8,346			9,388
Depreciation and amortization	608			600

OPERATING LOSS	(499		)	(1,782		)

OTHER INCOME (EXPENSE)
Interest income	15			12
Interest expense	(70		)	(92		)
TOTAL OTHER EXPENSE	(55		)	(80		)

LOSS BEFORE INCOME TAXES	(554		)	(1,862		)

INCOME TAX BENEFIT	(28		)	—

NET LOSS	$	(526	)	$	(1,862	)

NET LOSS PER COMMON SHARE - Basic and Diluted	$	(0.03	)	$	(0.12	)

WEIGHTED AVERAGE SHARES USED IN COMPUTING LOSS PER COMMON SHARE:
Basic and diluted	16,046			15,930

The accompanying notes are an integral part of these condensed consolidated financial statements.

SHARPS COMPLIANCE CORP. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(Unaudited)

(In thousands, except share data)



	Common Stock				Treasury Stock					Additional Paid-in Capital			Accumulated Deficit			Total Stockholders' Equity
	Shares		Amount		Shares		Amount			Additional Paid-in Capital			Accumulated Deficit			Total Stockholders' Equity

Balances, June 30, 2016		15,740,458	$	158	(295,615	)	$	(1,554	)	$	25,331		$	(92	)	$	23,843
Exercise of stock options		95,050	1		—		—			341			—			342
Stock-based compensation		—	—		—		—			496			—			496
Issuance of common shares for acquisition		415,527	4		—		—			1,895			—			1,899
Issuance of restricted stock		52,992	—		—		—			—			—			—
Net loss		—	—		—		—			—			(1,293		)	(1,293		)
Balances, June 30, 2017		16,304,027	163		(295,615	)	(1,554		)	28,063			(1,385		)	25,287
Stock-based compensation		—	—		—		—			375			—			375
Issuance of common shares for lease		20,617	—		—		—			83			—			83
Issuance of restricted stock		52,992	1		—		—			(1		)	—			—
Net loss		—	—		—		—			—			(526		)	(526		)
Balances, March 31, 2018		16,377,636	$	164	(295,615	)	$	(1,554	)	$	28,520		$	(1,911	)	$	25,219

The accompanying notes are an integral part of these condensed consolidated financial statements.

SHARPS COMPLIANCE CORP. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(In thousands)



	Nine-Months Ended March 31,
	2018			2017
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$	(526	)	$	(1,862	)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	1,174			1,100
Loss on disposal of property, plant and equipment	—			10
Stock-based compensation expense	375			389
Deferred tax benefit	(37		)	—
Changes in operating assets and liabilities, net of effects of business acquisitions:
Accounts receivable	1,450			1,118
Inventory	101			(477		)
Prepaid and other assets	14			(192		)
Accounts payable and accrued liabilities	(111		)	335
Deferred revenue	(317		)	(239		)
NET CASH PROVIDED BY OPERATING ACTIVITIES	2,123			182

CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property, plant and equipment	(800		)	(2,439		)
Cash proceeds from sale of property, plant and equipment	10			23
Additions to intangible assets	(58		)	(128		)
Payments for business acquisitions, net of cash acquired	—			(7,261		)
NET CASH USED IN INVESTING ACTIVITIES	(848		)	(9,805		)

CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from exercise of stock options	—			342
Proceeds from long-term debt	—			5,600
Repayments of long-term debt	(451		)	(3,062		)
NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES	(451		)	2,880

NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	824			(6,743		)

CASH AND CASH EQUIVALENTS, beginning of period	4,675			12,435

CASH AND CASH EQUIVALENTS, end of period	$	5,499		$	5,692

SUPPLEMENTAL CASH FLOW DISCLOSURES:
Income taxes paid	$	3		$	—

Interest paid on long-term debt	$	64		$	91

NON-CASH INVESTING AND FINANCING ACTIVITIES:

Issuance of common stock for acquisition	$	—		$	1,889
Issuance of common stock for lease	$	83		$	—
Unpaid consideration related to acquisitions	$	—		$	52
Transfer of equipment to inventory	$	166		$	130
Property, plant and equipment financed through accounts payable	$	89		$	66

The accompanying notes are an integral part of these condensed consolidated financial statements.

SHARPS COMPLIANCE CORP. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

NOTE 1 - ORGANIZATION AND BACKGROUND

Organization: The accompanying unaudited condensed consolidated financial statements include the financial transactions and accounts of Sharps Compliance Corp. and its wholly owned subsidiaries, Sharps Compliance, Inc. of Texas (dba Sharps Compliance, Inc.), Sharps e-Tools.com Inc. (“Sharps e-Tools”), Sharps Manufacturing, Inc., Sharps Environmental Services, Inc. (dba Sharps Environmental Services of Texas, Inc.), Sharps Safety, Inc., Alpha Bio/Med Services LLC, Bio-Team Mobile LLC and Citiwaste, LLC (collectively, “Sharps” or the “Company”). All significant intercompany accounts and transactions have been eliminated upon consolidation.

Business: Sharps is a leading full-service national provider of comprehensive waste management services including medical, pharmaceutical and hazardous for small and medium quantity generators. The Company’s solutions include Sharps Recovery System™ (formerly Sharps Disposal by Mail System^®), TakeAway Medication Recovery System™, MedSafe^®, TakeAway Recycle System™,ComplianceTRAC^SM, SharpsTracer^®, Sharps Secure^®Needle Disposal System, Complete Needle™ Collection & Disposal System, TakeAway Environmental Return System™, Pitch-It IV™ Poles, Asset Return System and Spill Kit and Recovery System. The Company also offers its route-based pick-up service in a twenty-three (23) state region of the South, Southeast and Northeast portions of the United States.

NOTE 2 - BASIS OF PRESENTATION

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information and with instructions to Form 10-Q and, accordingly, do not include all information and footnotes required under generally accepted accounting principles in the United States of America ("GAAP") for complete financial statements. Additionally, the preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect reported amounts. In the opinion of management, these interim condensed consolidated financial statements contain all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the consolidated financial position of the Company as of March 31, 2018, the results of its operations for the three and nine months ended March 31, 2018 and 2017, cash flows for the nine months ended March 31, 2018 and 2017 and stockholders’ equity for the nine months ended March 31, 2018. The results of operations for the three and nine months ended March 31, 2018 are not necessarily indicative of the results to be expected for the entire fiscal year ending June 30, 2018. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended June 30, 2017.

NOTE 3 - SIGNIFICANT ACCOUNTING POLICIES

Revenue Recognition: The Company recognizes revenue when services are provided and from product sales when (i) goods are shipped or delivered, and title and risk of loss pass to the customer, (ii) the price is substantially fixed or determinable and (iii) collectability is reasonably assured except for those sales via multiple-deliverable revenue arrangements. Provisions for certain rebates, product returns and discounts to customers are accounted for as reductions in sales in the same period the related sales are recorded. Product discounts granted are based on the terms of arrangements with direct, indirect and other market participants, as well as market conditions, including prices charged by competitors. Rebates are estimated based on contractual terms, historical experience, trend analysis and projected market conditions in the various markets served. Service agreements which include a vendor managed inventory program include terms that meet the “bill and hold” criteria and as such are recognized when the order is completed, at which point title has transferred, there are no acceptance provisions and amounts are segregated in the Company’s warehouse. During the three and nine months ended March 31, 2018, the Company recorded revenue from inventory builds that are held in vendor managed inventory under these service agreements of $0.5 million and $2.4 million, respectively. During the three and nine months ended March 31, 2017, the Company recorded revenue from inventory builds that are held in vendor managed inventory under these service agreements of $0.7 million and $2.7 million, respectively. As of March 31, 2018 and June 30, 2017, $2.8 million and $2.7 million, respectively, of solutions sold through that date were held in vendor managed inventory pending fulfillment or shipment to patients of pharmaceutical manufacturers who offer these solutions to patients in an ongoing patient support program.

Certain products offered by the Company have revenue producing components that are recognized over multiple delivery points (Sharps Recovery System and various other solutions like the TakeAway Medication Recovery Systems referred to as “Mailbacks” and Sharps Pump and Asset Return Systems, referred to as “Pump Returns”) and can consist of up to three separate elements, or units of measure, as follows: (1) the sale of the compliance and container system, (2) return transportation and (3) treatment service. In accordance with the relative selling price methodology, an estimated selling price is determined for all deliverables that qualify for separate units of accounting. The actual consideration received in a multiple-deliverable arrangement is then

SHARPS COMPLIANCE CORP. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

allocated to the units based on their relative sales price. The selling price for the transportation revenue and the treatment revenue utilizes third party evidence. The Company estimates the selling price of the compliance and container system based on the product and services provided, including compliance with local, state and federal laws, adherence to stringent manufacturing and testing requirements, safety to the patient and the community, as well as storage and containment capabilities.

Revenue for the sale of the compliance and container is recognized upon delivery to the customer, at which time the customer takes title and assumes risk of ownership. Transportation revenue is recognized when the customer returns the compliance and container system and the container has been received at the Company’s owned or contracted facilities. The compliance and container system is mailed or delivered by an alternative logistics provider to the Company’s owned or contracted facilities. Treatment revenue is recognized upon the destruction or conversion and proof of receipt and treatment having been performed on the container. Since the transportation element and the treatment elements are undelivered services at the point of initial sale of the compliance and container, transportation and treatment revenue is deferred until the services are performed. The current and long-term portions of deferred revenues are determined through regression analysis and historical trends. Furthermore, through regression analysis of historical data, the Company has determined that a certain percentage of all compliance and container systems sold may not be returned. Accordingly, a portion of the transportation and treatment elements are recognized at the point of sale.

Income Taxes: Deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is established when it is more likely than not that some portion or all of the deferred tax assets will not be realized. The establishment of valuation allowances and development of projected annual effective tax rates requires significant judgment and is impacted by various estimates. Both positive and negative evidence, as well as the objectivity and verifiability of that evidence, is considered in determining the appropriateness of recording a valuation allowance on deferred tax assets. Under GAAP, the valuation allowance has been recorded to reduce the Company’s deferred tax assets to an amount that is more likely than not to be realized and is based upon the uncertainty of the realization of certain federal and state deferred tax assets related to net operating loss carryforwards and other tax attributes.

Goodwill and Other Identifiable Intangible Assets: Finite-lived intangible assets are amortized over their respective estimated useful lives and evaluated for impairment periodically whenever events or changes in circumstances indicate that their related carrying values may not be fully recoverable. Goodwill is assessed for impairment at least annually. The Company generally performs its annual goodwill impairment analysis using a quantitative approach. The quantitative goodwill impairment test identifies the existence of potential impairment by comparing the fair value of our single reporting unit with its carrying value, including goodwill. If the fair value of a reporting unit exceeds its carrying value, the reporting unit's goodwill is considered not to be impaired. If the carrying value of a reporting unit exceeds its fair value, an impairment charge is recognized in an amount equal to that excess. The impairment charge recognized is limited to the amount of goodwill present in our single reporting unit. These estimates and assumptions could have a significant impact on whether or not an impairment charge is recognized and the amount of any such charge. The Company performs its annual impairment assessment of goodwill during the fourth quarter of each fiscal year. The Company determined that there was no impairment during the prior year ended June 30, 2017 and there have been no triggering events since that date that would warrant further impairment testing.

Accounts Receivable: Accounts receivable consist primarily of amounts due to the Company from normal business activities. Accounts receivable balances are determined to be delinquent when the amount is past due based on the contractual terms with the customer. The Company maintains an allowance for doubtful accounts to reflect the likelihood of not collecting certain accounts receivable based on past collection history and specific risks identified among uncollected accounts. Accounts receivable are charged to the allowance for doubtful accounts when the Company determines that the receivable will not be collected and/or when the account has been referred to a third party collection agency. The Company has a history of minimal uncollectible accounts.

Stock-Based Compensation: Stock-based compensation cost for options and restricted stock awarded to employees and directors is measured at the grant date, based on the calculated fair value of the award and is recognized as an expense over the requisite service period (generally the vesting period of the equity grant).

Fair Value of Financial Instruments: The Company considers the fair value of all financial instruments, including cash and cash equivalents, accounts receivable and accounts payable to approximate their carrying values at March 31, 2018 and June 30, 2017 due to their short-term nature. The carrying value of the Company’s debt approximates fair value due to the market rates of interest.

SHARPS COMPLIANCE CORP. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

NOTE 4 – RECENTLY ISSUED ACCOUNTING STANDARDS

In May 2014, and as subsequently amended, guidance for revenue recognition was issued which supersedes the revenue recognition requirements currently followed by the Company. The new guidance provides for a single five-step model to be applied in determining the amount and timing of the recognition of revenue related to contracts with customers. The new standard also requires additional financial statement disclosures that will enable users to understand the nature, amount, timing and uncertainty of revenue and cash flows relating to customer contracts. Companies have an option to use either a full retrospective approach or a modified retrospective approach to implement the standard. The guidance is effective for annual reporting periods beginning after December 15, 2017 (effective July 1, 2018 for the Company). The Company initiated a project to evaluate the impact that the new accounting guidance will have on its consolidated financial statements and related disclosures, which included identifying the material revenues streams and reviewing a representative sample of contracts. The Company is still in process of finalizing its evaluation, but has identified that for mailback and unused medication solutions, under the new guidance, the Company will recognize revenue over two performance obligations rather than the three separate elements under the current guidance. The Company is still evaluating the quantitative impact to the amount and timing of revenue recognition for the change to the identified performance obligations for the mailback solution. The Company is still evaluating the impact of the new standard on route-based pick up solution. No material changes to the amount and timing of revenue recognition over the third party treatment and other solutions are expected. The Company expects to adopt the standard using the modified retrospective approach, which involves retrospectively adopting the standard by recording a cumulative effect adjustment to all uncompleted contracts at July 1, 2018. The Company will continue to evaluate the standard as well as additional changes, modifications or interpretations which may impact the Company.

In February 2016, guidance for leases was issued, which requires balance sheet recognition for rights and obligations of all leases with terms in excess of twelve months. The new guidance also requires additional disclosures about the amount, timing and uncertainty of cash flows arising from leases. The provisions of the new guidance are effective for annual periods beginning after December 15, 2018 (effective July 1, 2019 for the Company), including interim periods within the reporting period, and early application is permitted. The Company is in the initial stages of evaluating the impact of the new guidance on its consolidated financial statements and related disclosures as well as evaluating the available transition methods. The Company will continue to evaluate the standard as well as additional changes, modifications or interpretations which may impact the Company.

NOTE 5 – INCOME TAXES

The Company’s effective tax rate for the nine months ended March 31, 2018 was (5.1)% reflecting the impact of the 2017 tax law change discussed below, net of estimated state income taxes. For the nine months ended March 31, 2018, the Company recorded a net income tax benefit of approximately $38,000, which was offset by estimated state income tax expense of $10,000. The Company’s effective tax rate for the three months ended March 31, 2018 was 4.4% due primarily to income tax expense related to the tax deductibility of goodwill amortization. No income tax expense was recorded for the nine months ended March 31, 2017 as it was not material due to the valuation allowance and net operating losses.

The Tax Cuts and Jobs Act of 2017, enacted on December 22, 2017, contains significant changes to U.S. tax law, including lowering the U.S. corporate income tax rate to 21%. During the nine months ended March 31, 2018, the Company recorded a $38,000 deferred tax asset in Other Assets on the balance sheet, representing the net benefit of remeasuring its deferred tax assets for recoverable alternative minimum tax credits offset by deferred tax liabilities related to indefinite lived assets, such as goodwill, which cannot be used as a source of future taxable income in evaluating the need for a valuation allowance against deferred tax assets. The Company's remaining net deferred tax assets continue to be fully offset by a valuation allowance. The Company's gross deferred tax assets and the offsetting valuation allowance decreased by approximately $0.8 million as a result of the reduction of the U.S. tax rate to 21%.

SHARPS COMPLIANCE CORP. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

NOTE 6 - NOTES PAYABLE AND LONG-TERM DEBT

On March 29, 2017, the Company entered into to a credit agreement with a commercial bank (“Credit Agreement”). The Credit Agreement, which replaced the Company’s prior credit agreement, provides for a $14.0 million credit facility, the proceeds of which may be utilized as follows: (i) $6.0 million for working capital, letters of credit (up to $2.0 million) and general corporate purposes and (ii) $8.0 million for acquisitions. Indebtedness under the Credit Agreement is secured by substantially all of the Company’s assets with advances outstanding under the working capital portion of the credit facility at any time limited to a Borrowing Base (as defined in the Credit Agreement) equal to 80% of eligible accounts receivable plus the lesser of 50% of eligible inventory and $3.0 million and was $2.1 million at March 31, 2018. Advances under the acquisition portion of the credit facility are limited to 75% of the purchase price of an acquired company and convert to a five-year term note at the time of the borrowing. Borrowings bear interest at the greater of (a) zero percent or (b) the One Month ICE LIBOR plus a LIBOR Margin of 2.5%. The LIBOR Margin may increase to as high as 3.0% depending on the Company’s cash flow leverage ratio. The interest rate as of March 31, 2018 was approximately 4.25%. The Company pays a fee of 0.25% per annum on the unused amount of the line of credit.

At March 31, 2018, long-term debt consisted of the following (in thousands):



Non-interest bearing, unsecured note payable assumed in acquisition, monthly payments of $7; maturing September 2018.	$	41

Term loan, bearing interest at 4.25%, monthly payments of $43; maturing March 2022.	2,111

Total long-term debt	2,152
Less: current portion	558
Long-term debt, net of current portion	$	1,594

The Company has availability under the Credit Agreement of $11.8 million ($6.0 million for the working capital and $5.8 million for the acquisitions) as of March 31, 2018. The Company also has $40,000 in letters of credit outstanding as of March 31, 2018.

The Credit Agreement contains affirmative and negative covenants that, among other things, require the Company to maintain a maximum cash flow leverage ratio of no more than 3.0 to 1.0 and a minimum debt service coverage ratio of not less than 1.15 to 1.00. The Credit Agreement, which expires on March 29, 2019 for the working capital portion of the Credit Agreement, also contains customary events of default which, if uncured, may terminate the Credit Agreement and require immediate repayment of all indebtedness to the lenders. The leverage ratio covenant may limit the amount available under the Credit Agreement.

Payments due on long-term debt during each of the five years subsequent to March 31, 2018 are as follows (in thousands):



Twelve Months Ending March 31,
2019	$	558
2020	517
2021	517
2022	517
2023	43
	$	2,152

The Company utilizes performance bonds to support operations based on certain state requirements. At March 31, 2018, the Company had performance bonds outstanding covering financial assurance up to $0.6 million.

SHARPS COMPLIANCE CORP. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

NOTE 7 – STOCK-BASED COMPENSATION

Stock-based compensation cost for options and restricted stock awarded to employees and directors is measured at the grant date, based on the calculated fair value of the award and is recognized as an expense over the requisite service period (generally the vesting period of the equity grant). During the three and nine months ended March 31, 2018 and 2017, stock-based compensation amounts are as follows (in thousands):



	Three-Months Ended March 31,				Nine-Months Ended March 31,
	2018		2017		2018		2017
Stock-based compensation expense included in:
Cost of revenues	$	6	$	8	$	33	$	33
Selling, general and administrative	108		108		342		356
Total	$	114	$	116	$	375	$	389

NOTE 8 - EARNINGS PER SHARE

Basic earnings per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the period. Diluted earnings per share is computed by dividing net income (loss) by the weighted average number of common shares after considering the additional dilution related to common stock options and restricted stock. In computing diluted earnings per share, the outstanding common stock options are considered dilutive using the treasury stock method.

The Company’s restricted stock awards are treated as outstanding for earnings per share calculations since these shares have full voting rights and are entitled to participate in dividends declared on common shares, if any, and undistributed earnings. As participating securities, the shares of restricted stock are included in the calculation of basic EPS using the two-class method. For the periods presented, the amount of earnings allocated to the participating securities was not material.

The following information is necessary to calculate earnings per share for the periods presented (in thousands, except per-share data):



	Three-Months Ended March 31,						Nine-Months Ended March 31,
	2018			2017			2018			2017
Net loss, as reported	$	(757	)	$	(668	)	$	(526	)	$	(1,862	)

Weighted average common shares outstanding	16,082			15,994			16,046			15,930
Effect of dilutive stock options	—			—			—			—
Weighted average diluted common shares outstanding	16,082			15,994			16,046			15,930

Net loss per common share
Basic and diluted	$	(0.05	)	$	(0.04	)	$	(0.03	)	$	(0.12	)

Employee stock options excluded from computation of dilutive loss per share amounts because their effect would be anti-dilutive	401			269			401			304

SHARPS COMPLIANCE CORP. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

NOTE 9 - EQUITY TRANSACTIONS

During the three and nine months ended March 31, 2018 and 2017, stock options to purchase shares of the Company’s common stock were exercised as follows:



	Three-Months Ended March 31,				Nine-Months Ended March 31,
	2018		2017		2018		2017
Options Exercised	—		19,300		—		95,050
Proceeds (in thousands)	$	—	$	84	$	—	$	342
Average exercise price per share	$	—	$	4.34	$	—	$	3.60

As of March 31, 2018, there was $0.4 million of stock compensation expense related to non-vested awards which is expected to be recognized over a weighted average period of 2.2 years.

During the nine months ended March 31, 2018, the Company issued 20,617 shares of common stock as a portion of consideration for a third-party lease agreement. The shares were issued at $4.00 per share based on the closing price on the date of grant. Non-cash expense recorded during the nine months ended March 31, 2018 was $25,000. The remaining cost will be amortized over the life of the lease and is included in Prepaid and Other Current Assets or Other Assets on the balance sheet.

NOTE 10 – GOODWILL AND INTANGIBLE ASSETS

At March 31, 2018 and June 30, 2017, intangible assets consisted of the following (in thousands):



		March 31, 2018							June 30, 2017
	Estimated Useful Lives	Original Amount		Accumulated Amortization			Net Amount		Original Amount		Accumulated Amortization			Net Amount
Customer relationships	7 years	$	3,007	$	(811	)	$	2,196	$	3,007	$	(490	)	$	2,517
Permits	6 - 15 years	1,430		(365		)	1,065		1,373		(288		)	1,085
Patents	5 - 17 years	383		(274		)	109		383		(264		)	119
Trade name	7 years	270		(68		)	202		270		(39		)	231
Non-compete	5 years	117		(41		)	76		117		(23		)	94
Total intangible assets, net		$	5,207	$	(1,559	)	$	3,648	$	5,150	$	(1,104	)	$	4,046

During both the nine months ended March 31, 2018 and 2017, amortization expense was $0.5 million. There have been no changes in the carrying amount of goodwill since June 30, 2017.

As of March 31, 2018, future amortization of intangible assets is as follows (in thousands):



Twelve Months Ending March 31,
2019	$	606
2020	606
2021	606
2022	586
2023	540
Thereafter	704
	$	3,648

SHARPS COMPLIANCE CORP. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

NOTE 11 – INVENTORY

The components of inventory are as follows (in thousands):



	March 31, 2018		June 30, 2017
Raw materials	$	1,374	$	1,272
Finished goods	2,789		2,826
Total	$	4,163	$	4,098

NOTE 12 – REVENUES BY SOLUTION

The components of revenues by solution are as follows (in thousands):



	Three-Months Ended March 31,
	2018		% Total		2017		% Total
REVENUES BY SOLUTION:
Mailbacks	$	4,602	48.8	%	$	4,997	58.2	%
Route-based pickup services	1,888		20.0	%	1,641		19.1	%
Unused medications	1,832		19.4	%	867		10.1	%
Third party treatment services	44		0.5	%	149		1.7	%
Other ⁽¹⁾	1,061		11.3	%	934		10.9	%
Total revenues	$	9,427	100.0	%	$	8,588	100.0	%


	Nine-Months Ended March 31,
	2018		% Total		2017		% Total
REVENUES BY SOLUTION:
Mailbacks	$	16,618	55.0	%	$	17,661	63.5	%
Route-based pickup services	5,479		18.1	%	4,686		16.8	%
Unused medications	4,321		14.3	%	2,400		8.6	%
Third party treatment services	815		2.7	%	291		1.0	%
Other ⁽¹⁾	2,996		9.9	%	2,788		10.1	%
Total revenues	$	30,229	100.0	%	$	27,826	100.0	%


(1)	The Company’s other products include non-mailback products such as IV poles, accessories, containers, asset return boxes and other miscellaneous items.

ITEM 2.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

INFORMATION REGARDING FORWARD-LOOKING STATEMENTS

This quarterly report on Form 10-Q contains certain forward-looking statements and information relating to the Company and its subsidiaries that are based on the beliefs of the Company’s management as well as assumptions made by and information currently available to the Company’s management. When used in this report, the words "will," "may," "position," "plan," "potential," "continue," "anticipate," "believe," "expect," "estimate," "project" and "intend" and words or phrases of similar import, as they relate to the Company or its subsidiaries or Company management, are intended to identify forward-looking statements. Such statements reflect the known and unknown risks, uncertainties and assumptions related to certain factors, including without limitations, competitive factors, general economic conditions, customer relations, relationships with vendors, governmental regulation and supervision, seasonality, distribution networks, product introductions and acceptance, technological change, changes in industry practices, onetime events and other factors described herein. Based upon changing conditions, should any one or more of these risks or uncertainties materialize, or should any underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, expected or intended. Consequently, no forward-looking statements can be guaranteed. When considering these forward-looking statements, you should keep in mind the risk factors and other cautionary statements in this Quarterly Report on Form 10-Q or refer to our Annual Report on Form 10-K. Actual results may vary materially. You are cautioned not to place undue reliance on any forward-looking statements. You should also understand that it is not possible to predict or identify all such factors and as such should not consider the preceding list or the risk factors to be a complete list of all potential risks and uncertainties. The Company does not intend to update these forward-looking statements.

GENERAL

Sharps Compliance Corp. is a leading full-service national provider of comprehensive waste management services including medical, pharmaceutical and hazardous. Our solutions facilitate the proper collection, containment, transportation and treatment of numerous types of healthcare-related materials, including hypodermic needles, lancets and other devices or objects used to puncture or lacerate the skin, or sharps, hazardous waste and unused consumer dispensed medications and over-the-counter drugs. We serve customers in multiple markets such as home health care, retail clinics and immunizing pharmacies, pharmaceutical manufacturers, professional offices (physicians, dentists and veterinarians), assisted living and long-term care facilities (assisted living, continuing care, long-term acute care, memory care and skilled nursing), government (federal, state and local), consumers, commercial and agriculture, as well as distributors to many of the aforementioned markets. We assist our customers in determining which of our solution offerings best fit their needs for the collection, containment, return transportation and treatment of medical waste, used healthcare materials, pharmaceutical waste, hazardous waste and unused dispensed medications. Our differentiated approach provides our customers the flexibility to return and properly treat medical waste, used healthcare materials or unused dispensed medications through a variety of solutions and products transported primarily through the United States Postal Service (“USPS”). For customers with facilities or locations that may generate larger quantities of medical waste, we integrate the route-based pick-up service into our complete offering. The benefits of this comprehensive offering include single point of contact, consolidated billing, integrated manifest and proof of destruction repository in addition to our cost savings. Furthermore, we provide comprehensive tracking and reporting tools that enable our customers to meet complex medical, pharmaceutical and hazardous waste disposal and compliance requirements. We believe the fully-integrated nature of our operations is a key factor leading to our success and continued recurring revenue growth. We continue to take advantage of the many opportunities in all markets served as we educate the market place and as prospective customers become more aware of alternatives to traditional methods of disposal (i.e., route-based pick-up services).

Our key markets include healthcare facilities, pharmaceutical manufacturers, home healthcare providers, assisted living/long-term care, surgery centers, retail pharmacies and clinics and the professional market, which is comprised of physicians, dentists and veterinary practices. The Company’s flagship product, the Sharps^® Recovery System, is a comprehensive solution for the containment, transportation, treatment and tracking of medical waste and used healthcare materials. In October 2014, the Company launched MedSafe^®, a patent pending solution for the safe collection, transportation and proper disposal of unwanted and expired prescription medications including controlled substances from ultimate users. MedSafe has been designed to meet or exceed the regulations issued by the Drug Enforcement Administration (“DEA”) implementing the Secure and Responsible Drug Disposal Act of 2010 (the “Act”), which became effective October 9, 2014. In July 2015 and December 2015, the Company augmented its network of medical and hazardous waste service providers with acquisitions of route-based pickup services in the Northeast serving Pennsylvania, Maryland, Ohio and other neighboring states. Additionally, the Company now services parts of Texas and Louisiana with route-based pickup services. In July 2016, the Company acquired another route-based pickup service which expanded service to New York and New Jersey and strengthened the Company’s position in the Northeast. The Company now offers its route-based pickup services in a twenty-three (23) state region of the South, Southeast and Northeast portions of the United States. Our other solutions include TakeAway Medication Recovery System™, TakeAway Recycle System™, ComplianceTRAC^SM, Universal Waste Shipback Systems, TakeAway Environmental Return System™, SharpsTracer^®, Sharps Secure^® Needle Disposal System, Complete Needle™ Collection & Disposal System, Pitch-It IV™ Poles, Asset Return System, Sharps^® MWMS™ (a Medical Waste Management System (“MWMS”)) and Spill Kit and Recovery System.

RESULTS OF OPERATIONS

The following analyzes changes in the consolidated operating results and financial condition of the Company during the three and nine months ended March 31, 2018 and 2017. The following table sets forth, for the periods indicated, certain items from the Company's Condensed Consolidated Statements of Operations (dollars in thousands and percentages expressed as a percentage of revenue):



	Three-Months Ended March 31,										Nine-Months Ended March 31,
	2018			%		2017			%		2018			%		2017			%
	(Unaudited)										(Unaudited)
Revenues	$	9,427		100.0	%	$	8,588		100.0	%	$	30,229		100.0	%	$	27,826		100.0	%
Cost of revenues	7,131			75.6	%	6,236			72.6	%	21,774			72.0	%	19,620			70.5	%
Gross profit	2,296			24.4	%	2,352			27.4	%	8,455			28.0	%	8,206			29.5	%
SG&A expense	2,800			29.7	%	2,790			32.5	%	8,346			27.6	%	9,388			33.7	%
Depreciation and amortization	203			2.2	%	200			2.3	%	608			2.0	%	600			2.2	%
Operating loss	(707		)	(7.5	)%	(638		)	(7.4	)%	(499		)	(1.7	)%	(1,782		)	(6.4	)%
Interest income	5					4					15					12
Interest expense	(23		)			(34		)			(70		)			(92		)
Total other expense	(18		)	(0.2	)%	(30		)	(0.3	)%	(55		)	(0.2	)%	(80		)	(0.3	)%
Loss before income taxes	(725		)	(7.7	)%	(668		)	(7.8	)%	(554		)	(1.8	)%	(1,862		)	(6.7	)%
Income tax expense (benefit)	32			0.3	%	—			—	%	(28		)	(0.1	)%	—			—	%
Net Loss	$	(757	)	(8.0	)%	$	(668	)	(7.8	)%	$	(526	)	(1.7	)%	$	(1,862	)	(6.7	)%

THREE MONTHS ENDED MARCH 31, 2018 AS COMPARED TO THREE MONTHS ENDED MARCH 31, 2017

Total revenues for the three months ended March 31, 2018 of $9.4 million increased by $0.8 million, or 9.8%, over the total revenues for the three months ended March 31, 2017 of $8.6 million. The increase in revenue is mainly due to increased billings across the Retail and Professional markets partially offset by decreased billings in the Pharmaceutical Manufacturer market. The components of billings by market are as follows (in thousands):



	Three-Months Ended March 31,
	(Unaudited)
	2018		2017		Variance
BILLINGS BY MARKET:
Professional	$	3,178	$	2,982	$	196
Home Health Care	1,872		1,873		(1		)
Retail	1,640		806		834
Pharmaceutical Manufacturer	973		1,377		(404		)
Assisted Living	657		625		32
Government	520		424		96
Environmental	44		149		(105		)
Other	232		195		37
Subtotal	9,116		8,431		685
GAAP Adjustment *	311		157		154
Revenue Reported	$	9,427	$	8,588	$	839

*Represents the net impact of the revenue recognition adjustment required to arrive at reported generally accepted accounting principles (“GAAP”) revenue. Customer billings include all invoiced amounts associated with products shipped or services rendered during the period reported. GAAP revenue includes customer billings as well as numerous adjustments necessary to reflect, (i) the deferral of a portion of current period sales and (ii) recognition of certain revenue associated with products returned for treatment and destruction. The difference between customer billings and GAAP revenue is reflected in the Company’s balance sheet as deferred revenue. See Note 3 “Revenue Recognition” in “Notes to Condensed Consolidated Financial Statements”.

The components of billings by solution are as follows (in thousands):



	Three-Months Ended March 31,
	2018		% Total		2017		% Total
BILLINGS BY SOLUTION:
Mailbacks	$	4,291	47.1	%	$	4,840	57.4	%
Route-based pickup services	1,888		20.7	%	1,641		19.5	%
Unused medications	1,832		20.1	%	867		10.3	%
Third party treatment services	44		0.5	%	149		1.8	%
Other ⁽¹⁾	1,061		11.6	%	934		11.0	%
Total billings	$	9,116	100.0	%	$	8,431	100.0	%
GAAP adjustment ⁽²⁾	311				157
Revenue reported	$	9,427			$	8,588


(1)	The Company’s other products include IV poles, accessories, containers, asset return boxes and other miscellaneous items.

(2)

Represents the net impact of the revenue recognition adjustment required to arrive at reported generally accepted accounting principles (“GAAP”) revenue. Customer billings include all invoiced amounts associated with products shipped or services rendered during the period reported. GAAP revenue includes customer billings as well as numerous adjustments necessary to reflect, (i) the deferral of a portion of current period sales and (ii) recognition of certain revenue associated with products returned for treatment and destruction. The difference between customer billings and GAAP revenue is reflected in the Company’s balance sheet as deferred revenue.

The increase in billings was mainly attributable to increased billings in the Retail ($0.8 million) and Professional ($0.2 million) markets, partially offset by decreased billings in the Pharmaceutical Manufacturer ($0.4 million) market. The increase in Retail billings was due mainly to increased order activity for unused medication solutions, including the MedSafe. The increase in Professional market billings reflected organic growth as the Company continued its focus on securing customers from the small to medium quantity generator sector, which consists largely of physicians, clinics, dentists, surgery centers, veterinarians and other healthcare professionals, who benefit from the cost-effective and convenient Sharps Recovery System™ and the Company’s route-based pick-up services. The decrease in Pharmaceutical Manufacturer billings was due to timing of inventory builds for patient support programs. Billings for Mailbacks, which represented 47.1% of total billings, decreased 11.3% to $4.3 million as compared to $4.8 million in the prior year period primarily related to the decrease in billings for the Pharmaceutical Manufacturer market. Billings for Route-Based Pickup Services increased 15.1% to $1.9 million as compared to $1.6 million in the prior year period and represented 20.7% of total billings. Billings for Unused Medications increased 111.3% to $1.8 million as compared to $0.9 million in the prior year period and represented 20.1% of total billings.

Cost of revenues for the three months ended March 31, 2018 of $7.1 million was 75.6% of revenues. Cost of revenues for the three months ended March 31, 2017 of $6.2 million was 72.6% of revenues. The gross margin for the three months ended March 31, 2018 of 24.4% decreased compared to the gross margin for the three months ended March 31, 2017 of 27.4%. Gross margin was adversely impacted in the third quarter of fiscal year 2018 by unplanned incremental costs associated with the Company’s treatment facility and route based operations in the Northeast related to severe winter storms. The gross margin also reflects a lower margin on unused medication collection receptacles related to the launch of a major new program.

Selling, general and administrative (“SG&A”) expenses for the three months ended March 31, 2018 and 2017 were consistent at $2.8 million.

The Company reported an operating loss of $0.7 million for the three months ended March 31, 2018 compared to an operating loss of $0.6 million for the three months ended March 31, 2017. Operating loss increased primarily due to lower gross margin (discussed above).

The Company reported a loss before income taxes of $0.7 million for the three months ended March 31, 2018 and 2017.

The Company’s effective tax rate for the three months ended March 31, 2018 was 4.4% reflecting income tax expense related to the tax deductibility of goodwill amortization of $32 thousand. No income tax expense was recorded for the three months ended March 31, 2017 as it was not material due to the valuation allowance and net operating losses.

The Company reported a net loss of $0.8 million for the three months ended March 31, 2018 compared to net loss of $0.7 million for the three months ended March 31, 2017. Net loss increased due to the change in the operating loss and tax expense (discussed above).

The Company reported basic and diluted loss per share of $(0.05) for the three months ended March 31, 2018 versus basic and diluted loss per share of $(0.04) for the three months ended March 31, 2017. Basic and diluted loss per share increased due to the change in net loss (discussed above).

NINE MONTHS ENDED MARCH 31, 2018 AS COMPARED TO NINE MONTHS ENDED MARCH 31, 2017

Total revenues for the nine months ended March 31, 2018 of $30.2 million increased by $2.4 million, or 8.6%, over the total revenues for the nine months ended March 31, 2017 of $27.8 million. The increase in revenue is mainly due to increased billings across the Retail, Professional, Environmental, Government and Home Health Care markets partially offset by decreased billings in the Pharmaceutical Manufacturer market. The components of billings by market are as follows (in thousands):



	Nine-Months Ended March 31,
	(Unaudited)
	2018		2017		Variance
BILLINGS BY MARKET:
Professional	$	9,634	$	8,817	$	817
Home Health Care	5,987		5,760		227
Retail	5,621		4,507		1,114
Pharmaceutical Manufacturer	3,972		4,568		(596		)
Assisted Living	1,882		1,789		93
Government	1,484		1,245		239
Environmental	815		291		524
Other	636		567		69
Subtotal	30,031		27,544		2,487
GAAP Adjustment *	198		282		(84		)
Revenue Reported	$	30,229	$	27,826	$	2,403

The components of billings by solution are as follows (in thousands):



	Nine-Months Ended March 31,
	2018		% Total		2017		% Total
BILLINGS BY SOLUTION:
Mailbacks	$	16,420	54.7	%	$	17,379	63.1	%
Route-based pickup services	5,479		18.2	%	4,686		17.0	%
Unused medications	4,321		14.4	%	2,400		8.7	%
Third party treatment services	815		2.7	%	291		1.1	%
Other ⁽¹⁾	2,996		10.0	%	2,788		10.1	%
Total billings	$	30,031	100.0	%	$	27,544	100.0	%
GAAP adjustment ⁽²⁾	198				282
Revenue reported	$	30,229			$	27,826


(1)	The Company’s other products include IV poles, accessories, containers, asset return boxes and other miscellaneous items.

(2)

The increase in billings was mainly due to an increase in the Retail ($1.1 million), Professional ($0.8 million), Environmental ($0.5 million), Government ($0.2 million) and Home Health Care ($0.2 million) markets, partially offset by a decrease in the Pharmaceutical Manufacturer ($0.6 million) market. The increase in Retail billings was due mainly to increased order activity for unused medication solutions, including the MedSafe. The increase in Professional market billings reflected organic growth as the Company continued its focus on securing customers from the small to medium quantity generator sector, which consists largely of physicians, clinics, dentists, surgery centers, veterinarians and other healthcare professionals, who benefit from the cost-effective and convenient Sharps Recovery System™ and the Company’s route-based pick-up services. The increase in Environmental billings was due to higher third party treatment billings from our treatment facilities in Texas and Pennsylvania. The increase in Government billings was due primarily to billings for unused medication related orders. Home Health Care billings increased due to the timing of distributor purchases. The decrease in Pharmaceutical Manufacturer billings was mainly due to timing of inventory builds for patient support programs. Billings for Mailbacks, which represented 54.7% of total billings, decreased 5.5% to $16.4 million as compared to $17.4 million in the prior year period primarily related to the decrease in billings for the Pharmaceutical Manufacturer market. Billings for Route-Based Pickup Services increased 16.9% to $5.5 million as compared to $4.7 million in the prior year period and represented 18.2% of total billings. Billings for Unused Medications increased 80.0% to $4.3 million as compared to $2.4 million in the prior year period and represented 14.4% of total billings.

Cost of revenues for the nine months ended March 31, 2018 of $21.8 million was 72.0% of revenues. Cost of revenues for the nine months ended March 31, 2017 of $19.6 million was 70.5% of revenues. The gross margin for the nine months ended March 31, 2018 of 28.0% decreased compared to the gross margin for the nine months ended March 31, 2017 of 29.5%. Gross margin was adversely impacted for the nine months ended March 31, 2018 by unplanned incremental costs associated with severe winter storms in the Northeast and the lower margin associated with the launch of a new unused medication program.

Selling, general and administrative (“SG&A”) expense for the nine months ended March 31, 2018 and 2017 was $8.3 million and $9.4 million, respectively. The nine months ended March 31, 2017 included $0.7 million of one-time acquisition-related expenses related to the Company's acquisition of Citiwaste, which closed on July 1, 2016. Without these costs, SG&A for the first nine months of fiscal 2017 was $8.7 million. The decrease in SG&A (after excluding one-time expenses) for the nine months ended March 31, 2018 of $0.3 million reflects the impact of cost savings initiatives launched in the second quarter of fiscal year 2017.

The Company reported an operating loss of $0.5 million for the nine months ended March 31, 2018 compared to an operating loss of $1.8 million for the nine months ended March 31, 2017. Operating loss decreased primarily due to higher revenue and lower SG&A costs (discussed above).

The Company reported loss before income taxes of $0.6 million for the nine months ended March 31, 2018 versus loss before income taxes of $1.9 million for the nine months ended March 31, 2017. Loss before income taxes decreased due to the change in operating loss (discussed above).

The Company’s effective tax rate for the nine months ended March 31, 2018 was (5.1)% reflecting the impact of the 2017 tax law change on the Company's alternative minimum tax credits of $38,000 net of estimated state income tax expense of $10,000. The benefit recorded of $38,000 represents the net benefit of remeasuring the deferred tax assets for recoverable alternative minimum tax credits offset by deferred tax liabilities related to indefinite lived assets, such as goodwill, which cannot be used as a source of future taxable income in evaluating the need for a valuation allowance against deferred tax assets. No income tax expense was recorded for the nine months ended March 31, 2017 as it was not material due to the valuation allowance and net operating losses.

The Company reported a net loss of $0.5 million for the nine months ended March 31, 2018 compared to net loss of $1.9 million for the nine months ended March 31, 2017. Net loss decreased due to the change in the operating loss (discussed above).

The Company reported basic and diluted loss per share of $(0.03) for the nine months ended March 31, 2018 versus basic and diluted loss per share of $(0.12) for the nine months ended March 31, 2017. Basic and diluted loss per share decreased due to the change in net loss (discussed above).

PROSPECTS FOR THE FUTURE

The Company continues to focus on core markets and solution offerings that fuel growth. Its key markets include healthcare facilities, pharmaceutical manufacturers, home healthcare providers, assisted living/long-term care, retail pharmacies and clinics, and the professional market which is comprised of physicians, dentists, surgery centers and veterinary practices. These markets require cost-effective services for managing medical, pharmaceutical and hazardous waste.

The Company believes its growth opportunities are supported by the following:

•

A large professional market that consists of dentists, veterinarians, clinics, private practice physicians, urgent care facilities, ambulatory surgical centers and other healthcare facilities. This regulated market consists of small to medium quantity generators of medical, pharmaceutical and hazardous waste where we can offer a lower cost to service with solutions to match individual facility needs. The Company addresses this market from two directions: (i) field sales which focus on larger-dollar and nationwide opportunities where we can integrate the route-based pickup service along with our mailback solutions to create a comprehensive medical waste management offering and (ii) inside and online sales which focus on the individual or small group professional offices, government agencies, smaller retail pharmacies and clinics and assisted living/long-term care facilities. The Company is able to compete more aggressively in the medium quantity generator market with the addition of route-based services where the mailback may not be as cost effective. The Company’s route-based business provides direct service to areas encompassing about 155 million people or 48% of the U.S. population.

•

In July 2015 and December 2015, the Company augmented its network of medical and hazardous waste service providers with acquisitions of route-based pickup services in the Northeast serving Pennsylvania, Maryland, Ohio and other neighboring states. In July 2016, the Company acquired another route-based pickup service which expanded service to New York and New Jersey and strengthened the Company’s position in the Northeast. Through a combination of acquisition and organic growth, the Company now offers route-based pickup services in a twenty-three (23) state region of the South, Southeast and Northeast portions of the United States. The Company directly serves more than 10,300 customer locations with route-based pickup services. With the addition of these route-based pickup regions and the network of medical and hazardous waste service providers servicing the entire U.S., the Company offers customers a blended product portfolio to effectively manage multi-site and multi-sized locations, including those that generate larger quantities of waste. The network has had a significant positive impact on our pipeline of sales opportunities - over 60% of this pipeline is attributable to opportunities providing comprehensive waste management service offerings where both the mailback and pickup service are integrated into the offering.

•

The changing demographics of the U.S. population – according to the U.S. Census Bureau, 2012 Population Estimates and National Projections, one out of five Americans will be 65 years or older by 2030, which will increase the need for cost-effective medical waste management solutions, especially in the long-term care and home healthcare markets. With multiple solutions for managing regulated healthcare-related waste, the Company delivers value as a single-source provider with blended mailback and route-based pickup services matched to the waste volumes of each facility.


•	The shift of healthcare from traditional settings to the retail pharmacy and clinic markets, where the Company focuses

on driving increased promotion of the Sharps Recovery System. According to the Centers for Disease Control ("CDC"), 38.5% of adults received a flu shot and 28.2% of flu shots for adults were administered in a retail clinic. Over the flu seasons from 2011 to 2014, the growth in the Retail flu business for Sharps was between 24% and 36%. In the 2015 flu season, the Company's flu business decreased 13% due to a mild flu season but increased 10% for the 2016 flu season. Despite the decrease in Retail flu business for fiscal year 2017 of 15% due to a mild flu season and the loss of one retail pharmacy customer, Sharps believes the Retail market should continue to contribute to long-term growth for the Company as consumers increasingly use alternative sites, such as retail pharmacies, to obtain flu and other immunizations.

•

The passage of regulations for ultimate user medication disposal allows the Company to offer new solutions (MedSafe and TakeAway Medication Recovery System envelopes) that meet the regulations for ultimate user controlled substances disposal (Schedules II-V) to retail pharmacies. Additionally, with the new regulations, the Company is able to provide the MedSafe and TakeAway Medication Recovery Systems to assisted living and hospice to address a long standing issue within long-term care.

•

Local, state and federal agencies have growing needs for solutions to manage medical and pharmaceutical waste — the Company's Sharps Recovery System is ideal for as-needed disposal of sharps and other small quantities of medical waste generated within government buildings, schools and communities. The Company also provides TakeAway Medication Recovery System envelopes and MedSafe solutions to government agencies in need of proper and regulatory compliant medication disposal.

•

With an increased number of self-injectable medication treatments and local regulations, the Company believes its flagship product, the Sharps Recovery System, continues to offer the best option for proper sharps disposal at an affordable price. The Company delivers comprehensive services to pharmaceutical manufacturers that sell high-dollar, self-injectable medications, which include data management, compliance reporting, fulfillment, proper containment with disposal, branding and conformity with applicable regulations. In addition, the Company provides self-injectors with online and retail purchase options of sharps mailback systems, such as the Sharp Recovery System and Complete Needle Collection & Disposal System, respectively.


•	A heightened interest by many commercial companies who are looking to improve workplace safety with proper sharps disposal and unused medication disposal solutions — the Company offers a variety of services to meet these needs, including the Sharps Secure Needle Disposal System, Sharps Recovery System, Spill Kits and TakeAway Medication Recovery System envelopes.

•

The Company continually develops new solution offerings such as ultimate user medication disposal (MedSafe and TakeAway Medication Recovery System), mailback services for DEA registrant expired inventory of controlled substances (TakeAway Medication Recovery System DEA Reverse Distribution for Registrants) and shipback services for collection and recycling of single-use medical devices from surgical centers and other healthcare facilities (TakeAway Recycle System).


•	The Company’s strong financial position with a cash balance of $5.5 million, debt of $2.2 million and additional availability under the Credit Agreement as of March 31, 2018.

LIQUIDITY AND CAPITAL RESOURCES

Cash Flow

Cash flow has historically been primarily influenced by demand for products and services, operating margins and related working capital needs as well as more strategic activities including acquisitions, stock repurchases and fixed asset additions. Cash and cash equivalents increased by $0.8 million to $5.5 million at March 31, 2018 from $4.7 million at June 30, 2017 due to the following:


•	Cash Flows from Operating Activities - Working capital decreased by $0.1 million to $10.4 million at March 31, 2018 from $10.5 million at June 30, 2017. The decrease in working capital is primarily attributed to an increase in cash and cash equivalents offset by:


•	a decrease in accounts receivable of $1.5 million to $6.1 million at March 31, 2018 from $7.6 million at June 30, 2017 due to timing of billings and collections.


•	a decrease in current deferred revenue of $0.3 million to $2.1 million at March 31, 2018 from $2.4 million at June 30, 2017.


•	Cash Flows used in Investing Activities - Investing activities include capital expenditures of $0.8 million for normal plant and equipment additions.


•	Cash Flows used in Financing Activities - Financing activities include repayments of debt of $0.5 million.

Off-Balance Sheet Arrangements

The Company was not a party to any off-balance sheet transactions as defined in Item 303 of Regulation S-K for the nine months ended March 31, 2018 and the year ended June 30, 2017.

Credit Facility

On March 29, 2017, the Company entered into to a credit agreement with a commercial bank (“Credit Agreement”). The Credit Agreement, which replaced the Company’s prior credit agreement, provides for a $14.0 million credit facility, the proceeds of which may be utilized as follows: (i) $6.0 million for working capital, letters of credit (up to $2.0 million) and general corporate purposes and (ii) $8.0 million for acquisitions. Indebtedness under the Credit Agreement is secured by substantially all of the Company’s assets with advances outstanding under the working capital portion of the credit facility at any time limited to a Borrowing Base (as defined in the Credit Agreement) equal to 80% of eligible accounts receivable plus the lesser of 50% of eligible inventory and $3 million. Advances under the acquisition portion of the credit facility are limited to 75% of the purchase price of an acquired company and convert to a five-year term note at the time of the borrowing. Borrowings bear interest at the greater of (a) zero percent or (b) the One Month ICE LIBOR plus a LIBOR Margin of 2.5%. The LIBOR Margin may increase to as high as 3.0% depending on the Company’s cash flow leverage ratio. The interest rate as of March 31, 2018 was approximately 4.25%. The Company pays a fee of 0.25% per annum on the unused amount of credit facility. At March 31, 2018, $2.1 million was outstanding related to the acquisition portion of the credit facility and $41,000 related to the unsecured note payable assumed in acquisition. No amounts were outstanding under the working capital portion of the credit facility at March 31, 2018.

The Company has availability under the Credit Agreement of approximately $11.8 million ($6.0 million for the working capital and $5.8 million for the acquisitions) as of March 31, 2018. The Company also had $40,000 in letters of credit outstanding as of March 31, 2018.

Management believes that the Company’s current cash resources (cash on hand) will be sufficient to fund operations for the twelve months ending April 30, 2019.

CRITICAL ACCOUNTING POLICIES

Critical accounting policies are defined as those that are reflective of significant judgments and uncertainties and could potentially result in materially different results under different assumptions and conditions. The Company's critical accounting policies are included in the discussion entitled Critical Accounting Policies in Item 7. Management's Discussions and Analysis of Financial Condition and Results of Operations in the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 2017, as filed with the SEC. There were no material changes to the critical accounting policies disclosed in the Annual Report on Form 10-K.

RECENTLY ISSUED ACCOUNTING STANDARDS

uncertainty of revenue and cash flows relating to customer contracts. Companies have an option to use either a full retrospective approach or a modified retrospective approach to implement the standard. The guidance is effective for annual reporting periods beginning after December 15, 2017 (effective July 1, 2018 for the Company). The Company initiated a project to evaluate the impact that the new accounting guidance will have on its consolidated financial statements and related disclosures, which included identifying the material revenues streams and reviewing a representative sample of contracts. The Company is still in process of finalizing its evaluation, but has identified that for mailback and unused medication solutions, under the new guidance, the Company will recognize revenue over two performance obligations rather than the three separate elements under the current guidance. The Company is still evaluating the quantitative impact to the amount and timing of revenue recognition for the change to the identified performance obligations for the mailback solution. The Company is still evaluating the impact of the new standard on route-based pick up solution. No material changes to the amount and timing of revenue recognition over the third party treatment and other solutions are expected. The Company expects to adopt the standard using the modified retrospective approach, which involves retrospectively adopting the standard by recording a cumulative effect adjustment to all uncompleted contracts at July 1, 2018. The Company will continue to evaluate the standard as well as additional changes, modifications or interpretations which may impact the Company.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

The Company maintains “disclosure controls and procedures,” as such term is defined in Rule 13a-15(e) under the Exchange Act, that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms, and that such information is accumulated and communicated to management, including the Chief Executive Officer (“CEO”) and the Chief Financial Officer (“CFO”) as appropriate, to allow timely decisions regarding required disclosure. The Company conducted an evaluation (the “Evaluation”), under the supervision and with the participation of the CEO and CFO, of the effectiveness of the design and operation of our disclosure controls and procedures (“Disclosure Controls”) as of March 31, 2018, pursuant to Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Based upon this Evaluation, the CEO and CFO concluded that our Disclosure Controls were effective as of March 31, 2018.

Changes in Internal Control

During the three months ended March 31, 2018, there were no changes in the Company’s internal controls over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act), that have materially affected, or are reasonably likely to materially affect the Company’s internal control over financial reporting.

PART II – OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

From time to time, the Company is involved in legal proceedings and litigation in the ordinary course of business. In the opinion of management, the outcome of such currently pending matters will not have a material adverse effect on the Company’s consolidated financial position or consolidated results of operations.

ITEM 1A. RISK FACTORS

Refer to Item 1A. Risk Factors in the Company’s annual report on Form 10-K for the year ended June 30, 2017 for the Company’s risk factors. During the period ended March 31, 2018, there have been no changes to the Company’s risk factors.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

None

ITEM 6. EXHIBITS



(a)	Exhibits:

31.1	Certification of Chief Executive Officer in accordance with Section 302 of the Sarbanes-Oxley Act (filed herewith)

31.2	Certification of Chief Financial Officer in accordance with Section 302 of the Sarbanes-Oxley Act (filed herewith)

32.1	Certification of Chief Executive Officer in accordance with Section 906 of the Sarbanes-Oxley Act (filed herewith)

32.2	Certification of Chief Financial Officer in accordance with Section 906 of the Sarbanes-Oxley Act (filed herewith)

101.INS	XBRL Instance Document (filed herewith)

101.SCH	XBRL Taxonomy Extension Schema Document (filed herewith)

101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document (filed herewith)

101.DEF	XBRL Taxonomy Extension Linkbase Document (filed herewith)

101.LAB	XBRL Taxonomy Extension Label Linkbase Document (filed herewith)

101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document (filed herewith)

ITEMS 3, 4 AND 5 ARE NOT APPLICABLE AND HAVE BEEN OMITTED.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.



	REGISTRANT:
	SHARPS COMPLIANCE CORP.

Dated: May 3, 2018	By: /s/ DAVID P. TUSA
	David P. Tusa
	Chief Executive Officer and President
	(Principal Executive Officer)



Dated: May 3, 2018	By: /s/ DIANA P. DIAZ
	Diana P. Diaz
	Vice President and Chief Financial Officer
	(Principal Financial and Accounting Officer)

EX-31.1 2 exhibit311.htm EXHIBIT 31.1 Exhibit

Exhibit 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

IN ACCORDANCE WITH SECTION 302 OF THE SARBANES-OXLEY ACT

I, David P. Tusa, certify that:


1.	I have reviewed this quarterly report on Form 10-Q of Sharps Compliance Corp.;


2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;


3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;


4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:


(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;


(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;


(c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and


(d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and


5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.



Date: May 3, 2018	/s/David P. Tusa
	Chief Executive Officer and President
	(Principal Executive Officer)

EX-31.2 3 exhibit312.htm EXHIBIT 31.2 Exhibit

Exhibit 31.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER

IN ACCORDANCE WITH SECTION 302 OF THE SARBANES-OXLEY ACT

I, Diana P. Diaz, certify that:


1.	I have reviewed this quarterly report on Form 10-Q of Sharps Compliance Corp.;


2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;


3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;


4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:


(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;


(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;


(c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and


(d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and


5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.



Date: May 3, 2018	/s/Diana P. Diaz
	Vice President and Chief Financial Officer
	(Principal Financial and Accounting Officer)

EX-32.1 4 exhibit321.htm EXHIBIT 32.1 Exhibit

Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

IN ACCORDANCE WITH SECTION 906 OF THE SARBANES-OXLEY ACT

In connection with the quarterly report of Sharps Compliance Corp. (the “Company”) on Form 10-Q for the period ended March 31, 2018, as filed with the Securities and Exchange Commission on the date hereof, I, David P. Tusa, Chief Executive Officer and President of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge that:


(1)	The Form 10-Q report for the period ended March 31, 2018, filed with the Securities and Exchange Commission on May 3, 2018 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and


(2)	The information contained in the Form 10-Q report for the period ended March 31, 2018 fairly presents, in all material respects, the financial condition and results of operations of Sharps Compliance Corp.



Date: May 3, 2018	/s/David P. Tusa
	Chief Executive Officer and President

EX-32.2 5 exhibit322.htm EXHIBIT 32.2 Exhibit

Exhibit 32.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER

IN ACCORDANCE WITH SECTION 906 OF THE SARBANES-OXLEY ACT

In connection with the quarterly report of Sharps Compliance Corp. (the “Company”) on Form 10-Q for the period ended March 31, 2018, as filed with the Securities and Exchange Commission on the date hereof, I, Diana P. Diaz, Vice President and Chief Financial Officer, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge that:


(1)	The Form 10-Q report for the period ended March 31, 2018, filed with the Securities and Exchange Commission on May 3, 2018 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and


(2)	The information contained in the Form 10-Q report for the period ended March 31, 2018 fairly presents, in all material respects, the financial condition and results of operations of Sharps Compliance Corp.



Date: May 3, 2018	/s/Diana P. Diaz
	Vice President and Chief Financial Officer

EX-101.INS 6 smed-20180331.xml XBRL INSTANCE DOCUMENT 0000898770 2017-07-01 2018-03-31 0000898770 2018-05-01 0000898770 2017-06-30 0000898770 2018-03-31 0000898770 2018-01-01 2018-03-31 0000898770 2017-01-01 2017-03-31 0000898770 2016-07-01 2017-03-31 0000898770 us-gaap:AdditionalPaidInCapitalMember 2016-06-30 0000898770 us-gaap:CommonStockMember 2016-07-01 2017-06-30 0000898770 us-gaap:AdditionalPaidInCapitalMember 2017-06-30 0000898770 2016-07-01 2017-06-30 0000898770 us-gaap:AdditionalPaidInCapitalMember 2017-07-01 2018-03-31 0000898770 us-gaap:AdditionalPaidInCapitalMember 2016-07-01 2017-06-30 0000898770 us-gaap:RetainedEarningsMember 2016-07-01 2017-06-30 0000898770 us-gaap:RetainedEarningsMember 2016-06-30 0000898770 us-gaap:CommonStockMember 2016-06-30 0000898770 us-gaap:TreasuryStockMember 2018-03-31 0000898770 us-gaap:RetainedEarningsMember 2017-06-30 0000898770 us-gaap:RetainedEarningsMember 2018-03-31 0000898770 2016-06-30 0000898770 us-gaap:CommonStockMember 2018-03-31 0000898770 us-gaap:TreasuryStockMember 2017-06-30 0000898770 us-gaap:RetainedEarningsMember 2017-07-01 2018-03-31 0000898770 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0000898770 us-gaap:CommonStockMember 2017-07-01 2018-03-31 0000898770 us-gaap:TreasuryStockMember 2016-06-30 0000898770 us-gaap:CommonStockMember 2017-06-30 0000898770 2017-03-31 0000898770 smed:TermLoanMember 2018-03-31 0000898770 us-gaap:UnsecuredDebtMember 2018-03-31 0000898770 smed:CreditAgreementMember us-gaap:MaximumMember 2017-03-29 2017-03-29 0000898770 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember smed:CreditAgreementMember 2017-03-29 2017-03-29 0000898770 smed:CreditAgreementMember us-gaap:LondonInterbankOfferedRateLIBORMember 2017-03-29 2017-03-29 0000898770 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember smed:CreditAgreementMember 2017-03-29 0000898770 smed:CreditAgreementMember us-gaap:MaximumMember us-gaap:LondonInterbankOfferedRateLIBORMember 2017-03-29 2017-03-29 0000898770 smed:CreditAgreementMember 2017-03-29 0000898770 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember smed:CreditAgreementMember 2018-03-31 0000898770 smed:CreditAgreementMember 2017-03-29 2017-03-29 0000898770 us-gaap:LetterOfCreditMember smed:CreditAgreementMember 2018-03-31 0000898770 smed:WorkingCapitalMember smed:CreditAgreementMember 2018-03-31 0000898770 smed:CreditAgreementMember us-gaap:MinimumMember 2017-03-29 2017-03-29 0000898770 smed:WorkingCapitalMember smed:CreditAgreementMember 2017-03-29 0000898770 smed:TermLoanMember 2017-03-29 2017-03-29 0000898770 us-gaap:LetterOfCreditMember smed:CreditAgreementMember 2017-03-29 0000898770 us-gaap:SuretyBondMember 2018-03-31 0000898770 smed:CreditAgreementMember 2018-03-31 0000898770 us-gaap:UnsecuredDebtMember 2017-07-01 2018-03-31 0000898770 smed:TermLoanMember 2017-07-01 2018-03-31 0000898770 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2016-07-01 2017-03-31 0000898770 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-07-01 2018-03-31 0000898770 us-gaap:CostOfSalesMember 2017-07-01 2018-03-31 0000898770 us-gaap:CostOfSalesMember 2017-01-01 2017-03-31 0000898770 us-gaap:CostOfSalesMember 2018-01-01 2018-03-31 0000898770 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-01-01 2018-03-31 0000898770 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-01-01 2017-03-31 0000898770 us-gaap:CostOfSalesMember 2016-07-01 2017-03-31 0000898770 us-gaap:ConstructionPermitsMember 2018-03-31 0000898770 us-gaap:PatentsMember 2018-03-31 0000898770 us-gaap:NoncompeteAgreementsMember 2017-07-01 2018-03-31 0000898770 us-gaap:ConstructionPermitsMember 2017-06-30 0000898770 us-gaap:CustomerRelationshipsMember 2017-07-01 2018-03-31 0000898770 us-gaap:NoncompeteAgreementsMember 2017-06-30 0000898770 us-gaap:TradeNamesMember 2018-03-31 0000898770 us-gaap:PatentsMember 2017-06-30 0000898770 us-gaap:CustomerRelationshipsMember 2018-03-31 0000898770 us-gaap:CustomerRelationshipsMember 2017-06-30 0000898770 us-gaap:TradeNamesMember 2017-06-30 0000898770 us-gaap:NoncompeteAgreementsMember 2018-03-31 0000898770 us-gaap:TradeNamesMember 2017-07-01 2018-03-31 0000898770 us-gaap:PatentsMember us-gaap:MinimumMember 2017-07-01 2018-03-31 0000898770 us-gaap:ConstructionPermitsMember us-gaap:MinimumMember 2017-07-01 2018-03-31 0000898770 us-gaap:ConstructionPermitsMember us-gaap:MaximumMember 2017-07-01 2018-03-31 0000898770 us-gaap:PatentsMember us-gaap:MaximumMember 2017-07-01 2018-03-31 0000898770 smed:RouteBasedPickupServicesMember 2016-07-01 2017-03-31 0000898770 us-gaap:AllOtherSegmentsMember 2017-07-01 2018-03-31 0000898770 smed:MailbacksMember 2017-07-01 2018-03-31 0000898770 smed:RouteBasedPickupServicesMember 2017-01-01 2017-03-31 0000898770 smed:RouteBasedPickupServicesMember 2017-07-01 2018-03-31 0000898770 smed:UnusedMedicationsMember 2017-01-01 2017-03-31 0000898770 us-gaap:AllOtherSegmentsMember 2018-01-01 2018-03-31 0000898770 us-gaap:AllOtherSegmentsMember 2016-07-01 2017-03-31 0000898770 us-gaap:AllOtherSegmentsMember 2017-01-01 2017-03-31 0000898770 smed:ThirdPartyTreatmentServicesMember 2017-07-01 2018-03-31 0000898770 smed:UnusedMedicationsMember 2016-07-01 2017-03-31 0000898770 smed:MailbacksMember 2016-07-01 2017-03-31 0000898770 smed:ThirdPartyTreatmentServicesMember 2016-07-01 2017-03-31 0000898770 smed:UnusedMedicationsMember 2017-07-01 2018-03-31 0000898770 smed:ThirdPartyTreatmentServicesMember 2017-01-01 2017-03-31 0000898770 smed:MailbacksMember 2017-01-01 2017-03-31 0000898770 smed:UnusedMedicationsMember 2018-01-01 2018-03-31 0000898770 smed:ThirdPartyTreatmentServicesMember 2018-01-01 2018-03-31 0000898770 smed:MailbacksMember 2018-01-01 2018-03-31 0000898770 smed:RouteBasedPickupServicesMember 2018-01-01 2018-03-31 xbrli:shares iso4217:USD xbrli:shares xbrli:pure smed:state_region iso4217:USD false --06-30 Q3 2018 2018-03-31 10-Q 0000898770 16082021 Smaller Reporting Company SHARPS COMPLIANCE CORP 2700000 2800000 3000000 3.0 P1M 1.15 1889000 0 66000 89000 0 83000 23 0.8 0.5 0.75 700000 2700000 500000 2400000 800000 130000 166000 52000 0

1710000

1836000

7553000

6103000

1800000

1618000

28063000

28520000

496000

375000

78000

95000

500000

269000

304000

401000

34464000

33606000

17020000

16526000

12435000

5692000

4675000

5499000

-6743000

824000

0.01

20000000

16304027

16377636

16008412

16082021

163000

164000

0.582

0.191

0.017

0.101

0.109

0.635

0.168

0.010

0.086

0.101

0.488

0.200

0.005

0.194

0.113

0.550

0.181

0.027

0.143

0.099

6236000

19620000

7131000

21774000

0.030

0.025

43000

7000

P5Y

-37000

2421000

2107000

478000

475000

200000

600000

203000

608000

1100000

1174000

-0.04

-0.12

-0.05

-0.03

0.044

-0.051

400000

P2Y2M27D

-38000

P15Y

P6Y

P7Y

P5Y

P17Y

P5Y

P7Y

1104000

288000

490000

23000

264000

39000

1559000

365000

811000

41000

274000

68000

704000

606000

540000

586000

606000

5150000

1373000

3007000

117000

383000

270000

5207000

1430000

3007000

117000

383000

270000

4046000

1085000

2517000

94000

119000

231000

3648000

1065000

2196000

76000

109000

202000

-10000

6735000

2352000

8206000

2296000

8455000

600000.0

-668000

-1862000

-725000

-554000

32000

-28000

3000

335000

-111000

-1118000

-1450000

-239000

-317000

477000

-101000

192000

-14000

34000

92000

23000

70000

91000

64000

2826000

2789000

4098000

4163000

1272000

1374000

4000

12000

5000

15000

25000

9177000

8387000

34464000

33606000

6532000

6119000

40000

0.0425

6000000.0

2000000.0

8000000.0

14000000.0

6000000

5800000

11800000

0.0025

2152000

2111000

41000

601000

558000

43000

517000

558000

2002000

1594000

2880000

-451000

-9805000

-848000

182000

2123000

-668000

-1862000

-1293000

-757000

-526000

-30000

-80000

-18000

-55000

-638000

-1782000

-707000

-499000

120000

159000

165000

199000

7261000

128000

58000

2439000

800000

694000

761000

5600000

23000

10000

84000

342000

6543000

6538000

3062000

451000

-1385000

-1911000

8588000

4997000

1641000

149000

867000

934000

27826000

17661000

4686000

291000

2400000

2788000

9427000

4602000

1888000

44000

1832000

1061000

30229000

16618000

5479000

815000

4321000

2996000

2790000

9388000

2800000

8346000

116000

8000

108000

389000

33000

356000

114000

6000

108000

375000

33000

342000

4.34

3.60

0.00

15740458

295615

16304027

295615

16377636

295615

10000

415527

20617

52992

19300

95050

1899000

1895000

4000

83000

-1000

1000

342000

341000

1000

23843000

25331000

158000

-92000

-1554000

25287000

28063000

163000

-1385000

-1554000

25219000

28520000

164000

-1911000

-1554000

295615

1554000

15994000

15930000

16082000

16046000

15994000

15930000

16082000

16046000

15994000

15930000

16082000

16046000

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the </font><font style="font-family:inherit;font-size:10pt;">three and nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">March 31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, stock options to purchase shares of the Company’s common stock were exercised as follows:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:52%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three-Months Ended<br clear="none"/>March 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine-Months Ended <br clear="none"/>March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,300</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">95,050</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds (in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">84</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">342</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Average exercise price per share</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.34</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Payments due on long-term debt during each of the five years subsequent to </font><font style="font-family:inherit;font-size:10pt;">March 31, 2018</font><font style="font-family:inherit;font-size:10pt;"> are as follows (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:89%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Twelve Months Ending March 31,</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">558</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">517</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">517</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">517</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,152</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Fair Value of Financial Instruments</font><font style="font-family:inherit;font-size:10pt;">: The Company considers the fair value of all financial instruments, including cash and cash equivalents, accounts receivable and accounts payable to approximate their carrying values at </font><font style="font-family:inherit;font-size:10pt;">March 31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">June 30, 2017</font><font style="font-family:inherit;font-size:10pt;"> due to their short-term nature. The carrying value of the Company’s debt approximates fair value due to the market rates of interest.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">GOODWILL AND INTANGIBLE ASSETS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;">March 31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">June 30, 2017</font><font style="font-family:inherit;font-size:10pt;">, intangible assets consisted of the following (in thousands):</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="27" rowspan="1"></td></tr><tr><td style="width:21%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Estimated<br clear="none"/>Useful Lives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Original</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Original</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer relationships</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,007</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(811</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,196</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,007</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(490</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,517</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Permits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6 - 15 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,430</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(365</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,065</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,373</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(288</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,085</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">5 - 17 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">383</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(274</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">109</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">383</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(264</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">119</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trade name</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">270</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(68</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">202</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">270</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(39</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">231</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-compete</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">117</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(41</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">117</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(23</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total intangible assets, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,207</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,559</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,648</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,150</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,104</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,046</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During both the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">March 31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, amortization expense was </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;">. There have been </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> changes in the carrying amount of goodwill since </font><font style="font-family:inherit;font-size:10pt;">June 30, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2018</font><font style="font-family:inherit;font-size:10pt;">, future amortization of intangible assets is as follows (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:80%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Twelve Months Ending March 31,</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">606</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">606</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">606</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">586</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">540</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">704</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,648</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Goodwill and Other Identifiable Intangible Assets:</font><font style="font-family:inherit;font-size:10pt;"> Finite-lived intangible assets are amortized over their respective estimated useful lives and evaluated for impairment periodically whenever events or changes in circumstances indicate that their related carrying values may not be fully recoverable. Goodwill is assessed for impairment at least annually. The Company generally performs its annual goodwill impairment analysis using a quantitative approach. The quantitative goodwill impairment test identifies the existence of potential impairment by comparing the fair value of our single reporting unit with its carrying value, including goodwill. If the fair value of a reporting unit exceeds its carrying value, the reporting unit's goodwill is considered not to be impaired. If the carrying value of a reporting unit exceeds its fair value, an impairment charge is recognized in an amount equal to that excess. The impairment charge recognized is limited to the amount of goodwill present in our single reporting unit. These estimates and assumptions could have a significant impact on whether or not an impairment charge is recognized and the amount of any such charge. The Company performs its annual impairment assessment of goodwill during the fourth quarter of each fiscal year. </font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Income Taxes</font><font style="font-family:inherit;font-size:10pt;">: Deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is established when it is more likely than not that some portion or all of the deferred tax assets will not be realized. The establishment of valuation allowances and development of projected annual effective tax rates requires significant judgment and is impacted by various estimates. Both positive and negative evidence, as well as the objectivity and verifiability of that evidence, is considered in determining the appropriateness of recording a valuation allowance on deferred tax assets. Under GAAP, the valuation allowance has been recorded to reduce the Company’s deferred tax assets to an amount that is more likely than not to be realized and is based upon the uncertainty of the realization of certain federal and state deferred tax assets related to net operating loss carryforwards and other tax attributes.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Accounts Receivable</font><font style="font-family:inherit;font-size:10pt;">: Accounts receivable consist primarily of amounts due to the Company from normal business activities. Accounts receivable balances are determined to be delinquent when the amount is past due based on the contractual terms with the customer. The Company maintains an allowance for doubtful accounts to reflect the likelihood of not collecting certain accounts receivable based on past collection history and specific risks identified among uncollected accounts. Accounts receivable are charged to the allowance for doubtful accounts when the Company determines that the receivable will not be collected and/or when the account has been referred to a third party collection agency. The Company has a history of minimal uncollectible accounts.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The components of revenues by solution are as follows (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15" rowspan="1"></td></tr><tr><td style="width:52%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three-Months Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">% Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">% Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">REVENUES BY SOLUTION:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mailbacks</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,602</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">48.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,997</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">58.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Route-based pickup services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,888</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">20.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,641</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">19.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unused medications</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,832</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">19.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">867</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">10.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Third party treatment services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">0.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">149</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">1.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-indent:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,061</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">11.3</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">934</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">10.9</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,427</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,588</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine-Months Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">% Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">% Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">REVENUES BY SOLUTION:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mailbacks</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,618</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">55.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,661</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">63.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Route-based pickup services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,479</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">18.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,686</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">16.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unused medications</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,321</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">14.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,400</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">8.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Third party treatment services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">815</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">2.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">291</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">1.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-indent:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,996</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">9.9</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,788</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">10.1</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,229</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,826</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:13px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company’s other products include non-mailback products such as IV poles, accessories, containers, asset return boxes and other miscellaneous items.</font></div></td></tr></table></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Revenue Recognition:</font><font style="font-family:inherit;font-size:10pt;"> The Company recognizes revenue when services are provided and from product sales when (i) goods are shipped or delivered, and title and risk of loss pass to the customer, (ii) the price is substantially fixed or determinable and (iii) collectability is reasonably assured except for those sales via multiple-deliverable revenue arrangements. Provisions for certain rebates, product returns and discounts to customers are accounted for as reductions in sales in the same period the related sales are recorded. Product discounts granted are based on the terms of arrangements with direct, indirect and other market participants, as well as market conditions, including prices charged by competitors. Rebates are estimated based on contractual terms, historical experience, trend analysis and projected market conditions in the various markets served. Service agreements which include a vendor managed inventory program include terms that meet the “bill and hold” criteria and as such are recognized when the order is completed, at which point title has transferred, there are no acceptance provisions and amounts are segregated in the Company’s warehouse. During the </font><font style="font-family:inherit;font-size:10pt;">three and nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">March 31, 2018</font><font style="font-family:inherit;font-size:10pt;">, the Company recorded revenue from inventory builds that are held in vendor managed inventory under these service agreements of </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$2.4 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. During the </font><font style="font-family:inherit;font-size:10pt;">three and nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">March 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company recorded revenue from inventory builds that are held in vendor managed inventory under these service agreements of </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$2.7 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. As of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">June 30, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$2.8 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$2.7 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, of solutions sold through that date were held in vendor managed inventory pending fulfillment or shipment to patients of pharmaceutical manufacturers who offer these solutions to patients in an ongoing patient support program.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain products offered by the Company have revenue producing components that are recognized over multiple delivery points (Sharps Recovery System and various other solutions like the TakeAway Medication Recovery Systems referred to as “Mailbacks” and Sharps Pump and Asset Return Systems, referred to as “Pump Returns”) and can consist of up to three separate elements, or units of measure, as follows: (1) the sale of the compliance and container system, (2) return transportation and (3) treatment service. In accordance with the relative selling price methodology, an estimated selling price is determined for all deliverables that qualify for separate units of accounting. The actual consideration received in a multiple-deliverable arrangement is then allocated to the units based on their relative sales price. The selling price for the transportation revenue and the treatment revenue utilizes third party evidence. The Company estimates the selling price of the compliance and container system based on the product and services provided, including compliance with local, state and federal laws, adherence to stringent manufacturing and testing requirements, safety to the patient and the community, as well as storage and containment capabilities.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue for the sale of the compliance and container is recognized upon delivery to the customer, at which time the customer takes title and assumes risk of ownership. Transportation revenue is recognized when the customer returns the compliance and container system and the container has been received at the Company’s owned or contracted facilities. The compliance and container system is mailed or delivered by an alternative logistics provider to the Company’s owned or contracted facilities. Treatment revenue is recognized upon the destruction or conversion and proof of receipt and treatment having been performed on the container. Since the transportation element and the treatment elements are undelivered services at the point of initial sale of the compliance and container, transportation and treatment revenue is deferred until the services are performed. The current and long-term portions of deferred revenues are determined through regression analysis and historical trends. Furthermore, through regression analysis of historical data, the Company has determined that a certain percentage of all compliance and container systems sold may not be returned. Accordingly, a portion of the transportation and treatment elements are recognized at the point of sale.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;">March 31, 2018</font><font style="font-family:inherit;font-size:10pt;">, long-term debt consisted of the following (in thousands):</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:89%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-interest bearing, unsecured note payable assumed in acquisition, monthly payments of $7; maturing September 2018.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Term loan, bearing interest at 4.25%, monthly payments of $43; maturing March 2022.</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,111</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total long-term debt</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,152</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: current portion</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">558</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term debt, net of current portion</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,594</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following information is necessary to calculate earnings per share for the periods presented (in thousands, except per-share data):</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three-Months Ended<br clear="none"/>March 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine-Months Ended <br clear="none"/>March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss, as reported</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(757</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(668</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(526</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,862</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average common shares outstanding</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,082</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,994</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,046</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,930</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effect of dilutive stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average diluted common shares outstanding</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,082</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,994</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,046</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,930</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss per common share</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.05</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.04</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.03</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.12</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employee stock options excluded from computation of dilutive loss per share amounts because their effect would be anti-dilutive</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">401</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">269</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">401</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">304</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the </font><font style="font-family:inherit;font-size:10pt;">three and nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">March 31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, stock-based compensation amounts are as follows (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:52%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three-Months Ended<br clear="none"/>March 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine-Months Ended <br clear="none"/>March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation expense included in:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">108</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">108</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">342</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">356</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">114</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">116</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">375</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">389</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;">March 31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">June 30, 2017</font><font style="font-family:inherit;font-size:10pt;">, intangible assets consisted of the following (in thousands):</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="27" rowspan="1"></td></tr><tr><td style="width:21%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">March 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">June 30, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Estimated<br clear="none"/>Useful Lives</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Original</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Original</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customer relationships</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,007</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(811</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,196</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,007</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(490</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,517</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Permits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6 - 15 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,430</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(365</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,065</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,373</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(288</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,085</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">5 - 17 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">383</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(274</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">109</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">383</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(264</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">119</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trade name</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">270</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(68</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">202</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">270</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(39</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">231</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-compete</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">117</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(41</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">117</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(23</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total intangible assets, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,207</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,559</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,648</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,150</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,104</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,046</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2018</font><font style="font-family:inherit;font-size:10pt;">, future amortization of intangible assets is as follows (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:80%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Twelve Months Ending March 31,</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">606</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">606</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">606</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">586</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">540</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">704</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,648</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">REVENUES BY SOLUTION</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The components of revenues by solution are as follows (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15" rowspan="1"></td></tr><tr><td style="width:52%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three-Months Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">% Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">% Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">REVENUES BY SOLUTION:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mailbacks</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,602</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">48.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,997</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">58.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Route-based pickup services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,888</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">20.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,641</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">19.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unused medications</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,832</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">19.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">867</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">10.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Third party treatment services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">0.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">149</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">1.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-indent:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,061</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">11.3</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">934</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">10.9</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,427</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,588</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine-Months Ended March 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">% Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">% Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">REVENUES BY SOLUTION:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mailbacks</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,618</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">55.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,661</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">63.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Route-based pickup services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,479</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">18.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,686</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">16.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unused medications</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,321</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">14.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,400</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">8.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Third party treatment services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">815</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">2.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">291</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">1.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-indent:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,996</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">9.9</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,788</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">10.1</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,229</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,826</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:13px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company’s other products include non-mailback products such as IV poles, accessories, containers, asset return boxes and other miscellaneous items.</font></div></td></tr></table></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Stock-Based Compensation</font><font style="font-family:inherit;font-size:10pt;">: Stock-based compensation cost for options and restricted stock awarded to employees and directors is measured at the grant date, based on the calculated fair value of the award and is recognized as an expense over the requisite service period (generally the vesting period of the equity grant).</font></div></div>

EX-101.SCH 7 smed-20180331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2102100 - Disclosure - BASIS OF PRESENTATION link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1001501 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - EARNINGS PER SHARE link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - EARNINGS PER SHARE (Details) link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - EARNINGS PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - EQUITY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 2409402 - Disclosure - EQUITY TRANSACTIONS (Details) link:presentationLink link:calculationLink link:definitionLink 2309301 - Disclosure - EQUITY TRANSACTIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - GOODWILL AND INTANGIBLE ASSETS link:presentationLink link:calculationLink link:definitionLink 2410402 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Details) link:presentationLink link:calculationLink link:definitionLink 2410402 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Details) link:presentationLink link:calculationLink link:definitionLink 2310301 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 2405401 - Disclosure - INCOME TAXES (Details) link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - INVENTORY link:presentationLink link:calculationLink link:definitionLink 2411402 - Disclosure - INVENTORY (Details) link:presentationLink link:calculationLink link:definitionLink 2311301 - Disclosure - INVENTORY (Tables) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - NOTES PAYABLE AND LONG-TERM DEBT link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - NOTES PAYABLE AND LONG-TERM DEBT - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2406403 - Disclosure - NOTES PAYABLE AND LONG-TERM DEBT - Schedule of debt instruments (Details) link:presentationLink link:calculationLink link:definitionLink 2406404 - Disclosure - NOTES PAYABLE AND LONG-TERM DEBT - Schedule of payments due on long-term debt (Details) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - NOTES PAYABLE AND LONG-TERM DEBT (Tables) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - ORGANIZATION AND BACKGROUND link:presentationLink link:calculationLink link:definitionLink 2401401 - Disclosure - ORGANIZATION AND BACKGROUND (Details) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - RECENTLY ISSUED ACCOUNTING STANDARDS link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - REVENUES BY SOLUTION link:presentationLink link:calculationLink link:definitionLink 2412402 - Disclosure - REVENUES BY SOLUTION (Details) link:presentationLink link:calculationLink link:definitionLink 2312301 - Disclosure - REVENUES BY SOLUTION (Tables) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 2403402 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details) link:presentationLink link:calculationLink link:definitionLink 2203201 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - STOCK-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - STOCK-BASED COMPENSATION (Details) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - STOCK-BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 smed-20180331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 smed-20180331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 smed-20180331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Debt Disclosure [Abstract] Schedule of long-term debt Schedule of Long-term Debt Instruments [Table Text Block] Schedule of payments due on long-term debt Contractual Obligation, Fiscal Year Maturity Schedule [Table Text Block] Earnings Per Share [Abstract] EARNINGS PER SHARE Earnings Per Share [Text Block] Income Tax Disclosure [Abstract] Effective income tax rate Effective Income Tax Rate Reconciliation, Percent Income tax benefit Federal Income Tax Expense (Benefit), Continuing Operations State income tax expense State and Local Income Tax Expense (Benefit), Continuing Operations Income tax expense Income Tax Expense (Benefit) Decrease of deferred tax assets and offsetting valuation allowance Tax Cuts And Jobs Act Of 2017, Incomplete Accounting, Change In Tax Rate, Deferred Tax Asset, Provisional Income Tax Expense (Benefit) Tax Cuts And Jobs Act Of 2017, Incomplete Accounting, Change In Tax Rate, Deferred Tax Asset, Provisional Income Tax Expense (Benefit) Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Net loss Net Income (Loss) Attributable to Parent Adjustments to reconcile net loss to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation and amortization Depreciation, Depletion and Amortization Loss on disposal of property, plant and equipment Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property Stock-based compensation expense Share-based Compensation Deferred tax benefit Deferred Income Tax Expense (Benefit) Changes in operating assets and liabilities, net of effects of business acquisitions: Increase (Decrease) in Operating Capital [Abstract] Accounts receivable Increase (Decrease) in Accounts Receivable Inventory Increase (Decrease) in Inventories Prepaid and other assets Increase (Decrease) in Prepaid Expense and Other Assets Accounts payable and accrued liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Deferred revenue Increase (Decrease) in Deferred Revenue NET CASH PROVIDED BY OPERATING ACTIVITIES Net Cash Provided by (Used in) Operating Activities CASH FLOWS FROM INVESTING ACTIVITIES Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Purchase of property, plant and equipment Payments to Acquire Property, Plant, and Equipment Cash proceeds from sale of property, plant and equipment Proceeds from Sale of Property, Plant, and Equipment Additions to intangible assets Payments to Acquire Intangible Assets Payments for business acquisitions, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired NET CASH USED IN INVESTING ACTIVITIES Net Cash Provided by (Used in) Investing Activities CASH FLOWS FROM FINANCING ACTIVITIES Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Proceeds from exercise of stock options Proceeds from Stock Options Exercised Proceeds from long-term debt Proceeds from Issuance of Long-term Debt Repayments of long-term debt Repayments of Long-term Debt NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES Net Cash Provided by (Used in) Financing Activities NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS Cash and Cash Equivalents, Period Increase (Decrease) CASH AND CASH EQUIVALENTS, beginning of period Cash and Cash Equivalents, at Carrying Value CASH AND CASH EQUIVALENTS, end of period SUPPLEMENTAL CASH FLOW DISCLOSURES: Supplemental Cash Flow Elements [Abstract] Income taxes paid Income Taxes Paid, Net Interest paid on long-term debt Interest Expense, Long-term Debt NON-CASH INVESTING AND FINANCING ACTIVITIES: Noncash Investing and Financing Items [Abstract] Issuance of common stock for acquisition Noncash Or Part Noncash Acquisition, Noncash Financial Or Equity Instrument Consideration, Value Noncash Or Part Noncash Acquisition, Noncash Financial Or Equity Instrument Consideration, Value Issuance of common stock for lease Noncash Or Part Noncash Transaction, Noncash Financial Or Equity Instrument Consideration, Value Noncash Or Part Noncash Transaction, Noncash Financial Or Equity Instrument Consideration, Value Unpaid consideration related to acquisitions Unpaid consideration related to acquisition Business acquisition amount of escrow deposit and other unpaid consideration. Transfer of equipment to inventory Transfer of equipment to inventory This element represents the noncash transfer of equipment from fixed assets into inventory. Property, plant and equipment financed through accounts payable Noncash or Part Noncash Related Purchases of Property Plant And Equipment The amount of noncash or part noncash for purchases of and capital improvements on property, plant and equipment. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Schedule of Stock-Based Compensation Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Statement of Stockholders' Equity [Abstract] Statement [Table] Statement [Table] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Common Stock Common Stock [Member] Treasury Stock Treasury Stock [Member] Additional Paid-in Capital Additional Paid-in Capital [Member] Accumulated Deficit Retained Earnings [Member] Statement [Line Items] Statement [Line Items] Balance at beginning (in shares) Shares, Issued Balances at beginning Stockholders' Equity Attributable to Parent Exercise of stock options (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Stock-based compensation Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Issuance of common shares for acquisition (in shares) Stock Issued During Period, Shares, Acquisitions Issuance of common shares for acquisition Stock Issued During Period, Value, Acquisitions Issuance of common shares for lease (in shares) Stock Issued During Period, Shares, Issued for Services Issuance of common shares for lease Stock Issued During Period, Value, Issued for Services Issuance of restricted stock (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Gross Issuance of restricted stock Stock Issued During Period, Value, Restricted Stock Award, Gross Balance at end (in shares) Balances at end Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Cost of revenues Cost of Sales [Member] Selling, general and administrative Selling, General and Administrative Expenses [Member] Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Accounting Policies [Abstract] Revenue Recognition Revenue Recognition, Policy [Policy Text Block] Income Taxes Income Tax, Policy [Policy Text Block] Goodwill and Other Identifiable Intangible Assets Goodwill and Intangible Assets, Policy [Policy Text Block] Accounts Receivable Receivables, Policy [Policy Text Block] Stock-Based Compensation Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] New Accounting Pronouncement New Accounting Pronouncements, Policy [Policy Text Block] Net loss, as reported Weighted average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Effect of dilutive stock options (in shares) Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants Weighted average diluted common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Diluted Net loss per common share Earnings Per Share, Basic and Diluted [Abstract] Basic and Diluted (in dollars per share) Earnings Per Share, Basic and Diluted Employee stock options excluded from computation of dilutive loss per share amounts because their effect would be anti-dilutive (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Document and Entity Information [Abstract] Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Statement of Financial Position [Abstract] Accounts receivable, allowance for doubtful accounts Allowance for Doubtful Accounts Receivable, Current Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Common stock, shares authorized (in shares) Common Stock, Shares Authorized Common stock, shares issued (in shares) Common Stock, Shares, Issued Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Treasury stock, shares repurchased (in shares) Treasury Stock, Shares Segment Reporting [Abstract] Schedule of billings by solution Reconciliation of Other Significant Reconciling Items from Segments to Consolidated [Table Text Block] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Segments [Axis] Segments [Axis] Segments [Domain] Segments [Domain] Mailbacks Mailbacks [Member] Refers to revenue from mailbacks. Route-based pickup services Route-based Pickup Services [Member] Refers to revenue from route-based pickup services. Unused medications Unused Medications [Member] Refers to revenue from unused medications. Third party treatment services Third Party Treatment Services [Member] Refers to revenue from third party treatment services. Other Other Segments [Member] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Revenue reported Revenue, Net Revenue percentage Concentration Risk, Percentage Schedule of Earnings Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Stockholders' Equity Note [Abstract] Stock options exercised to purchase common stock Stock options exercised to purchase common stock [Table Text Block] Tabular disclosure of stock options exercised to purchase common shares. ASSETS Assets [Abstract] CURRENT ASSETS Assets, Current [Abstract] Cash and cash equivalents Accounts receivable, net of allowance for doubtful accounts of $95 and $78, respectively Accounts Receivable, Net, Current Inventory, net Inventory, Net Prepaid and other current assets Prepaid Expense and Other Assets, Current TOTAL CURRENT ASSETS Assets, Current PROPERTY, PLANT AND EQUIPMENT, net Property, Plant and Equipment, Net OTHER ASSETS Other Assets, Noncurrent GOODWILL Goodwill INTANGIBLE ASSETS, net Finite-Lived Intangible Assets, Net TOTAL ASSETS Assets LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity [Abstract] CURRENT LIABILITIES Liabilities, Current [Abstract] Accounts payable Accounts Payable, Current Accrued liabilities Accrued Liabilities, Current Current maturities of long-term debt Long-term Debt, Current Maturities Deferred revenue Deferred Revenue, Current TOTAL CURRENT LIABILITIES Liabilities, Current LONG-TERM DEFERRED REVENUE, net of current portion Deferred Revenue, Noncurrent OTHER LONG-TERM LIABILITIES Other Liabilities, Noncurrent LONG-TERM DEBT, net of current portion Long-term Debt, Excluding Current Maturities TOTAL LIABILITIES Liabilities COMMITMENTS AND CONTINGENCIES Commitments and Contingencies STOCKHOLDERS' EQUITY Stockholders' Equity Attributable to Parent [Abstract] Common stock, $0.01 par value per share; 20,000,000 shares authorized; 16,377,636 and 16,304,027 shares issued, respectively, and 16,082,021 and 16,008,412 shares outstanding, respectively. Common Stock, Value, Issued Treasury stock, at cost, 295,615 shares repurchased Treasury Stock, Value Additional paid-in capital Additional Paid in Capital, Common Stock Accumulated deficit Retained Earnings (Accumulated Deficit) TOTAL STOCKHOLDERS' EQUITY TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity INCOME TAXES Income Tax Disclosure [Text Block] Organization, Consolidation and Presentation of Financial Statements [Abstract] ORGANIZATION AND BACKGROUND Nature of Operations [Text Block] Revenue Recognition [Abstract] Revenue Recognition [Abstract] Revenue recorded from inventory builds Recognition of Bill and hold Revenue The amount of revenue recognized during the period relating to bill and hold inventory. Solutions sold that were held in vendor managed inventory Bill and hold inventory Amount of bill and hold inventory as of balance sheet date. Long-term Debt, Fiscal Year Maturity [Abstract] Long-term Debt, Fiscal Year Maturity [Abstract] 2019 Long-term Debt, Maturities, Repayments of Principal, Remainder of Fiscal Year 2020 Long-term Debt, Maturities, Repayments of Principal in Year Two 2021 Long-term Debt, Maturities, Repayments of Principal in Year Three 2022 Long-term Debt, Maturities, Repayments of Principal in Year Four 2023 Long-term Debt, Maturities, Repayments of Principal in Year Five Total long-term debt Long-term Debt Income Statement [Abstract] REVENUES Cost of revenues Cost of Revenue GROSS PROFIT Gross Profit Selling, general and administrative Selling, General and Administrative Expense Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction OPERATING LOSS Operating Income (Loss) OTHER INCOME (EXPENSE) Nonoperating Income (Expense) [Abstract] Interest income Investment Income, Interest Interest expense Interest Expense TOTAL OTHER EXPENSE Nonoperating Income (Expense) LOSS BEFORE INCOME TAXES Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest INCOME TAX EXPENSE NET LOSS NET LOSS PER COMMON SHARE - Basic and Diluted WEIGHTED AVERAGE SHARES USED IN COMPUTING LOSS PER COMMON SHARE: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Basic and diluted (in shares) Weighted Average Number of Shares Outstanding, Basic and Diluted Goodwill and Intangible Assets Disclosure [Abstract] Schedule of intangible assets Schedule of Finite-Lived Intangible Assets [Table Text Block] EX-101.PRE 11 smed-20180331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Mar. 31, 2018	May 01, 2018
Document and Entity Information [Abstract]
Entity Registrant Name	SHARPS COMPLIANCE CORP
Entity Central Index Key	0000898770
Current Fiscal Year End Date	--06-30
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		16,082,021
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q3
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2018

XML 13 R2.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2018	Jun. 30, 2017
CURRENT ASSETS
Cash and cash equivalents	$ 5,499	$ 4,675
Accounts receivable, net of allowance for doubtful accounts of $95 and $78, respectively	6,103	7,553
Inventory, net	4,163	4,098
Prepaid and other current assets	761	694
TOTAL CURRENT ASSETS	16,526	17,020
PROPERTY, PLANT AND EQUIPMENT, net	6,538	6,543
OTHER ASSETS	159	120
GOODWILL	6,735	6,735
INTANGIBLE ASSETS, net	3,648	4,046
TOTAL ASSETS	33,606	34,464
CURRENT LIABILITIES
Accounts payable	1,836	1,710
Accrued liabilities	1,618	1,800
Current maturities of long-term debt	558	601
Deferred revenue	2,107	2,421
TOTAL CURRENT LIABILITIES	6,119	6,532
LONG-TERM DEFERRED REVENUE, net of current portion	475	478
OTHER LONG-TERM LIABILITIES	199	165
LONG-TERM DEBT, net of current portion	1,594	2,002
TOTAL LIABILITIES	8,387	9,177
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' EQUITY
Common stock, $0.01 par value per share; 20,000,000 shares authorized; 16,377,636 and 16,304,027 shares issued, respectively, and 16,082,021 and 16,008,412 shares outstanding, respectively.	164	163
Treasury stock, at cost, 295,615 shares repurchased	(1,554)	(1,554)
Additional paid-in capital	28,520	28,063
Accumulated deficit	(1,911)	(1,385)
TOTAL STOCKHOLDERS' EQUITY	25,219	25,287
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 33,606	$ 34,464

XML 14 R3.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2018	Jun. 30, 2017
Statement of Financial Position [Abstract]
Accounts receivable, allowance for doubtful accounts	$ 95	$ 78
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	20,000,000	20,000,000
Common stock, shares issued (in shares)	16,377,636	16,304,027
Common stock, shares outstanding (in shares)	16,082,021	16,008,412
Treasury stock, shares repurchased (in shares)	295,615	295,615

XML 15 R4.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) shares in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2018	Mar. 31, 2017
Income Statement [Abstract]
REVENUES	$ 9,427,000	$ 8,588,000	$ 30,229,000	$ 27,826,000
Cost of revenues	7,131,000	6,236,000	21,774,000	19,620,000
GROSS PROFIT	2,296,000	2,352,000	8,455,000	8,206,000
Selling, general and administrative	2,800,000	2,790,000	8,346,000	9,388,000
Depreciation and amortization	203,000	200,000	608,000	600,000
OPERATING LOSS	(707,000)	(638,000)	(499,000)	(1,782,000)
OTHER INCOME (EXPENSE)
Interest income	5,000	4,000	15,000	12,000
Interest expense	(23,000)	(34,000)	(70,000)	(92,000)
TOTAL OTHER EXPENSE	(18,000)	(30,000)	(55,000)	(80,000)
LOSS BEFORE INCOME TAXES	(725,000)	(668,000)	(554,000)	(1,862,000)
INCOME TAX EXPENSE	32,000	0	(28,000)	0
NET LOSS	$ (757,000)	$ (668,000)	$ (526,000)	$ (1,862,000)
NET LOSS PER COMMON SHARE - Basic and Diluted
Basic and Diluted (in dollars per share)	$ (0.05)	$ (0.04)	$ (0.03)	$ (0.12)
WEIGHTED AVERAGE SHARES USED IN COMPUTING LOSS PER COMMON SHARE:
Basic and diluted (in shares)	16,082	15,994	16,046	15,930

XML 16 R5.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) - USD ($) $ in Thousands	Total	Common Stock	Treasury Stock	Additional Paid-in Capital	Accumulated Deficit
Balance at beginning (in shares) at Jun. 30, 2016		15,740,458	295,615
Balances at beginning at Jun. 30, 2016	$ 23,843	$ 158	$ (1,554)	$ 25,331	$ (92)
Exercise of stock options (in shares)		95,050
Exercise of stock options	342	$ 1		341
Stock-based compensation	496			496
Issuance of common shares for acquisition (in shares)		415,527
Issuance of common shares for acquisition	1,899	$ 4		1,895
Issuance of restricted stock (in shares)		52,992
Net loss	(1,293)				(1,293)
Balance at end (in shares) at Jun. 30, 2017		16,304,027	295,615
Balances at end at Jun. 30, 2017	$ 25,287	$ 163	$ (1,554)	28,063	(1,385)
Exercise of stock options (in shares)	0
Stock-based compensation	$ 375			375
Issuance of common shares for lease (in shares)		20,617
Issuance of common shares for lease	83			83
Issuance of restricted stock (in shares)		52,992
Issuance of restricted stock	0	$ 1		(1)
Net loss	(526)				(526)
Balance at end (in shares) at Mar. 31, 2018		16,377,636	295,615
Balances at end at Mar. 31, 2018	$ 25,219	$ 164	$ (1,554)	$ 28,520	$ (1,911)

XML 17 R6.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (526)	$ (1,862)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	1,174	1,100
Loss on disposal of property, plant and equipment	0	10
Stock-based compensation expense	375	389
Deferred tax benefit	(37)	0
Changes in operating assets and liabilities, net of effects of business acquisitions:
Accounts receivable	1,450	1,118
Inventory	101	(477)
Prepaid and other assets	14	(192)
Accounts payable and accrued liabilities	(111)	335
Deferred revenue	(317)	(239)
NET CASH PROVIDED BY OPERATING ACTIVITIES	2,123	182
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property, plant and equipment	(800)	(2,439)
Cash proceeds from sale of property, plant and equipment	10	23
Additions to intangible assets	(58)	(128)
Payments for business acquisitions, net of cash acquired	0	(7,261)
NET CASH USED IN INVESTING ACTIVITIES	(848)	(9,805)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from exercise of stock options	0	342
Proceeds from long-term debt	0	5,600
Repayments of long-term debt	(451)	(3,062)
NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES	(451)	2,880
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	824	(6,743)
CASH AND CASH EQUIVALENTS, beginning of period	4,675	12,435
CASH AND CASH EQUIVALENTS, end of period	5,499	5,692
SUPPLEMENTAL CASH FLOW DISCLOSURES:
Income taxes paid	3	0
Interest paid on long-term debt	64	91
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Issuance of common stock for acquisition	0	1,889
Issuance of common stock for lease	83	0
Unpaid consideration related to acquisitions	0	52
Transfer of equipment to inventory	166	130
Property, plant and equipment financed through accounts payable	$ 89	$ 66

XML 18 R7.htm IDEA: XBRL DOCUMENT

ORGANIZATION AND BACKGROUND	9 Months Ended
ORGANIZATION AND BACKGROUND	Mar. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION AND BACKGROUND	ORGANIZATION AND BACKGROUND Organization: The accompanying unaudited condensed consolidated financial statements include the financial transactions and accounts of Sharps Compliance Corp. and its wholly owned subsidiaries, Sharps Compliance, Inc. of Texas (dba Sharps Compliance, Inc.), Sharps e-Tools.com Inc. (“Sharps e-Tools”), Sharps Manufacturing, Inc., Sharps Environmental Services, Inc. (dba Sharps Environmental Services of Texas, Inc.), Sharps Safety, Inc., Alpha Bio/Med Services LLC, Bio-Team Mobile LLC and Citiwaste, LLC (collectively, “Sharps” or the “Company”). All significant intercompany accounts and transactions have been eliminated upon consolidation. Business: Sharps is a leading full-service national provider of comprehensive waste management services including medical, pharmaceutical and hazardous for small and medium quantity generators. The Company’s solutions include Sharps Recovery System™ (formerly Sharps Disposal by Mail System^®), TakeAway Medication Recovery System™, MedSafe^®, TakeAway Recycle System™,ComplianceTRAC^SM, SharpsTracer^®, Sharps Secure^®Needle Disposal System, Complete Needle™ Collection & Disposal System, TakeAway Environmental Return System™, Pitch-It IV™ Poles, Asset Return System and Spill Kit and Recovery System. The Company also offers its route-based pick-up service in a twenty-three (23) state region of the South, Southeast and Northeast portions of the United States.

XML 19 R8.htm IDEA: XBRL DOCUMENT

BASIS OF PRESENTATION	9 Months Ended
BASIS OF PRESENTATION	Mar. 31, 2018
BASIS OF PRESENTATION [Abstract]
BASIS OF PRESENTATION	BASIS OF PRESENTATION The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information and with instructions to Form 10-Q and, accordingly, do not include all information and footnotes required under generally accepted accounting principles in the United States of America ("GAAP") for complete financial statements. Additionally, the preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect reported amounts. In the opinion of management, these interim condensed consolidated financial statements contain all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the consolidated financial position of the Company as of March 31, 2018, the results of its operations for the three and nine months ended March 31, 2018 and 2017, cash flows for the nine months ended March 31, 2018 and 2017 and stockholders’ equity for the nine months ended March 31, 2018. The results of operations for the three and nine months ended March 31, 2018 are not necessarily indicative of the results to be expected for the entire fiscal year ending June 30, 2018. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended June 30, 2017.

XML 20 R9.htm IDEA: XBRL DOCUMENT

SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
SIGNIFICANT ACCOUNTING POLICIES	Mar. 31, 2018
Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	SIGNIFICANT ACCOUNTING POLICIES Revenue Recognition: The Company recognizes revenue when services are provided and from product sales when (i) goods are shipped or delivered, and title and risk of loss pass to the customer, (ii) the price is substantially fixed or determinable and (iii) collectability is reasonably assured except for those sales via multiple-deliverable revenue arrangements. Provisions for certain rebates, product returns and discounts to customers are accounted for as reductions in sales in the same period the related sales are recorded. Product discounts granted are based on the terms of arrangements with direct, indirect and other market participants, as well as market conditions, including prices charged by competitors. Rebates are estimated based on contractual terms, historical experience, trend analysis and projected market conditions in the various markets served. Service agreements which include a vendor managed inventory program include terms that meet the “bill and hold” criteria and as such are recognized when the order is completed, at which point title has transferred, there are no acceptance provisions and amounts are segregated in the Company’s warehouse. During the three and nine months ended March 31, 2018, the Company recorded revenue from inventory builds that are held in vendor managed inventory under these service agreements of $0.5 million and $2.4 million, respectively. During the three and nine months ended March 31, 2017, the Company recorded revenue from inventory builds that are held in vendor managed inventory under these service agreements of $0.7 million and $2.7 million, respectively. As of March 31, 2018 and June 30, 2017, $2.8 million and $2.7 million, respectively, of solutions sold through that date were held in vendor managed inventory pending fulfillment or shipment to patients of pharmaceutical manufacturers who offer these solutions to patients in an ongoing patient support program. Certain products offered by the Company have revenue producing components that are recognized over multiple delivery points (Sharps Recovery System and various other solutions like the TakeAway Medication Recovery Systems referred to as “Mailbacks” and Sharps Pump and Asset Return Systems, referred to as “Pump Returns”) and can consist of up to three separate elements, or units of measure, as follows: (1) the sale of the compliance and container system, (2) return transportation and (3) treatment service. In accordance with the relative selling price methodology, an estimated selling price is determined for all deliverables that qualify for separate units of accounting. The actual consideration received in a multiple-deliverable arrangement is then allocated to the units based on their relative sales price. The selling price for the transportation revenue and the treatment revenue utilizes third party evidence. The Company estimates the selling price of the compliance and container system based on the product and services provided, including compliance with local, state and federal laws, adherence to stringent manufacturing and testing requirements, safety to the patient and the community, as well as storage and containment capabilities. Revenue for the sale of the compliance and container is recognized upon delivery to the customer, at which time the customer takes title and assumes risk of ownership. Transportation revenue is recognized when the customer returns the compliance and container system and the container has been received at the Company’s owned or contracted facilities. The compliance and container system is mailed or delivered by an alternative logistics provider to the Company’s owned or contracted facilities. Treatment revenue is recognized upon the destruction or conversion and proof of receipt and treatment having been performed on the container. Since the transportation element and the treatment elements are undelivered services at the point of initial sale of the compliance and container, transportation and treatment revenue is deferred until the services are performed. The current and long-term portions of deferred revenues are determined through regression analysis and historical trends. Furthermore, through regression analysis of historical data, the Company has determined that a certain percentage of all compliance and container systems sold may not be returned. Accordingly, a portion of the transportation and treatment elements are recognized at the point of sale. Income Taxes: Deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is established when it is more likely than not that some portion or all of the deferred tax assets will not be realized. The establishment of valuation allowances and development of projected annual effective tax rates requires significant judgment and is impacted by various estimates. Both positive and negative evidence, as well as the objectivity and verifiability of that evidence, is considered in determining the appropriateness of recording a valuation allowance on deferred tax assets. Under GAAP, the valuation allowance has been recorded to reduce the Company’s deferred tax assets to an amount that is more likely than not to be realized and is based upon the uncertainty of the realization of certain federal and state deferred tax assets related to net operating loss carryforwards and other tax attributes. Goodwill and Other Identifiable Intangible Assets: Finite-lived intangible assets are amortized over their respective estimated useful lives and evaluated for impairment periodically whenever events or changes in circumstances indicate that their related carrying values may not be fully recoverable. Goodwill is assessed for impairment at least annually. The Company generally performs its annual goodwill impairment analysis using a quantitative approach. The quantitative goodwill impairment test identifies the existence of potential impairment by comparing the fair value of our single reporting unit with its carrying value, including goodwill. If the fair value of a reporting unit exceeds its carrying value, the reporting unit's goodwill is considered not to be impaired. If the carrying value of a reporting unit exceeds its fair value, an impairment charge is recognized in an amount equal to that excess. The impairment charge recognized is limited to the amount of goodwill present in our single reporting unit. These estimates and assumptions could have a significant impact on whether or not an impairment charge is recognized and the amount of any such charge. The Company performs its annual impairment assessment of goodwill during the fourth quarter of each fiscal year. The Company determined that there was no impairment during the prior year ended June 30, 2017 and there have been no triggering events since that date that would warrant further impairment testing. Accounts Receivable: Accounts receivable consist primarily of amounts due to the Company from normal business activities. Accounts receivable balances are determined to be delinquent when the amount is past due based on the contractual terms with the customer. The Company maintains an allowance for doubtful accounts to reflect the likelihood of not collecting certain accounts receivable based on past collection history and specific risks identified among uncollected accounts. Accounts receivable are charged to the allowance for doubtful accounts when the Company determines that the receivable will not be collected and/or when the account has been referred to a third party collection agency. The Company has a history of minimal uncollectible accounts. Stock-Based Compensation: Stock-based compensation cost for options and restricted stock awarded to employees and directors is measured at the grant date, based on the calculated fair value of the award and is recognized as an expense over the requisite service period (generally the vesting period of the equity grant). Fair Value of Financial Instruments: The Company considers the fair value of all financial instruments, including cash and cash equivalents, accounts receivable and accounts payable to approximate their carrying values at March 31, 2018 and June 30, 2017 due to their short-term nature. The carrying value of the Company’s debt approximates fair value due to the market rates of interest.

XML 21 R10.htm IDEA: XBRL DOCUMENT

RECENTLY ISSUED ACCOUNTING STANDARDS	9 Months Ended
RECENTLY ISSUED ACCOUNTING STANDARDS	Mar. 31, 2018
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
RECENTLY ISSUED ACCOUNTING STANDARDS	RECENTLY ISSUED ACCOUNTING STANDARDS In May 2014, and as subsequently amended, guidance for revenue recognition was issued which supersedes the revenue recognition requirements currently followed by the Company. The new guidance provides for a single five-step model to be applied in determining the amount and timing of the recognition of revenue related to contracts with customers. The new standard also requires additional financial statement disclosures that will enable users to understand the nature, amount, timing and uncertainty of revenue and cash flows relating to customer contracts. Companies have an option to use either a full retrospective approach or a modified retrospective approach to implement the standard. The guidance is effective for annual reporting periods beginning after December 15, 2017 (effective July 1, 2018 for the Company). The Company initiated a project to evaluate the impact that the new accounting guidance will have on its consolidated financial statements and related disclosures, which included identifying the material revenues streams and reviewing a representative sample of contracts. The Company is still in process of finalizing its evaluation, but has identified that for mailback and unused medication solutions, under the new guidance, the Company will recognize revenue over two performance obligations rather than the three separate elements under the current guidance. The Company is still evaluating the quantitative impact to the amount and timing of revenue recognition for the change to the identified performance obligations for the mailback solution. The Company is still evaluating the impact of the new standard on route-based pick up solution. No material changes to the amount and timing of revenue recognition over the third party treatment and other solutions are expected. The Company expects to adopt the standard using the modified retrospective approach, which involves retrospectively adopting the standard by recording a cumulative effect adjustment to all uncompleted contracts at July 1, 2018. The Company will continue to evaluate the standard as well as additional changes, modifications or interpretations which may impact the Company. In February 2016, guidance for leases was issued, which requires balance sheet recognition for rights and obligations of all leases with terms in excess of twelve months. The new guidance also requires additional disclosures about the amount, timing and uncertainty of cash flows arising from leases. The provisions of the new guidance are effective for annual periods beginning after December 15, 2018 (effective July 1, 2019 for the Company), including interim periods within the reporting period, and early application is permitted. The Company is in the initial stages of evaluating the impact of the new guidance on its consolidated financial statements and related disclosures as well as evaluating the available transition methods. The Company will continue to evaluate the standard as well as additional changes, modifications or interpretations which may impact the Company.

XML 22 R11.htm IDEA: XBRL DOCUMENT

INCOME TAXES	9 Months Ended
INCOME TAXES	Mar. 31, 2018
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES The Company’s effective tax rate for the nine months ended March 31, 2018 was (5.1)% reflecting the impact of the 2017 tax law change discussed below, net of estimated state income taxes. For the nine months ended March 31, 2018, the Company recorded a net income tax benefit of approximately $38,000, which was offset by estimated state income tax expense of $10,000. The Company’s effective tax rate for the three months ended March 31, 2018 was 4.4% due primarily to income tax expense related to the tax deductibility of goodwill amortization. No income tax expense was recorded for the nine months ended March 31, 2017 as it was not material due to the valuation allowance and net operating losses. The Tax Cuts and Jobs Act of 2017, enacted on December 22, 2017, contains significant changes to U.S. tax law, including lowering the U.S. corporate income tax rate to 21%. During the nine months ended March 31, 2018, the Company recorded a $38,000 deferred tax asset in Other Assets on the balance sheet, representing the net benefit of remeasuring its deferred tax assets for recoverable alternative minimum tax credits offset by deferred tax liabilities related to indefinite lived assets, such as goodwill, which cannot be used as a source of future taxable income in evaluating the need for a valuation allowance against deferred tax assets. The Company's remaining net deferred tax assets continue to be fully offset by a valuation allowance. The Company's gross deferred tax assets and the offsetting valuation allowance decreased by approximately $0.8 million as a result of the reduction of the U.S. tax rate to 21%.

XML 23 R12.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE AND LONG-TERM DEBT

9 Months Ended

Mar. 31, 2018

Debt Disclosure [Abstract]

NOTES PAYABLE AND LONG-TERM DEBT

At March 31, 2018, long-term debt consisted of the following (in thousands):



Non-interest bearing, unsecured note payable assumed in acquisition, monthly payments of $7; maturing September 2018.	$	41

Term loan, bearing interest at 4.25%, monthly payments of $43; maturing March 2022.	2,111

Total long-term debt	2,152
Less: current portion	558
Long-term debt, net of current portion	$	1,594

Payments due on long-term debt during each of the five years subsequent to March 31, 2018 are as follows (in thousands):



Twelve Months Ending March 31,
2019	$	558
2020	517
2021	517
2022	517
2023	43
	$	2,152

XML 24 R13.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION

9 Months Ended

Mar. 31, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

STOCK-BASED COMPENSATION



	Three-Months Ended March 31,				Nine-Months Ended March 31,
	2018		2017		2018		2017
Stock-based compensation expense included in:
Cost of revenues	$	6	$	8	$	33	$	33
Selling, general and administrative	108		108		342		356
Total	$	114	$	116	$	375	$	389

XML 25 R14.htm IDEA: XBRL DOCUMENT

EARNINGS PER SHARE

9 Months Ended

Mar. 31, 2018

Earnings Per Share [Abstract]

EARNINGS PER SHARE

The following information is necessary to calculate earnings per share for the periods presented (in thousands, except per-share data):



	Three-Months Ended March 31,						Nine-Months Ended March 31,
	2018			2017			2018			2017
Net loss, as reported	$	(757	)	$	(668	)	$	(526	)	$	(1,862	)

Weighted average common shares outstanding	16,082			15,994			16,046			15,930
Effect of dilutive stock options	—			—			—			—
Weighted average diluted common shares outstanding	16,082			15,994			16,046			15,930

Net loss per common share
Basic and diluted	$	(0.05	)	$	(0.04	)	$	(0.03	)	$	(0.12	)

Employee stock options excluded from computation of dilutive loss per share amounts because their effect would be anti-dilutive	401			269			401			304

XML 26 R15.htm IDEA: XBRL DOCUMENT

EQUITY TRANSACTIONS

9 Months Ended

Mar. 31, 2018

Stockholders' Equity Note [Abstract]

EQUITY TRANSACTIONS

During the three and nine months ended March 31, 2018 and 2017, stock options to purchase shares of the Company’s common stock were exercised as follows:



	Three-Months Ended March 31,				Nine-Months Ended March 31,
	2018		2017		2018		2017
Options Exercised	—		19,300		—		95,050
Proceeds (in thousands)	$	—	$	84	$	—	$	342
Average exercise price per share	$	—	$	4.34	$	—	$	3.60

As of March 31, 2018, there was $0.4 million of stock compensation expense related to non-vested awards which is expected to be recognized over a weighted average period of 2.2 years.

XML 27 R16.htm IDEA: XBRL DOCUMENT

GOODWILL AND INTANGIBLE ASSETS

9 Months Ended

Mar. 31, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

GOODWILL AND INTANGIBLE ASSETS

At March 31, 2018 and June 30, 2017, intangible assets consisted of the following (in thousands):



		March 31, 2018							June 30, 2017
	Estimated Useful Lives	Original Amount		Accumulated Amortization			Net Amount		Original Amount		Accumulated Amortization			Net Amount
Customer relationships	7 years	$	3,007	$	(811	)	$	2,196	$	3,007	$	(490	)	$	2,517
Permits	6 - 15 years	1,430		(365		)	1,065		1,373		(288		)	1,085
Patents	5 - 17 years	383		(274		)	109		383		(264		)	119
Trade name	7 years	270		(68		)	202		270		(39		)	231
Non-compete	5 years	117		(41		)	76		117		(23		)	94
Total intangible assets, net		$	5,207	$	(1,559	)	$	3,648	$	5,150	$	(1,104	)	$	4,046

During both the nine months ended March 31, 2018 and 2017, amortization expense was $0.5 million. There have been no changes in the carrying amount of goodwill since June 30, 2017.

As of March 31, 2018, future amortization of intangible assets is as follows (in thousands):



Twelve Months Ending March 31,
2019	$	606
2020	606
2021	606
2022	586
2023	540
Thereafter	704
	$	3,648

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

XML 28 R17.htm IDEA: XBRL DOCUMENT

INVENTORY

9 Months Ended

Mar. 31, 2018

Inventory Disclosure [Abstract]

INVENTORY

The components of inventory are as follows (in thousands):



	March 31, 2018		June 30, 2017
Raw materials	$	1,374	$	1,272
Finished goods	2,789		2,826
Total	$	4,163	$	4,098

XML 29 R18.htm IDEA: XBRL DOCUMENT

REVENUES BY SOLUTION

9 Months Ended

Mar. 31, 2018

Segment Reporting [Abstract]

REVENUES BY SOLUTION

The components of revenues by solution are as follows (in thousands):



	Three-Months Ended March 31,
	2018		% Total		2017		% Total
REVENUES BY SOLUTION:
Mailbacks	$	4,602	48.8	%	$	4,997	58.2	%
Route-based pickup services	1,888		20.0	%	1,641		19.1	%
Unused medications	1,832		19.4	%	867		10.1	%
Third party treatment services	44		0.5	%	149		1.7	%
Other ⁽¹⁾	1,061		11.3	%	934		10.9	%
Total revenues	$	9,427	100.0	%	$	8,588	100.0	%


	Nine-Months Ended March 31,
	2018		% Total		2017		% Total
REVENUES BY SOLUTION:
Mailbacks	$	16,618	55.0	%	$	17,661	63.5	%
Route-based pickup services	5,479		18.1	%	4,686		16.8	%
Unused medications	4,321		14.3	%	2,400		8.6	%
Third party treatment services	815		2.7	%	291		1.0	%
Other ⁽¹⁾	2,996		9.9	%	2,788		10.1	%
Total revenues	$	30,229	100.0	%	$	27,826	100.0	%


(1)	The Company’s other products include non-mailback products such as IV poles, accessories, containers, asset return boxes and other miscellaneous items.

XML 30 R19.htm IDEA: XBRL DOCUMENT

SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
SIGNIFICANT ACCOUNTING POLICIES (Policies)	Mar. 31, 2018
Accounting Policies [Abstract]
Revenue Recognition	Revenue Recognition: The Company recognizes revenue when services are provided and from product sales when (i) goods are shipped or delivered, and title and risk of loss pass to the customer, (ii) the price is substantially fixed or determinable and (iii) collectability is reasonably assured except for those sales via multiple-deliverable revenue arrangements. Provisions for certain rebates, product returns and discounts to customers are accounted for as reductions in sales in the same period the related sales are recorded. Product discounts granted are based on the terms of arrangements with direct, indirect and other market participants, as well as market conditions, including prices charged by competitors. Rebates are estimated based on contractual terms, historical experience, trend analysis and projected market conditions in the various markets served. Service agreements which include a vendor managed inventory program include terms that meet the “bill and hold” criteria and as such are recognized when the order is completed, at which point title has transferred, there are no acceptance provisions and amounts are segregated in the Company’s warehouse. During the three and nine months ended March 31, 2018, the Company recorded revenue from inventory builds that are held in vendor managed inventory under these service agreements of $0.5 million and $2.4 million, respectively. During the three and nine months ended March 31, 2017, the Company recorded revenue from inventory builds that are held in vendor managed inventory under these service agreements of $0.7 million and $2.7 million, respectively. As of March 31, 2018 and June 30, 2017, $2.8 million and $2.7 million, respectively, of solutions sold through that date were held in vendor managed inventory pending fulfillment or shipment to patients of pharmaceutical manufacturers who offer these solutions to patients in an ongoing patient support program. Certain products offered by the Company have revenue producing components that are recognized over multiple delivery points (Sharps Recovery System and various other solutions like the TakeAway Medication Recovery Systems referred to as “Mailbacks” and Sharps Pump and Asset Return Systems, referred to as “Pump Returns”) and can consist of up to three separate elements, or units of measure, as follows: (1) the sale of the compliance and container system, (2) return transportation and (3) treatment service. In accordance with the relative selling price methodology, an estimated selling price is determined for all deliverables that qualify for separate units of accounting. The actual consideration received in a multiple-deliverable arrangement is then allocated to the units based on their relative sales price. The selling price for the transportation revenue and the treatment revenue utilizes third party evidence. The Company estimates the selling price of the compliance and container system based on the product and services provided, including compliance with local, state and federal laws, adherence to stringent manufacturing and testing requirements, safety to the patient and the community, as well as storage and containment capabilities. Revenue for the sale of the compliance and container is recognized upon delivery to the customer, at which time the customer takes title and assumes risk of ownership. Transportation revenue is recognized when the customer returns the compliance and container system and the container has been received at the Company’s owned or contracted facilities. The compliance and container system is mailed or delivered by an alternative logistics provider to the Company’s owned or contracted facilities. Treatment revenue is recognized upon the destruction or conversion and proof of receipt and treatment having been performed on the container. Since the transportation element and the treatment elements are undelivered services at the point of initial sale of the compliance and container, transportation and treatment revenue is deferred until the services are performed. The current and long-term portions of deferred revenues are determined through regression analysis and historical trends. Furthermore, through regression analysis of historical data, the Company has determined that a certain percentage of all compliance and container systems sold may not be returned. Accordingly, a portion of the transportation and treatment elements are recognized at the point of sale.
Income Taxes	Income Taxes: Deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is established when it is more likely than not that some portion or all of the deferred tax assets will not be realized. The establishment of valuation allowances and development of projected annual effective tax rates requires significant judgment and is impacted by various estimates. Both positive and negative evidence, as well as the objectivity and verifiability of that evidence, is considered in determining the appropriateness of recording a valuation allowance on deferred tax assets. Under GAAP, the valuation allowance has been recorded to reduce the Company’s deferred tax assets to an amount that is more likely than not to be realized and is based upon the uncertainty of the realization of certain federal and state deferred tax assets related to net operating loss carryforwards and other tax attributes.
Goodwill and Other Identifiable Intangible Assets	Goodwill and Other Identifiable Intangible Assets: Finite-lived intangible assets are amortized over their respective estimated useful lives and evaluated for impairment periodically whenever events or changes in circumstances indicate that their related carrying values may not be fully recoverable. Goodwill is assessed for impairment at least annually. The Company generally performs its annual goodwill impairment analysis using a quantitative approach. The quantitative goodwill impairment test identifies the existence of potential impairment by comparing the fair value of our single reporting unit with its carrying value, including goodwill. If the fair value of a reporting unit exceeds its carrying value, the reporting unit's goodwill is considered not to be impaired. If the carrying value of a reporting unit exceeds its fair value, an impairment charge is recognized in an amount equal to that excess. The impairment charge recognized is limited to the amount of goodwill present in our single reporting unit. These estimates and assumptions could have a significant impact on whether or not an impairment charge is recognized and the amount of any such charge. The Company performs its annual impairment assessment of goodwill during the fourth quarter of each fiscal year.
Accounts Receivable	Accounts Receivable: Accounts receivable consist primarily of amounts due to the Company from normal business activities. Accounts receivable balances are determined to be delinquent when the amount is past due based on the contractual terms with the customer. The Company maintains an allowance for doubtful accounts to reflect the likelihood of not collecting certain accounts receivable based on past collection history and specific risks identified among uncollected accounts. Accounts receivable are charged to the allowance for doubtful accounts when the Company determines that the receivable will not be collected and/or when the account has been referred to a third party collection agency. The Company has a history of minimal uncollectible accounts.
Stock-Based Compensation	Stock-Based Compensation: Stock-based compensation cost for options and restricted stock awarded to employees and directors is measured at the grant date, based on the calculated fair value of the award and is recognized as an expense over the requisite service period (generally the vesting period of the equity grant).
Fair Value of Financial Instruments	Fair Value of Financial Instruments: The Company considers the fair value of all financial instruments, including cash and cash equivalents, accounts receivable and accounts payable to approximate their carrying values at March 31, 2018 and June 30, 2017 due to their short-term nature. The carrying value of the Company’s debt approximates fair value due to the market rates of interest.
New Accounting Pronouncement	In February 2016, guidance for leases was issued, which requires balance sheet recognition for rights and obligations of all leases with terms in excess of twelve months. The new guidance also requires additional disclosures about the amount, timing and uncertainty of cash flows arising from leases. The provisions of the new guidance are effective for annual periods beginning after December 15, 2018 (effective July 1, 2019 for the Company), including interim periods within the reporting period, and early application is permitted. The Company is in the initial stages of evaluating the impact of the new guidance on its consolidated financial statements and related disclosures as well as evaluating the available transition methods. The Company will continue to evaluate the standard as well as additional changes, modifications or interpretations which may impact the Company.

- Definition

Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.

+ References + Details

- Definition

Disclosure of accounting policy for trade and other accounts receivable, and finance, loan and lease receivables, including those classified as held for investment and held for sale. This disclosure may include (1) the basis at which such receivables are carried in the entity's statements of financial position (2) how the level of the valuation allowance for receivables is determined (3) when impairments, charge-offs or recoveries are recognized for such receivables (4) the treatment of origination fees and costs, including the amortization method for net deferred fees or costs (5) the treatment of any premiums or discounts or unearned income (6) the entity's income recognition policies for such receivables, including those that are impaired, past due or placed on nonaccrual status and (7) the treatment of foreclosures or repossessions (8) the nature and amount of any guarantees to repurchase receivables.

+ References + Details

XML 31 R20.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE AND LONG-TERM DEBT (Tables)

9 Months Ended

Mar. 31, 2018

Debt Disclosure [Abstract]

Schedule of long-term debt

At March 31, 2018, long-term debt consisted of the following (in thousands):



Non-interest bearing, unsecured note payable assumed in acquisition, monthly payments of $7; maturing September 2018.	$	41

Term loan, bearing interest at 4.25%, monthly payments of $43; maturing March 2022.	2,111

Total long-term debt	2,152
Less: current portion	558
Long-term debt, net of current portion	$	1,594

Schedule of payments due on long-term debt

Payments due on long-term debt during each of the five years subsequent to March 31, 2018 are as follows (in thousands):



Twelve Months Ending March 31,
2019	$	558
2020	517
2021	517
2022	517
2023	43
	$	2,152

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21475-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=64930739&loc=d3e28878-108400

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21538-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28541-108399

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=64930785&loc=d3e28551-108399

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21521-112644

+ Details

XML 32 R21.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION (Tables)

9 Months Ended

Mar. 31, 2018

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Stock-Based Compensation

During the three and nine months ended March 31, 2018 and 2017, stock-based compensation amounts are as follows (in thousands):



	Three-Months Ended March 31,				Nine-Months Ended March 31,
	2018		2017		2018		2017
Stock-based compensation expense included in:
Cost of revenues	$	6	$	8	$	33	$	33
Selling, general and administrative	108		108		342		356
Total	$	114	$	116	$	375	$	389

XML 33 R22.htm IDEA: XBRL DOCUMENT

EARNINGS PER SHARE (Tables)

9 Months Ended

Mar. 31, 2018

Earnings Per Share [Abstract]

Schedule of Earnings Per Share

The following information is necessary to calculate earnings per share for the periods presented (in thousands, except per-share data):



	Three-Months Ended March 31,						Nine-Months Ended March 31,
	2018			2017			2018			2017
Net loss, as reported	$	(757	)	$	(668	)	$	(526	)	$	(1,862	)

Weighted average common shares outstanding	16,082			15,994			16,046			15,930
Effect of dilutive stock options	—			—			—			—
Weighted average diluted common shares outstanding	16,082			15,994			16,046			15,930

Net loss per common share
Basic and diluted	$	(0.05	)	$	(0.04	)	$	(0.03	)	$	(0.12	)

Employee stock options excluded from computation of dilutive loss per share amounts because their effect would be anti-dilutive	401			269			401			304

XML 34 R23.htm IDEA: XBRL DOCUMENT

EQUITY TRANSACTIONS (Tables)

9 Months Ended

Mar. 31, 2018

Stockholders' Equity Note [Abstract]

Stock options exercised to purchase common stock

During the three and nine months ended March 31, 2018 and 2017, stock options to purchase shares of the Company’s common stock were exercised as follows:



	Three-Months Ended March 31,				Nine-Months Ended March 31,
	2018		2017		2018		2017
Options Exercised	—		19,300		—		95,050
Proceeds (in thousands)	$	—	$	84	$	—	$	342
Average exercise price per share	$	—	$	4.34	$	—	$	3.60

XML 35 R24.htm IDEA: XBRL DOCUMENT

GOODWILL AND INTANGIBLE ASSETS (Tables)

9 Months Ended

Mar. 31, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of intangible assets

At March 31, 2018 and June 30, 2017, intangible assets consisted of the following (in thousands):



		March 31, 2018							June 30, 2017
	Estimated Useful Lives	Original Amount		Accumulated Amortization			Net Amount		Original Amount		Accumulated Amortization			Net Amount
Customer relationships	7 years	$	3,007	$	(811	)	$	2,196	$	3,007	$	(490	)	$	2,517
Permits	6 - 15 years	1,430		(365		)	1,065		1,373		(288		)	1,085
Patents	5 - 17 years	383		(274		)	109		383		(264		)	119
Trade name	7 years	270		(68		)	202		270		(39		)	231
Non-compete	5 years	117		(41		)	76		117		(23		)	94
Total intangible assets, net		$	5,207	$	(1,559	)	$	3,648	$	5,150	$	(1,104	)	$	4,046

Schedule of future amortization of intangible assets

As of March 31, 2018, future amortization of intangible assets is as follows (in thousands):



Twelve Months Ending March 31,
2019	$	606
2020	606
2021	606
2022	586
2023	540
Thereafter	704
	$	3,648

XML 36 R25.htm IDEA: XBRL DOCUMENT

INVENTORY (Tables)

9 Months Ended

Mar. 31, 2018

Inventory Disclosure [Abstract]

Schedule of Inventory

The components of inventory are as follows (in thousands):



	March 31, 2018		June 30, 2017
Raw materials	$	1,374	$	1,272
Finished goods	2,789		2,826
Total	$	4,163	$	4,098

XML 37 R26.htm IDEA: XBRL DOCUMENT

REVENUES BY SOLUTION (Tables)

9 Months Ended

Mar. 31, 2018

Segment Reporting [Abstract]

Schedule of billings by solution

The components of revenues by solution are as follows (in thousands):



	Three-Months Ended March 31,
	2018		% Total		2017		% Total
REVENUES BY SOLUTION:
Mailbacks	$	4,602	48.8	%	$	4,997	58.2	%
Route-based pickup services	1,888		20.0	%	1,641		19.1	%
Unused medications	1,832		19.4	%	867		10.1	%
Third party treatment services	44		0.5	%	149		1.7	%
Other ⁽¹⁾	1,061		11.3	%	934		10.9	%
Total revenues	$	9,427	100.0	%	$	8,588	100.0	%


	Nine-Months Ended March 31,
	2018		% Total		2017		% Total
REVENUES BY SOLUTION:
Mailbacks	$	16,618	55.0	%	$	17,661	63.5	%
Route-based pickup services	5,479		18.1	%	4,686		16.8	%
Unused medications	4,321		14.3	%	2,400		8.6	%
Third party treatment services	815		2.7	%	291		1.0	%
Other ⁽¹⁾	2,996		9.9	%	2,788		10.1	%
Total revenues	$	30,229	100.0	%	$	27,826	100.0	%


(1)	The Company’s other products include non-mailback products such as IV poles, accessories, containers, asset return boxes and other miscellaneous items.

XML 38 R27.htm IDEA: XBRL DOCUMENT

ORGANIZATION AND BACKGROUND (Details)	9 Months Ended
ORGANIZATION AND BACKGROUND (Details)	Mar. 31, 2018 state_region
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of route-based pick-up service in state region	23

XML 39 R28.htm IDEA: XBRL DOCUMENT

SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2018	Mar. 31, 2017	Jun. 30, 2017
Revenue Recognition [Abstract]
Revenue recorded from inventory builds	$ 0.5	$ 0.7	$ 2.4	$ 2.7
Solutions sold that were held in vendor managed inventory	$ 2.8		$ 2.8		$ 2.7

XML 40 R29.htm IDEA: XBRL DOCUMENT

INCOME TAXES (Details) - USD ($)	3 Months Ended		9 Months Ended
INCOME TAXES (Details) - USD ($)	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2018	Mar. 31, 2017
Income Tax Disclosure [Abstract]
Effective income tax rate	4.40%		(5.10%)
Income tax benefit			$ 38,000
State income tax expense			10,000
Income tax expense	$ 32,000	$ 0	(28,000)	$ 0
Decrease of deferred tax assets and offsetting valuation allowance			$ 800,000

XML 41 R30.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE AND LONG-TERM DEBT - Narrative (Details)	Mar. 29, 2017 USD ($)	Mar. 31, 2018 USD ($)
Line of Credit Facility [Line Items]
Borrowings outstanding		$ 2,152,000
Performance bonds
Line of Credit Facility [Line Items]
Performance bonds outstanding, financial assurance		600,000.0
Unsecured Note Payable
Line of Credit Facility [Line Items]
Borrowings outstanding		41,000
Term Loan
Line of Credit Facility [Line Items]
Borrowings outstanding		$ 2,111,000
Maturity period	5 years
Interest rate		4.25%
Credit Agreement
Line of Credit Facility [Line Items]
Maximum borrowing capacity	$ 14,000,000.0
Percentage of eligible accounts receivable considered for borrowing base	80.00%
Percentage of eligible inventory considered for borrowing base	50.00%
Borrowing base, monetary benchmark	$ 3,000,000
Basis spread of variable rate	0.00%
Unused capacity, commitment fee percentage	0.25%
Remaining borrowing capacity		$ 11,800,000
Credit Agreement \| Minimum
Line of Credit Facility [Line Items]
Debt service coverage ratio	1.15
Credit Agreement \| Maximum
Line of Credit Facility [Line Items]
Debt cash flow leverage ratio	3.0
Credit Agreement \| Working Capital
Line of Credit Facility [Line Items]
Maximum borrowing capacity	$ 6,000,000.0
Remaining borrowing capacity		6,000,000
Credit Agreement \| Letter of Credit
Line of Credit Facility [Line Items]
Maximum borrowing capacity	2,000,000.0
Amount outstanding		40,000
Credit Agreement \| Acquisitions
Line of Credit Facility [Line Items]
Maximum borrowing capacity	$ 8,000,000.0
Percentage of portion allocated to acquisition purchase price	75.00%
Remaining borrowing capacity		$ 5,800,000
Credit Agreement \| LIBOR
Line of Credit Facility [Line Items]
Basis spread of variable rate	2.50%
Debt instrument, term of variable rate	1 month
Credit Agreement \| LIBOR \| Maximum
Line of Credit Facility [Line Items]
Basis spread of variable rate	3.00%

XML 42 R31.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE AND LONG-TERM DEBT - Schedule of debt instruments (Details) - USD ($) $ in Thousands	9 Months Ended
	Mar. 31, 2018	Jun. 30, 2017
Long-term Debt, Unclassified [Abstract]
Total long-term debt	$ 2,152
Less: current portion	558	$ 601
Long-term debt, net of current portion	1,594	$ 2,002
Unsecured Note Payable
Long-term Debt, Unclassified [Abstract]
Monthly payments	7
Total long-term debt	41
Term Loan
Long-term Debt, Unclassified [Abstract]
Monthly payments	$ 43
Interest rate	4.25%
Total long-term debt	$ 2,111

XML 43 R32.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE AND LONG-TERM DEBT - Schedule of payments due on long-term debt (Details) $ in Thousands	Mar. 31, 2018 USD ($)
Long-term Debt, Fiscal Year Maturity [Abstract]
2019	$ 558
2020	517
2021	517
2022	517
2023	43
Total long-term debt	$ 2,152

XML 44 R33.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
STOCK-BASED COMPENSATION (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2018	Mar. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	$ 114	$ 116	$ 375	$ 389
Cost of revenues
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	6	8	33	33
Selling, general and administrative
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	$ 108	$ 108	$ 342	$ 356

XML 45 R34.htm IDEA: XBRL DOCUMENT

EARNINGS PER SHARE (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2018	Mar. 31, 2017	Jun. 30, 2017
Earnings Per Share [Abstract]
Net loss, as reported	$ (757)	$ (668)	$ (526)	$ (1,862)	$ (1,293)
Weighted average common shares outstanding (in shares)	16,082	15,994	16,046	15,930
Effect of dilutive stock options (in shares)	0	0	0	0
Weighted average diluted common shares outstanding (in shares)	16,082	15,994	16,046	15,930
Net loss per common share
Basic and Diluted (in dollars per share)	$ (0.05)	$ (0.04)	$ (0.03)	$ (0.12)
Employee stock options excluded from computation of dilutive loss per share amounts because their effect would be anti-dilutive (in shares)	401	269	401	304

XML 46 R35.htm IDEA: XBRL DOCUMENT

EQUITY TRANSACTIONS (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2018	Mar. 31, 2017
Stock options exercised [Abstract]
Options exercised (in shares)	0	19,300	0	95,050
Proceeds	$ 0	$ 84	$ 0	$ 342
Average exercise price per share (in dollars per share)	$ 0.00	$ 4.34	$ 0.00	$ 3.60
Compensation expense related to non-vested awards	$ 400		$ 400
Weighted average period			2 years 2 months 27 days
Shares of common stock issued for third-party lease agreement (in shares)	20,617
Price per share (in dollars per share)	$ 4		$ 4
Noncash expense	$ 25

XML 47 R36.htm IDEA: XBRL DOCUMENT

GOODWILL AND INTANGIBLE ASSETS (Details) - USD ($)	9 Months Ended
GOODWILL AND INTANGIBLE ASSETS (Details) - USD ($)	Mar. 31, 2018	Mar. 31, 2017	Jun. 30, 2017
Finite-Lived Intangible Assets [Line Items]
Original Amount	$ 5,207,000		$ 5,150,000
Accumulated Amortization	(1,559,000)		(1,104,000)
Net Amount	3,648,000		4,046,000
Intangible assets, amortization expense	500,000	$ 500,000
Changes in goodwill	0
Future amortization of intangible assets [Abstract]
2019	606,000
2020	606,000
2021	606,000
2022	586,000
2023	540,000
Thereafter	704,000
Net Amount	$ 3,648,000		4,046,000
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Lives	7 years
Original Amount	$ 3,007,000		3,007,000
Accumulated Amortization	(811,000)		(490,000)
Net Amount	2,196,000		2,517,000
Future amortization of intangible assets [Abstract]
Net Amount	2,196,000		2,517,000
Permits
Finite-Lived Intangible Assets [Line Items]
Original Amount	1,430,000		1,373,000
Accumulated Amortization	(365,000)		(288,000)
Net Amount	1,065,000		1,085,000
Future amortization of intangible assets [Abstract]
Net Amount	$ 1,065,000		1,085,000
Permits \| Minimum
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Lives	6 years
Permits \| Maximum
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Lives	15 years
Patents
Finite-Lived Intangible Assets [Line Items]
Original Amount	$ 383,000		383,000
Accumulated Amortization	(274,000)		(264,000)
Net Amount	109,000		119,000
Future amortization of intangible assets [Abstract]
Net Amount	$ 109,000		119,000
Patents \| Minimum
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Lives	5 years
Patents \| Maximum
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Lives	17 years
Trade name
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Lives	7 years
Original Amount	$ 270,000		270,000
Accumulated Amortization	(68,000)		(39,000)
Net Amount	202,000		231,000
Future amortization of intangible assets [Abstract]
Net Amount	$ 202,000		231,000
Non-compete
Finite-Lived Intangible Assets [Line Items]
Estimated Useful Lives	5 years
Original Amount	$ 117,000		117,000
Accumulated Amortization	(41,000)		(23,000)
Net Amount	76,000		94,000
Future amortization of intangible assets [Abstract]
Net Amount	$ 76,000		$ 94,000

XML 48 R37.htm IDEA: XBRL DOCUMENT

INVENTORY (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Jun. 30, 2017
Components of inventory [Abstract]
Raw materials	$ 1,374	$ 1,272
Finished goods	2,789	2,826
Total	$ 4,163	$ 4,098

XML 49 R38.htm IDEA: XBRL DOCUMENT

REVENUES BY SOLUTION (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
REVENUES BY SOLUTION (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2018	Mar. 31, 2017
Segment Reporting Information [Line Items]
Revenue reported	$ 9,427	$ 8,588	$ 30,229	$ 27,826
Revenue percentage	100.00%	100.00%	100.00%	100.00%
Mailbacks
Segment Reporting Information [Line Items]
Revenue reported	$ 4,602	$ 4,997	$ 16,618	$ 17,661
Revenue percentage	48.80%	58.20%	55.00%	63.50%
Route-based pickup services
Segment Reporting Information [Line Items]
Revenue reported	$ 1,888	$ 1,641	$ 5,479	$ 4,686
Revenue percentage	20.00%	19.10%	18.10%	16.80%
Unused medications
Segment Reporting Information [Line Items]
Revenue reported	$ 1,832	$ 867	$ 4,321	$ 2,400
Revenue percentage	19.40%	10.10%	14.30%	8.60%
Third party treatment services
Segment Reporting Information [Line Items]
Revenue reported	$ 44	$ 149	$ 815	$ 291
Revenue percentage	0.50%	1.70%	2.70%	1.00%
Other
Segment Reporting Information [Line Items]
Revenue reported	$ 1,061	$ 934	$ 2,996	$ 2,788
Revenue percentage	11.30%	10.90%	9.90%	10.10%

EXCEL 50 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 52 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 54 FilingSummary.xml IDEA: XBRL DOCUMENT 3.8.0.1 html 93 173 1 false 26 0 false 5 false false R1.htm 0001000 - Document - Document and Entity Information Sheet http://www.sharpsinc.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) Sheet http://www.sharpsinc.com/role/CondensedConsolidatedBalanceSheetsUnaudited CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) Statements 2 false false R3.htm 1001501 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Sheet http://www.sharpsinc.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Statements 3 false false R4.htm 1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Sheet http://www.sharpsinc.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Statements 4 false false R5.htm 1003000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) Sheet http://www.sharpsinc.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) Statements 5 false false R6.htm 1004000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Sheet http://www.sharpsinc.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Statements 6 false false R7.htm 2101100 - Disclosure - ORGANIZATION AND BACKGROUND Sheet http://www.sharpsinc.com/role/OrganizationAndBackground ORGANIZATION AND BACKGROUND Notes 7 false false R8.htm 2102100 - Disclosure - BASIS OF PRESENTATION Sheet http://www.sharpsinc.com/role/BasisOfPresentation BASIS OF PRESENTATION Notes 8 false false R9.htm 2103100 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.sharpsinc.com/role/SignificantAccountingPolicies SIGNIFICANT ACCOUNTING POLICIES Notes 9 false false R10.htm 2104100 - Disclosure - RECENTLY ISSUED ACCOUNTING STANDARDS Sheet http://www.sharpsinc.com/role/RecentlyIssuedAccountingStandards RECENTLY ISSUED ACCOUNTING STANDARDS Notes 10 false false R11.htm 2105100 - Disclosure - INCOME TAXES Sheet http://www.sharpsinc.com/role/IncomeTaxes INCOME TAXES Notes 11 false false R12.htm 2106100 - Disclosure - NOTES PAYABLE AND LONG-TERM DEBT Notes http://www.sharpsinc.com/role/NotesPayableAndLongTermDebt NOTES PAYABLE AND LONG-TERM DEBT Notes 12 false false R13.htm 2107100 - Disclosure - STOCK-BASED COMPENSATION Sheet http://www.sharpsinc.com/role/StockBasedCompensation STOCK-BASED COMPENSATION Notes 13 false false R14.htm 2108100 - Disclosure - EARNINGS PER SHARE Sheet http://www.sharpsinc.com/role/EarningsPerShare EARNINGS PER SHARE Notes 14 false false R15.htm 2109100 - Disclosure - EQUITY TRANSACTIONS Sheet http://www.sharpsinc.com/role/EquityTransactions EQUITY TRANSACTIONS Notes 15 false false R16.htm 2110100 - Disclosure - GOODWILL AND INTANGIBLE ASSETS Sheet http://www.sharpsinc.com/role/GoodwillAndIntangibleAssets GOODWILL AND INTANGIBLE ASSETS Notes 16 false false R17.htm 2111100 - Disclosure - INVENTORY Sheet http://www.sharpsinc.com/role/Inventory INVENTORY Notes 17 false false R18.htm 2112100 - Disclosure - REVENUES BY SOLUTION Sheet http://www.sharpsinc.com/role/RevenuesBySolution REVENUES BY SOLUTION Notes 18 false false R19.htm 2203201 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.sharpsinc.com/role/SignificantAccountingPoliciesPolicies SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 19 false false R20.htm 2306301 - Disclosure - NOTES PAYABLE AND LONG-TERM DEBT (Tables) Notes http://www.sharpsinc.com/role/NotesPayableAndLongTermDebtTables NOTES PAYABLE AND LONG-TERM DEBT (Tables) Tables http://www.sharpsinc.com/role/NotesPayableAndLongTermDebt 20 false false R21.htm 2307301 - Disclosure - STOCK-BASED COMPENSATION (Tables) Sheet http://www.sharpsinc.com/role/StockBasedCompensationTables STOCK-BASED COMPENSATION (Tables) Tables http://www.sharpsinc.com/role/StockBasedCompensation 21 false false R22.htm 2308301 - Disclosure - EARNINGS PER SHARE (Tables) Sheet http://www.sharpsinc.com/role/EarningsPerShareTables EARNINGS PER SHARE (Tables) Tables http://www.sharpsinc.com/role/EarningsPerShare 22 false false R23.htm 2309301 - Disclosure - EQUITY TRANSACTIONS (Tables) Sheet http://www.sharpsinc.com/role/EquityTransactionsTables EQUITY TRANSACTIONS (Tables) Tables http://www.sharpsinc.com/role/EquityTransactions 23 false false R24.htm 2310301 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables) Sheet http://www.sharpsinc.com/role/GoodwillAndIntangibleAssetsTables GOODWILL AND INTANGIBLE ASSETS (Tables) Tables http://www.sharpsinc.com/role/GoodwillAndIntangibleAssets 24 false false R25.htm 2311301 - Disclosure - INVENTORY (Tables) Sheet http://www.sharpsinc.com/role/InventoryTables INVENTORY (Tables) Tables http://www.sharpsinc.com/role/Inventory 25 false false R26.htm 2312301 - Disclosure - REVENUES BY SOLUTION (Tables) Sheet http://www.sharpsinc.com/role/RevenuesBySolutionTables REVENUES BY SOLUTION (Tables) Tables http://www.sharpsinc.com/role/RevenuesBySolution 26 false false R27.htm 2401401 - Disclosure - ORGANIZATION AND BACKGROUND (Details) Sheet http://www.sharpsinc.com/role/OrganizationAndBackgroundDetails ORGANIZATION AND BACKGROUND (Details) Details http://www.sharpsinc.com/role/OrganizationAndBackground 27 false false R28.htm 2403402 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details) Sheet http://www.sharpsinc.com/role/SignificantAccountingPoliciesDetails SIGNIFICANT ACCOUNTING POLICIES (Details) Details http://www.sharpsinc.com/role/SignificantAccountingPoliciesPolicies 28 false false R29.htm 2405401 - Disclosure - INCOME TAXES (Details) Sheet http://www.sharpsinc.com/role/IncomeTaxesDetails INCOME TAXES (Details) Details http://www.sharpsinc.com/role/IncomeTaxes 29 false false R30.htm 2406402 - Disclosure - NOTES PAYABLE AND LONG-TERM DEBT - Narrative (Details) Notes http://www.sharpsinc.com/role/NotesPayableAndLongTermDebtNarrativeDetails NOTES PAYABLE AND LONG-TERM DEBT - Narrative (Details) Details 30 false false R31.htm 2406403 - Disclosure - NOTES PAYABLE AND LONG-TERM DEBT - Schedule of debt instruments (Details) Notes http://www.sharpsinc.com/role/NotesPayableAndLongTermDebtScheduleOfDebtInstrumentsDetails NOTES PAYABLE AND LONG-TERM DEBT - Schedule of debt instruments (Details) Details 31 false false R32.htm 2406404 - Disclosure - NOTES PAYABLE AND LONG-TERM DEBT - Schedule of payments due on long-term debt (Details) Notes http://www.sharpsinc.com/role/NotesPayableAndLongTermDebtScheduleOfPaymentsDueOnLongTermDebtDetails NOTES PAYABLE AND LONG-TERM DEBT - Schedule of payments due on long-term debt (Details) Details 32 false false R33.htm 2407402 - Disclosure - STOCK-BASED COMPENSATION (Details) Sheet http://www.sharpsinc.com/role/StockBasedCompensationDetails STOCK-BASED COMPENSATION (Details) Details http://www.sharpsinc.com/role/StockBasedCompensationTables 33 false false R34.htm 2408402 - Disclosure - EARNINGS PER SHARE (Details) Sheet http://www.sharpsinc.com/role/EarningsPerShareDetails EARNINGS PER SHARE (Details) Details http://www.sharpsinc.com/role/EarningsPerShareTables 34 false false R35.htm 2409402 - Disclosure - EQUITY TRANSACTIONS (Details) Sheet http://www.sharpsinc.com/role/EquityTransactionsDetails EQUITY TRANSACTIONS (Details) Details http://www.sharpsinc.com/role/EquityTransactionsTables 35 false false R36.htm 2410402 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Details) Sheet http://www.sharpsinc.com/role/GoodwillAndIntangibleAssetsDetails GOODWILL AND INTANGIBLE ASSETS (Details) Details http://www.sharpsinc.com/role/GoodwillAndIntangibleAssetsTables 36 false false R37.htm 2411402 - Disclosure - INVENTORY (Details) Sheet http://www.sharpsinc.com/role/InventoryDetails INVENTORY (Details) Details http://www.sharpsinc.com/role/InventoryTables 37 false false R38.htm 2412402 - Disclosure - REVENUES BY SOLUTION (Details) Sheet http://www.sharpsinc.com/role/RevenuesBySolutionDetails REVENUES BY SOLUTION (Details) Details http://www.sharpsinc.com/role/RevenuesBySolutionTables 38 false false All Reports Book All Reports smed-20180331.xml smed-20180331.xsd smed-20180331_cal.xml smed-20180331_def.xml smed-20180331_lab.xml smed-20180331_pre.xml http://fasb.org/us-gaap/2017-01-31 http://xbrl.sec.gov/dei/2014-01-31 true true ZIP 56 0000898770-18-000019-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000898770-18-000019-xbrl.zip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�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
D-!HC=0/:8WG7G&BE[T[*=Y#40[U M;HZ^>9$'QLTB*).IX$1#-Z=01F[! *#BAY%@A Y,-H%/^--Y_[C9)8LRN8+ M/&L8JPW:J^Z)Z(^JO6>.4IO1VU" .VBO_LMP%TX&B'%GG-:^P%\4X]_6Y>TN M9\[RE\GG:2X6BWRYT)/%:%HL5GL1ND(02\Q@JJ32#$F",TUIJC6SEIN,U+W% M'F0T8]K-IS.%L@*\A^0)_L>OBPA!IX5S\&^_4$]=S$A\GJ/N=KO!]*P&]([*\EZ,2C M3DK8)];7!L0>4-F8S=0/K8WJX5)#"@@C*J=0H,V)0J!\MBITR:I0Z8%92Y_TO'IY8G5.J' M$O*S7 ,="OAIFC%,V7O7@K$D_R)9>_,L\T%U0KXWXT$7S5%CH#AIJ_=K!#FM MZ^\,+6?@_]B8LRY(/UQ,RASQ^2)WJ,K\$=NIA0%<4(H 99@0:'2:9J7P<&B@ M(L>NR1Q]/LTX-DH@E&)+N51< "VE(91P:2 *2D4;)B)2W%W>)=JS_K!Y'/(-4E],5K]D(P/7XO@PS@C0@>\^@-0>N, MA/.*4W=N%!V_'&&!JEPM)K-\L=#Y8C2?/&WRSKR!8T^]I,J 3(U(H>(T+*GRRZ%U*.I:]([W,F*PW>TK:RS M*6L8F6UWL\);I1^*&LNY)OM933FLGV3U\_(M:RD05E&K$3 N5+*<<0LWBVM MR8R&)EA]VPH QJ_5:6?)4@*0Q!0136&*B-!*!54F:G02\^KZWMPE-^+OHE1% M)Y*?KJ\^?K@WMS\GVLC =/2-R:PGA:=@,4SS/*)^*-L[W!R0L+9L]D.K6GOQ M*F%J%ZR$9 >;.?I^O+&!GRH F+294HHQG&;::EXM[P.-ZYZ'.V2"I0PQ B@1 M*:',(A>9 .J4E:!4 ZFC7D+>H.K#$9<#%!WH/UT0VX\^U(DG;Z2]ZH:=\*,I M6]MJ-9^[KUZLED-H,LO<[$N+E'*.-&*LZE@2@;"B$76- 4P !PX)*FPHN M)7$=VR(-N$YCEU?;WQW;(FUZ^*0MOZ$G3DY(;?,]QRW(BV0#LS=;B<<8K'6> MI*-&Z(?B=>_6NR='.N6MMA9.OLPF#Y/1<+84HU&Q\AD,OMP4T\EHDB]VQI%A MC!ANB<8. TDEA[;JJ0)J'#;)J6DTM2DSU#B- $X>4C^3RXS* .,@128-.FG? M:,YS=_GQZM)>*G%UGPBEKG^Y*J^:W5Q_NE27H6ENNF*ZIB:>GN) 1=P!3'8( MDPKB&2=(]:@[)(7=S8J9\,Y\$7B0%XD)5S_ MY;KR:8DXV8-\_OEQ34[K3)J[;IY^R&D\]]Z;7L?A,5AB;X>__3QT5B?#Z3,H MBX&$)#52PE0!9H6+:Z'D5;_V)]4:B>K[YA! 64:Q=4,*I48SG@I)("(04D)< MY!591AVPY+%"UE Q6W 9J)&GH;&Q*GHRM_@N7BCC^^S&UNT)[YG. M=>#0>\K6%5?!6N8/Y"[<]-WO3[ZP+*25U,W@8"K\U3HDE,ZJ#LBM"*H[5,=> MJI!1AJ09URE-&9"440JA234BDO"@G:T&:E8A2[YX: WEK V=@7IV(B8;"]J6 MSQ)@7Q3M?=;J2%H'G/=,T[KPZ#U1ZXRM)I-@%S\8YCJ9)18(PK V5&SCAQ1Q M$980>^_!@&H"742).2"4NN)A9V@;Y/3W?W*^.5'-^4YMEGK6 M'X*@'YBG!/H?7UA')Y?0 8Y,H*#0$ 1F!((:/5@1. $0X9I]]Z MOANQC 78",XD3;.,2TLP(!ETSS<9.N5%Q4_%[,L']XS'I#R,LD-:76T.7+AI M1&>]<3HVD\TW[UJ0&.TTSPNFCISD:\:0!J8(DQF22IIEP:"83*+,2< M""8USR)KS_.NJG;;HXG$XF0V(M<@O^U&K.4!89PAO^P>2(&B+ZAT3&66IFWQGF5*: M"N \8 *H+"/N"\Y56'VNKO1EC:VEPM3EL)G&1*"O"Y4YQMQ)=&8-(D!I LGL MI]:$.G%$;1IQ4E=O?IDM\M%JGH^]M9]SGS!P *'6D (BE6%"$7]PA6V/[2L8 MM'7SUO-37\.!.LA:IM1RR5V/A)8[/;668Q;[;M@64G)5+//D9OC#QXIA$M.( MMGKZ$INQ,''9D57.D'Y= SJQK+Q!R0%-:4-@/P2EE0=%=Z]30-Z0>R=8GXKA M;&.!6BF$0#PS&AIA,@ZWV>= 1G2MW']O/M= RQ214"M)L0NTL%48$8%]AG^D M8B_ >#2)AQ.0$"24F<,J$9N4,'78\G%<&-H3$Y <)2)!C?*A_)M(R@!MZJF: M+))A\EC,\N5P_F/]H^77X=+_?)X_#2?C9#)S7WU938?SY&GX8[T>57S+Y^[O M%ODR>A%LEJLAM.I>^IPL4P^Y\O?\GR6.%/EY=RE M^_I'/IPO_EQ7OM_)U/*DN$TC]" ?2U/D1?M7L,T:^*?)+"\/!0VL)2(U M%J8IAYSSS&:X2A'GXA-MFJ^#[VQ("IF6DJ> "II:)-+4!SY4$:9UBM/(4OQB MP3;YU2-;GZ5KM?(=0&*3U>\X_(6I=B/J3K#>O>6F]IIW.)O]"/!:>W%P[;LI M*R%K5/>;">KNH*$4++,:6X1HBADE0*&JMPC+6>@*U2L#AD@CJ"' /9MF+)64 M2/+599?9B,WR"XF#Y-Z!7$Z9++^.E54$MNM4H7R%VV]ZB5' M1U:K&E/:#^5IY\(;*U4M^6@6Z=R4$?!D=+..C@<^GQU6*$5*IY)I+C&L[LP# M"A5I'N^\M 0%@3(%"F"34H$9@S855*+4>4I$]+Q&/Q?_?W?7MMRVCF7?YROP M-MU5SA1X 2_ST%6XL+D_N!+_)ZP*W./AZ M,>.(,Y@XF,8R57+%'$Q MN7%=\+*#!38"EV:89)-=Q>CI3,1J!E5RXE;=@3U.T &] >R)5:0UZW8 0%W MY A+G<>^P,M!:TQ# IUX]C),<\:>R8RQK814Z,!#Z*.99EF$*&&*1)$F>IEW!/]$R2^5H'H$R=Z^H\Q)\JE;XI[&=_?%,W[LKY_K9@?36!( M:9*1$,*$AM3K2NNE,&,XT=K8HF(OC7F8QC@.XCA B%'B<>A[81+%'A_WQBWZ%>2NDJ@7<8_.I%VBWZ, !WC2J?RJ0UJ-9-BF? MAH!9]>AE31OK;"GG/@^61!1?K>1-0,WN@YMB*:+W!:VV];:YXY?DVV+1)CI. MRNS$S">)G_"4)#&-:" "[T-A/IZ@4+.F\4 TB3P&E@F=$%J!PH"3" =9F,4H M\H),1#7.XXW;S]?T?SX0?,L9H->_?>)7MP:7;SAO%,5LZX1:0S,?>Q10F<$X MP0Y:\*!!?[&_#OW#5^E EZL]9T6Q@93WY79':LQIB/5HWK[,#X_*\H"2T$>3 M69:P*$OC-$M0 .4Y<=8M"6>(,JV;.WL-10$B48PS(H,XCC"."!$618Q'&8_B MS'6.^$I$K)^O;WXWK#EAQ)V:T(Y&FYZ*OEY0^VS:V,=2C_!9(7<:JF;'E?>K M:IOR8__&]UF]OVO6L59IWS6NN3?( M9@,H3L'/P[WF3-P>[6>^U[UO9FZ_)::ACBX<,[Z\79,[5>7L,4N>?LO_K]I0 MN?.M.40<092%(?>S.*1QG/B0AEZ'(/%\K8RD3;N.M?.=COOU"31X00/8J,J MU490D\]S\:^GGU:I=Z*@&CSV2*B+UIB&ACKQK'+_+EM3T:/]JWS5'8\F:>#) MHH*A"(41E[74$MZA($&D5:+1MNVSJNG%LPXM41N65;#>(H-EU7ECV)16DW88 M6U]?(]1,8P1U=IAWZEIK@455O:6[;5VMBDV3!2VK]?:A?-RVAQ?]$.$T M23*,(,SB3%X;?U!XF(1:QPF'V'&LHQTTL#G%IB>2@VA4$\2Q&-03OP-YSV"= MJ6!$#T4]<$$VA!G4MYWJ*G3W<&4SH1 MU1GNQTO-L<2,JN)\RFNYUMO:R+R(A81G?AA%GI_$C/M):X.FJ5[1/;TGNU:6 M/1@]9='D1DU-W-&BIR MCC.)QC,6>H3"C*UIB(,A]LK&^Z(G I\W^:*0\ZW. M#$E#'"1Q$@5!PAA+*?3#SHP71%JGB[4?[E@*&CQ@+0#IJ8$^26J"X)0?/4W8 M4]-@.9,NO"2C1QJ,>9N&.IC#KRR]/WH:(8\SR*UC=8'O-T6Q.A$E'H4A"7R8 M>BR)XA3&+ LZ@R1 GHY:###C6#<$L@\M-#WA&,*F!Q!@2.J,\G* MVP3U"(P%5JK7T5\B (*!>13RHF/81#BGQXD+?80UK+ M7NI/=2PN#1"C97\-8M3$Q TG>MJA1(<3I3AXWR,,^@Q-0P<,<%=#WPV#7MYE M6 E',4)<'C\.. I9EARF.LS'6M>+Z#QWG)YNM!ZM18]&;W? C%%_/\OB\ D# M[_5Y39XFU.MUD;_6[XV\5^WYOY7K[+CWMV#TNKTF-VH=WQTM>EV_Q7&FB<$S%GJZOQE;TQ 0^R5C?=%4P3R M'R3 (/1JC;]4%I1K46(_2>[%H$]F T14"/&T41<$:+I@CL M<9Q+!$Y9Z!,!([8F(@)FV%^*P &+&R#_7@H\YR2*(9)ZJ6(08ZICQB+#^L@ M#%)+>U_5#3J6C/?._7PT+05OAVTUM1F=:#T1LL'QV-M7/RH4D+=*^S34S*Y+ MZKM33?D:KGU?ML7=;OFQO"MF'*64I2( 2[,T)C1.HN,:L.]GV([V:1ATK'U\ M6Y>KICK&'A.0<#6W+4HLQ='#F^>WN9:V25.])FI'(&K$]=Y4Q< M4E8Y8[XL1'A_W53;[UZ2K([8G)PY&:?1)M1VP5H\$U%R?9LF<5J>D1/7<%TW5&/T4QXLJ!< M>#[?K79-/271DS=U^:_]K7T^(X22#'O(0RB,8YRDA^5P%(7I;%WEK.J'VEW!A'V,440 MAC@..2RJQ2(C$JL7 M=YP"DX7*?@H]QE6O?IYZU,L2P=-0+UO.5$Y>0CWU^FM5+;Z7R^7^XI[+]7Q3 MY-N"%?N_9UGF,8P(BE.$:.K%24@[HXQCJ)44'VC*L7K1![D9:RNO3+]O@>HI MU5 FU91J1!+UE*H#UEV'"#ILX$\=NC^/*U;]5/6(E26.IR%6MIRIG+R'UF8O MV:[>;8I3">7[<.-PG6S,,Y)Q#R+J>]@+$\@BV$'*D-X!!Z= 7.]Y: ^#\U$ M9%&^C-Z,[Z)VVTJ#DTOC-I#=--.57$I\%A.VV"] 5F[G^1+\7N0;\%LN7"SK MI[-=ASV$?K,YL+U6G89LC^.J^OS9-K\VE@9^!G-3R),.HFEDS5[9'V1WF(4I M8Y"%Q N2*/0XB;W#KEI&L]#2S@Y[>!P/ *+/IO86":PUPO!5@W/P;WD9X55I M/WBQ+U5^T/G):+HJ\X:K#;;;=?(*;]]CC?4(-VR[T7L)Y//W:I;2"/H\B\(H MB1'S8MOVI4NY)?ZRR/IKX2^=3%5V*TJKU: MS?6K2J^>DX.5UX!3A\(K/CMC$41>QGCB>W[*?"^%AULS&$I3K2*NCB"X%][ MN? J4>U,>&VS/)[PBM^9O/"*S]H57IWF^F6%5\O)X<*KSZD;X<5W0J(.B&(B MP"0\#7TN6$<\",D!40AC6_=<#L;A6((_/Q2;(I>(7 JQ)O4NU-@=ZV-(HQ" M/_;]U(N1SW'FLY#'^UH=#/HD]K0VU)E;<2RT$IA<=M]# QTVLYO8!W"IIJWC MT*BGG*8,.M'$-PGJ4;SAI$Y#SRSX4=E^W?2TB!5?Z\OF(B=9&;TIF)S%7IJ$ MG'D!P3SF+/,#UAF*,?5U1,C@\8[51R("1TA&EW.9$FVN*(PT$*HTK?"$JC=,?V8$:GJ#HF;O1JCS$O[RG0=E4L9OM0 MZ7"W2UOPE2&21"2-PSB-@I0@B&+2&@I0"I6T9\#C':M.&_^7;+;&UJ*:-V_^ONS(F5E[!D:9/0R$>#2G4';Y$N2;C3S*V]#X MO:P?0 Z61;-]?M?\^?VAG#^ K]5F4WTOU_=;,,_7X&L!5O*6OMTCJ"OQ&]O' M8E[>E7-Y3FXG'I2+_]=/X+$JQ1?E&M3E2N;WUHNW'EKMZFTM?BZ^$$]^D@8* M 49\=/M0;>H/HB>MA%J"9;6^;[ZX (OBL=C_PNZQ$B8>"O"8;^IROEOFF^U_ MJ8XPLJGDN)' H!TUWFZ\5\8+"RU]WI'"A@.5M;=>+S[]6[XIY03Z)J_W%P)% M&&.811'AR/&!XE6M7[MASL>&3H\0 (RFMOJTZ46?3IE2F]DT"+) M2:SYDHR>&-.8MVG$EN;P*TOOC[E:M$%KS&*:1DD2HBR.,T2SD 6=(8\DJ:E> M*#Y^7,4PFKF:D*:O&@[X&J0;9YFE_DR(HG9HLC<]]=!UH$<_C+A07MVKUHMJ M?;D6??%KOO[C^NZN$-&.-/OQDES?M+%.'(F0QH,P$L8HH6G(O;"S'4:>UKUA M=BRZ7O634#37]NPPJ;C.-SJ)FFM^#3YP A:A'LQ^E,#\L]GNI9(B;N^Y4"K MW$]#NBS[]'*9T %CJ@+W?'&RB<52$H2$4)_%"4JC%$C5%",^E)8!_UYM_BC7]S1_+.M\V<8_F"5A$E)/1CWBL2'%H=?9 M(7X2SKZ)\*E26@KY.WSB%HMQ%6E2@A:6QLF7&E\(RH'.B]$3D!4,FBX!F M5&FL 3JGS&P)L*-NWE)7;L&J6A=/(/^6E\LF$=:LZ\VKU:-6N5;1"7$UAD&X:_LO56:::\BKJ6I:SV8M^MYB6R M=B%*"4T(\S+,<.AWIK#'B5:&R\2 ZX16@^FX#5LSMV5$F6(JRS5;FIFK%T2= M*TGU"BM].:DA)$XCD!OFPLN,TW ^5.7DMMB4Q5;6ZU^4W\K%+E\NGRY7\F+5 M39DOR6Y;KHOM%L__N2NW93/"M'#\$$<1#:"\\I9RY+$XB [J1CRB%N\YA^$\ M+#S%I"=+[JA7DZY)<*XG;WO(^YM$CJ#!$37H8(-3W&=205.">Y32>9M-0TW= MNUF-W!;^/[,G35=X4L9:Y0C^0]UAF<$X RNWKS44 )@L$P^E54]A1F=53TD&DNKGOY!VR M>E31&L_34#][[KR\]<0N3T/4;&^TS5%&H4^\Q$]%6.L%/,-A!-/.;)81K9I$ M@XV=5\V,%BJ&$VRN9\ZXM:IG9UG.>(\N344S8GJZBF;FCH*B#>!)>=8L#-1/ MI%HOVC 00@*C+(YY&"">4AQ$X4$X<1+%.@JF_7#'BO6IV-Q5FU4N6AI\%:AT MI[G:7"E.7UW2I#DM;: B>5<4\T79/1-(4UYFX:4F,-_.>4;QL.0 C3R>Y=U ML=K.HM1#F#*?PP1'F<>#%./.)HNQ5AWR899<9_#?*J/2_*"!:*$:C0:QBNG] MT3C5S/,/H7.TTC0'IOIR_U88GH8V6?)%H4R-*4-#5.NW_$>YVJU(=TB4YH_B M)_73C,0L];,TPPQ%&0N%C"9=K8N0^'I74UHU[%C36ES'8[-R^;Y!-ES)S,DV M%[91>+:B@X_X %M#WN!]-]M[B45,%!S?'=$5QN&L*&FF)/Z4M<6*.-)>; M?NX%"BYFHDW=P_E/V:/+UVTQ/I?\LFT]A3.*FF,]M_:*L)0;X%B^).J/&B*3/R(#Z_ M'[KSK@#%T!V*0]E^:S?C:*TX@9V/X_E:G:.?#!RX+]??"KF4\-0#)8&)3Q,1 M0& ,HRC)(#J<9P[3.%6ZE-DI@/,,TV6'W*G26VD@PS%Y[+:Q,A3_0LTR<-P= MNWFL#K>*S72F05:!6IVQU69+371(M>KB>R.I?3Z5!M!G!GZKUD6=;YY(L9X_ MK/+-'P)!WZ@_2ZF?I%D0!A3[H>H/GL1E(TPP=='# #@1X<"+>UW>@PP\Z!Z;35!I# MZ72:S&Q ==QT:H/F(!+?&CK':9D)#* C.5J-_M9KE[2Z_UQL5K*N\RQ.*,Z0 M%_M11#*,68@;$YC%2882I'5+KM:#QQKPGA6:';V0TH&/OI49$]HFLO)B!/WG MZD>F_FLG8#[)*Z*J-5XVS!6+S]7)B8M/XEUZ$/WTTZ:<%[,@HQD7%E%$<,K\ MP/06\.C!_!@\<6/7B4\ VG^C9; M2#,!WV M1=&7[>:#-KERUVVRRK?RLTW>158^;\XCND["J#.LDH-QT%X3B"!=>_A6!L89 MFV;7 LG1>A;C@(>8HR0CA'J$)A'KBHF%."-:&TL-'N]\YU6]V\BN*/IA62V& MW/VCQI;:IBK'1.D-13_=]R/QG/.:'VF_)] >0-XTPNTA#O1>ZF/ A9ERB&EP MN;U]W!3YXGI]6L39FT$OY)'OH9 R%J0!PA[M*L"'01)Z>N4>K)EU'F0WV,"V M 2?'^6]=7?*-P#=$=X9P;:)&(Y$\4*/V=-^V=*_!LS+PYQ2OM^E3EC0++3!% MH;/A5J_\6>--*1_QL_1>WYT:G7$8IYC ), I$>8P0OP@Q!F$4"/S,-B6<_EK M.FAYTD'W]SX9Z: E>A72!J/R:B$JDX2J*9T+0C7F_*,2:S:[[_@L9;WV8ELW M+ZB8GN=B K_K9B]%#L0'=\M:_EJ^WD_^ET_-CY MXZJ-^,:B^#%TAO\>GV_-Y:VUPP1F[?9\J5R\JX M*XJ3%-WP$U:6FD4M%I]&B^@-51_?.GO5MA(]M-(1.Q#@3U;9SW\62XGDON4_ MYPTWC9A^!#\5CFRY8':(=-\4LHB(W"#PTR&RC'+HI4&:0LR2F# 8>?YA_$"1 MULV6EDT[%ND#,B<'7X=0;J[%([%M28"/+3#%XZ]OP;+&!IC"_YH3>D$/%U(A[^@QR(A(4D*A !PO< M9@[$/8-FR8\&!VBB\[H"BT)FZ^0@T.K7E!UD21@E-2(8]S(((^MWM%8BB MC&NFN8ULC)/>WNZAB3XP0+'-.%04;.?D&>AUBPETH(S4VHPU3;%VSMY@K?[Z M!)IK9I=5OA:*?"?0"FDNUP<%EP%^N18B+7=ORLM^ZJ?FPX.O^WF+GSZ]'L3G M1.1ZF \OU=H"(R99BAE+.8,PX3Y-(U^8B"GJBL\C@KG2Z3FC!SL.I?%*GK!0 M.AI@@23]K(%5?C1S M7Z_D.S"/L\.W"^:;_BI%Z9L^E-V=6A]TS(-?T?4EN] MW>#,?SQ6V]VFF'G$1[X'0Q8Q'*49@5':;3H5.I0-OBQ"UYYC]?BI7O&ID%R MNW(M?B3OBLFW J[\V/!JZ]J4JXG.V&SK:=$;-=>[_?4=0KE@M"BWS:FYXNV] MNJ.58']!8(]^V:1_&K)FU2.%6NS#V%*:P=[6U?R/Z\?&'/]1;.:E"*GQUVV] MR>?U+,1QPA$4 HL(0U%,211GC'&/^H@37SWO.,R,8\EKP(%JCPX4'3SPCPZ@ MSAVL PE5F-..QZ6>H$V)1HU)[GAT&LUT7_1@M8EIKT]OS4[M$#&!*:HE1RKK M+XGF-1G2YJ6(LHH%VVU$]/6I.:YS^Y"+M^550#/"(YZ*40$A+V$\)EZ:P@,0 MG&EM@W)@WK&.7_\D/7\JUV#; /[SR#=*:)/7$T@Y;(EIQ%4N'7QY;X5K+E5[ M]Z=--2^*Q383;+QN-\:!QPD+$DX@2Q!C%&:=788)U3LT--R>\_6$#N*X7?5= M8GIZICU2I]$1+?I3N7K]- =1V;%E@9H%K5:/Q7K;!%]X(^9:]\TQ\RUY.G[F M4_XDOX>_YYO%"X#;R_5>*OY>E/)Q E&*?,Q(+#U#K M1.11I'65_,2@N\Y:MPMAW>"]+[31E IH1O!F+%]4RV6^V1Z_^_:P_DN\#6IY MK(FA=CB#E$Y\D%7\%N#457#JJUSO._U@ZR]H'+X KIQ63T51;LD_+I/ M5]7Z6[&5P"3Z[>>JSI>G/Z?5MKZJZM^+^J:85_?K\E\BNJ">SY ?0()\%H6I M0)ZD![Q1IG5)[OE0.AZ#GVEN\4/^NP";8MD57UI7ZP][IT#>>*4W^IZQ==4& MVE^C8?7&U,ZGPY:CMP;9"W#P;#^6;B^>#\+2,?&9&CP5-3CZ-NZ8Z:R)>H;' M\[\6TQ@))\!#-;4..Y'Q;3]B9]6F_9;\G#?S:!9$?D)\(A S,4XG6=@Y@7B@ M=;7@Q* ['@D/\X2\G2>8E,J:&&7G'@3=-_3$1L:+=MK97$)QXO2_R8CY:GN> M8Q@=]F+]FX^M \D9:\"UT896%E;WWQ= 6A>W,WD1L#PMC:#OQ3@* PR##@1' M&=%;A[%LW/FBS!Y84\BU6JV$V&V;;1YE@[11MOJAW"P^/.;-MOJBN6&GJ^$Z MT078GV@V77PU;Z]IJ(XKYW0678=RJ+42U%IK807A M-7[>2_8/XG0BVC7&,21UK$D(PN.E4B$A\V)ZC;!K'DXR8PS-;EQ3Y>>U%P+8181\_H> M-,BVLG:)"*KX.\2Y.;3T&C<],C.,RVE(S$ ?7IYGLL"(UA3GH5H*@K;\G[NR M?A(3KH*5V_FR.4KPN?A1$^'J'[,THW$61UY*D4>XYV./QPA%3$RU,J%LFJ6I MU>U"#B&-0H\(1441]!*4<$["# :^EPD*G$]L^/]^N?S\._A\@Z]N,?U\>7UU MJQG]V.-8,1HZ"[F:T=$)QO\$>Y0R-5: (T[P#XD4-%#?/A/@;EJH0N%[,T*K MS3 -M7/@UVOS0 ?,*9UTNMJMOA:;Z[N;:E>WFR#*^1]?'MMIY^7ZML[KXJ:X MEYLA9I1!E"110J(PA&F&8>;#?9?ED'E4Z=2G@=DPCL,(48H"/T,ABW &"<8$ M$^@QXG'7.^CW8&6R9R/AMKGP1P'XP^[Q4.I#YG0D:+!I4&N6;Z M]72S9?[Z#C1(FXLX%T!B!5\>#RL4EVO0X 4MX/-1KW' ZGQ-8%A:I+B3!43J MJJGMM#;I$H,KBVAQ]LI8Y9#X"1SP F+LY"$3+#,1$\.:=J%GDGJO7>/ MH$TH >11C'S(>B#[\;,/ M=DZH'&)U$K!:(+XGE!VS6:<1Y([J<76^3J1[D=5VOBF;?<#7=STP]ZNV>%$] MUD(C8&47WW^^#NXO+W]PAG E%Y_N?I\>?57K)^@E?&9_TJWVW/:6&?,0=A1'./B+MMMFG(MF,??[I!RSVC1VD^??L^ MBG_]Y3^Z[X@_Y'3C+__Q_U!+ P04 " !=7:-,K=,.$Z\_ "N^0( %0 M '-M960M,C Q.# S,S%?<')E+GAM;.5]V98;.9+E>W]%3LYS5F)?^G1U'ZPU MFE$J="1E5]<3#D5ZA-C)H$=ST5)?/P!)9ZPDG82[TX-9BY80 >N70!F!H/A MW_[C^^WDIZ_%;#XNIW_]&?X%_/Q3,1V6H_'TYJ\___[Q%_71O'GS\W_\^[_\ MV__ZY9?_TA_>_F3+X?*VF"Y^,K-BL"A&/WT;+[[\]/=1,?_CI^M9>?O3W\O9 M'^.O@U]^65?Z:?6'R7CZQ[^F7SX/YL5/W^?C?YT/OQ2W@[?E<+!8??O+8G'W MK[_^^NW;M[]\_SR;_*6EH93RU]6_;HO.QR\5C,W"7__KM[-3+_,IC=SVOJ<2O M>C ?SZ^NW\^*>81_A5KLPJJE+[/B^J\_SV^+41P]% "OQ_Z_]U19_+@K8I7Q M[=TD#OK7DWMERNFHF,Z+4?S#O)R,1XD3>C!)8_WXI2@6\]^G@^5H'']ZJ+#B8-#BD%]MM=7P?(R.*-)4C1C MNKHK9BO6-SBL/6UV-JZ/BW+XQY=R,HH+M_N?Y7CQH[GQU6B[J7%66XF:CMQT M$;_T9GI=SFYK+6UUZC;53S>83>.&.']?S#[&?RT.]6U7^;;Z8XO%8#R9']NM M)]7:ZMVGP>=)<73G'M=JK&\K0G^:#:;SP7 UB0_V:V>-]OI45YZ'*K;7PYHR M/5"OJ?[]K2Q'W\:325P+WD0U9WHSCE]1\WG<7@]UL4;5#GI94^#U6^B@S_4H M4+N!IGK\)EHOMW'U^'ZX;R\4;:$7-66[NT9S??H:]\MR]N-P5YX4;+P'M3%Y MN7SC_:G'Y1W%F^K-NW)1S-\/?J3&XW1Y6TYO/A6S6UM\7ASJ68VJ'?3RW6"6 M-..O=?61$YKJ8!3)7A\M)\75=?K;FVBVSU:*9MV)W$#3G8XR_ONZ#\OB:OJP M2)/CK?N1#D9>;Z[7;J"I'E_-;@;3\3]7]DO\H!X,_[B9EUB3 M*'7K-]7?#\4P4F[RX\U\OBQ&:CB,WUI$$R,:N]/18#8ZV.':#337X[C!+(NY M_O&QG"SK6,&[:[37IYKB/EBQO1[6F^*'ZC75OX_CF^GX>CP<3!?W''I?3L;# M\>%.UJK<24]KBOV8-CKI=R-(MX9X;;:7O4;>8-8SYKH8;[G]4C^=% MLSU_WF33?2X7@TG#?7[69'-]/H$8B^?=K,F"NP>'QF_C#S;E4[L9)]7KSQ7? M%\5T5(Q6A^'5!R?E\,!:G7X27FA2FVD E9K1RB1VD%$'G=\DL(5RMD&J%T]WZ"SDL?U8/YY)93E_)>;P> N M"A3R7XO)8E[])(V1_P+@)F#A?V]^'/0RHEK,H](T'\[&=UNSZ=E8/D4X=>S# M'R^,__3& A.4,RJT9@!38(0D$B/!$,<*>L5D'60>DDC-AC^5LU$Q^^O/\.>? MXK]<%[/99O_:$YFQ8M3BV4HPF V?4?%QQ4V)7^]6!^N_#+^,)UN;. 6J-$V0 MLF/$X_BJ"?OKBS.VD;E\S$S9'E]?7?OQ-/9L/)B\+^?C VO#,=6# M(I)A*(0F44A(_.=@LBSVT*96 M_2 \X4#R"!N$CB. G-XB*1U47=+H:S'[7'9"I),94+:/<6?+T-JY-D_>]=CS MSY/B7;'8 +-O-=I3+2"%M"7<*,B+;X4LT,8O4:')9DL34'9%DRIT>@\S MJB*!15U<2X90Q,5@*ZG"J!J!EI)VJ9R\&C*/!Y/!DOQL4\ZD3/KW36H[4$N9G8%W]8Z;=E4*(1NJ[X#W^DA0?O,:E[XN]F5AW371P6;>QCU#PD>5PC L.P(\ C!K'%7-JM M8XD8?F$GW4V(><<901:N';)FMHS2> ;#?N*\7"?$(4I("5;,*>01-HK1:HS> MJ1PSNX>[6SO<:03:SC:Q!U>]#A/GA=)!8ZF\4%8AIZ3"6%B$JW$!R&J%%+X> MSTP+E,D'M2NRV(TL-G>)#O/EY0I!:@PL@Q ##;U%3EOJMJ/#.,<"ZZ'_I@7* M-(+K^?3DH_3C0!B0T52-6R]FGE"E$=YZ&[#P.0<%/3Q<:F.!R<7T3.M+K>." MG74"<"8:"\[2.$0:@>) ;/W<&*N<5:;?NDP[]E130'=Z[O0 E?J'3R]6"L83 M;) DEGD *")QUI#ML8GA%Q92TSJ=&D/Z')IR+2Z]7"% S!V)]J+@R12PEDJ^ MW:0EHOYBE9^6W#Q-H'P&5:B>#A288I99K(G70%O.M;!;0\ AT.WQ59?*3^M. MP2.A[2P@O;R]'2]6Z6-2S'.YNIA?3(?[*;.G5F!((J4)M2R.$DE-Z;VNYX7N M]KSK]2\XS4'=%:5..A#;@YP$ BADN<8:(A?-37YO9DHBCWE2--H*$%N/E ($1(O!2\VK V2((WZ7=3C1A&A?6'XR$.V*(Y]F MQ6"^G/VHQ9+GA8/CEO$X("2<@DI&O7\;: 1=SF'6/6-]SV)3%X!4[)1[>P( M:S1:!10,)N\'X]&;J1GYMS ML-Y#R[T%)C6.<5?,^I R,$V+495N6PV'R]OE),UF6UR/A^-]&M#ARL%A$ =G M,=<134*LH>: MP+MW*6OV/+IS8?EK@&?8&6&08Y(2[06.OU DN"$4PGI7Y%M2=B>3\EN2C2]G MMEQ^7EPO)\\OI=>(X3JFG1!5,H3BVAKU?T]YI*W%6EL%N=9<"YX3U]5+L[M) MBCQ5AEL$_@P>G+@F7,U6@(U6-N+35WSV.W5VU0X:8)0@C:LCIDYQ28$SWG $ M):8&7E@@8:N$:Q[N,]!LU.\H2]?D MC180&)7NOCJ0$PO42U.^&UIEPGPV.JU3U1]#I76-0!U$ F**$'846JL,\C : M&Q9+!AW+\0CUTF[ODD8G07PV"ETM%^FETO0"[#$\>E MF(B1@=:Q+I[Q3TO"H*DJL* )H M%??-E.=."J]U#H-Z>$+?*G_RX3VCU7[,>[+G,=BWO3K.4']6+3B"HEH!@:7, M.N:P%TA#+8&U"&-C:NW [8PVY8.+W7T_*[^.([[ZQ^_S= M^\Q#N]$8-%^.O MZV#J5>S',O[L_I7<&K@T\X& $;=(88&QIA(ZZZV@%8(NSLJ+->DSR%3V0!)= M;4MQ<.M7%M^6\WT;TJ-R 7D#A<( 0FXE@D(;NH522'9A"6^[)L!S_IT,?7>' M\_^]G*_#W3Z5'XIA&??K5=+,^YY_*FN"6"<-[J;%)N'#]1M.5ML7O_;P_8ZU0/0 M4 C ;;1S" (*"07<9N2$(YEC'?1P23XO>9[=>6I+M$_.;+,RZ MF!;7>P/^#M0,-*KD1!)*N5(46>^Y4-L9ANV%1?OUBH'-BJ8K*L;>)G=D88OU M[P^PV830UK"(ZC<2G%>" P^ ERQ.S6@U:ERA #R\M%R7?2)H:U(Z'U>?![4< MQ=+GU8.#CEKK/"$<0(":,HH[2">63(?:8QND.,B[;-S/Q[CJY8W]=UWW MU@O<&ZV\5C2"1A 30!M;C94!G*,H]M)".0O'3@?\?.3:O,E1:1(OOLUQ%.OJ M-!@L,U)3B07@SAAJ 6"\0L=1GG/YNK[=%6N'MA8'A9MLU9-^8&Y7 ^EC[)!G44(9_4#= H ' M6G&*+7&,.WSON6+=)GB[3.[E0=[AD75->ZV1\(H XWB-1Q@!IKVC1!+K*Q1P MU&%K'+Z8FVM3*T^9=]-^2.:29 ;HR1%EIM ML:?82 KJY$:R7/.%^L[B?[$U&Q.-OVSF1JQBP*6A @$/8Q3TV-#O(&5<4J9 M 65N?,_&Q-+F=FY^966GL6_9$?"- (JP54!$)H(5;&;+UUU.*LN(Y^WWIO MW:)O5Q)GL9C2Q<>KNU6WW?=B-AS/]RL A^J&=!G%8LV!2K%4#G@MJ]@JRG56 MNM\>QI]W391]UE$#XC@'!5,&@)0@Y^KZ87+^FAQ\N7+0SE'"; 22.^EUR@-8 MS7OJ39;J^7I,]'.0L!%Y=)?O\VZC,]?FWJXJ01)ON0# &(\<)DAA4QU"4&) MSJ6QUV2'=\6YAN30/]6Q$?4P<$,%D@)*X!64$B#(*AV=*I.59.3X^(QS&39= M<;$UN726YB9Y!J:C]%MRIGX=3-+$>E_,QN7H:7# 'GX>TTR0BG ',:0"805 MT R0K5[B4;?O&G60T;8%(Z5%O,_+/!7GTVSV(TZ=@P]&U*D?HH9A(ZR 4 93 M (+Q5E9CAQCG<.UH-\_=2CR1#[/%I3 N#^[+HII+Z8<0$8)R:@0A"F"WW4,H MSDFS4Z&E3,$V',5H_P/NMN80_?5&J%8BW@W&%\[?I:8S%/+VQ$_7-_0.V3PG%4 MGFFBL)>.:L((<4Q4H\(279B+KEE!/X^=S4.W.\Y$I(OY8G/;H::[8T^MH !S MUFL*34KT"I6B$FVW>8B[2>YP*2QJ"N;.'!KE=!A1N#^\FXZV]NZ;N%C7.NZJ MVT9 RD%&XN;.E=-<1TU9)C16W:=YOCZ@IRKFIU\,]M 7VE+T24*,T_C0;3.<1C YHG/FI M8 1B6$ AI/8,<\H5WRHK@,L<>[6'F_@9:-RM@$ZF\>_3="7VT?<_%*N'U3;A M9.N9N(N:-:L' 8#T& (DO?(I.C+:[5M8 >GV"M5KIUL[H)],H173(_Y7U]N( M[$]E=?7_I7?+:M0*D%()!%(P)8V"TEL-JY!NYE#6DV4]O&C<,F$:Q;K1'7/# MV_?+V?#+8%[,C[O$T42S 7K"(I!*1.TZ+K9 Z*WMQA3,2F7_J)0Y[J4;PW MI'=668RZ8"TYV@>38KZYHK[?!_JD9( ,>6Y4>A$6"LH)8T978W+QU\LRWK(E^]1SGH5F M9^=]Y7QQ=7TXX<2CYUSV-;#O ]-<^)T)#L[L"TFLUX.D[C7HR_%ANG_+[MI58#@0)@D5:2.J%/R_?_-(V\\%A8#3P"W!(HA8@+;35."W2G,4U=9+AN MFD[-8=L5A[:I;VJ]T_-"Z> -@MH3X:'3S,,\X1V&9ST^C:R?$0[ M/)PM'W>VRG%8ZU!V?]T L:7$0V.A\&@5=N6KV0&=R8JF[&'L4=,L:AK?[N)' MDJC\'*5(+@6@ CL.*>(6289V,X:QB_P[+0IB3\+&VD$X#.% M(-4/.PJ((D@-]XAX#!0R' I>C0=(DY/DI)=9FMND3 ZR9]_ 3MFX@C51\8<2 M:BR0P91B[:JE&@JEFB_M\>=IA#N-DPVZ6GI9NI+5[]T<5VF%#[;&,[? MQM-RMCJ27T^3:!D\;F5]8O];L?B2[MA4R^^!#,M=]2)$[9,A9Y2%7"67BO52 M;M51#G..UX^/DWMU"GY_)=5Y8'GM1Y!VO;"C'=0 0HBLL#".T I^O\9 FF-J MROZI>.TP,1?5#B\WG_!T,&,I^L1 CJGGVAAL@*O&HBC,>CH87/YBE0-F5\1P M@]DTKI_I2NKJ3;@:[H==50*. R*8 9VN94=]@WIL[I46DT67'AJ-3=.E(5S/ MQ1P]F(^'<7.UX\ERL3=!T8&:P2J%(:D4\LBD73@4@$@Q+NBT]^+\WG% 6W&L'\:KF8+P;348J".KQ '=M4<,02 M31TQSFG-@("65D@C2;*>2H&]?$Z\Z:6K9<3[P,$'HZB_TIW68'!1::1",R6) MA5&%-$YOT0$$YKQXUL,%L#WR','2QJ31DT#'5::Y+^4D"GV^-G#/'_#XX-+< M\^[5N79?IW[@R'-@'4D/[*2\I,B"*D60TL37"@5J>?R?#CR]^;A@,$1RBA$0 MF!J$-4\NX&I$QN*] M[ZT7'(["((19X6S5%8CX72B-CA3T+KXT &EGEMGCKMKR=C#>%\/T M8OF@@!0:0:4I9QH3A02ILO1%99#F',GTF2YYWY72UY/Y6 M),UH;T#VD[(!6,^E8X1#+)QA %);76#3SF8EM.XA6S+E^BPD.P_-KACR*:6I M6\Y^U./("Z6#61U"0N.0BOJ[QA)C5HU+*9<3IMW#T/UF69*/9U<\4:/1ZE;K M8)+R[;R9;A[!/,B8O?6"48P0P97PBB*#M&1H.R>0$#FAV3V\E]PL=YI$MBL6 M?2@6<<(H"(G,*F'(?W-\J812#NW MFM[&+J\NR-8QE;:% Q).&,<\DLZEE-3,;)4\ XFZL#?CFK:/3L6Q,W:LW(DI M]_U>C^W#8@%X%(DTD(GA54.0H81K'*U&:])SIO/1ZO1E\' QL#NSJ[_[^4F M./93N<.D7$VKSX/5R>1M"HS,:L"V">(,HC1G^3W^7G!WQFG+VW\&Q'W8]?-8]JR)P!CF!GL:<4!< M:$:=K-Q$AAF<WP&0CW8BE;_]R7L\TB??)Z]JRA0+AV4A$F-:4, M 9]>)][:>C9+I^QSSO"6%[5GCKJ:,U+A?F7BQT'XKY8C8>K@(I8S'U;3 ;K3)CG;K@[6PPF B%1-YZ MKBU&EBM$V78;X#!GX3O^8M4K,S,@"V_KSXR9PH0'CT6<+K(T@NH-W<4++E2LH9/UVL\F];/15#5%NI]>EXGUEJA%/*$ZB<-E@JZGC. M@QX]>M:ID\VG.9C;H5$U_OOES\>?O.1MVE,Z< @EYTI#P2@% BINI-($6NH) MMUF)]7L4#-$N89K!M@N6K%VJ]7GRH'S@*46(Q8AK%75SA06!6A$ #(7"()&3 M2:5'$0U=,N5T=-OERJ?XC0/T2$5"5,>!@0ZJ]#@>CWHX5H)YZ>/>RKG .=?! M>A1ST TC3@"T'1*HV)O1BJ.3P2Y%Y%&92%UA**)8($JIDTQ(1#2+ICLTT49# M.09OC\( VJ5!#J+M+@;O*Z?N'BOWQ;+!>.DTDUAK3BG&5' +.8*$(>2BLIV3 M%/>$E*>OE!A-0-N-E_IIKL03/-/]R\-JB168&P$0=-0!)&%4Z "-<]%*Q$DM M.[R;47Z*".OXJ3^.&.:V3N":$ X5D4"XN.0 +140A$""F59*Y=B-1_NTNPBB MR1?X@4RAIT)[GKEJT^7TR?PBIBR2R)N(+":2:RLB-S8O.!NGJ8.UM-(^184 M;UFT![@V5BC.D,'&5>/1V&0%N+VJJ5E;L'N#0XZ#LZLX@+J).U<)-?=0YZAV MHAIA"#%< X0Q1PK"E(EB@T54)'+2V/4R5V_CU&H3[JZH%^?&;!5/,9AL?)[K M^SR+Q6S\>;E(*2T^E68PF6RN5D85]^^#63JT/? .S*FM!LRDI%%3=MXX T2 M1OD*)ZM MR\8G2]I^:FD[ [Z,Z^.FZS"=8Y/3FPI,),,->68!L1%JPT"2RH\ MC#,Y3L_CS^%:?[6CJ_6Q(;B[HM^!5P!.4%9WM!#BIF 8D5I)!!%24B*EJO$S MBG(\JCTZOFN-;NW W!.:G4ZO(# F!@# L!2,$XBPU=5X"0 7$K'6&@N.?!3D M.+0[RS@Q78Q'J8?CK\7'8KB_2HOD'&(XC\]JE6SO,EQ6 M#!'##+/$>$D5@X);9)Q/KXH:+NJQOJ7["<,OQ6@Y*9XSYJ1OLC*I1;:H\O>K0">P=K02KJQJ?HL4Z MCY \S-AQAG=8GMX@>5 L[4>YZHYG6O%[/E';KG MM;=2((H+1T&*8-.1/-QH5O6>.HTN[IF39D19MH1O+Q*!=)#/53OF)&"24BBL MXQI*";:H*'\A;S$U28_\K*['8=X5$]_/RF%1C%8OT1]+O(-U U<8NK@M"J>! M%=1: WPU9JMTCF^V5X>E+3*M:9 [3=V@GZ;<5.G,[&;]2J3^<5_F_>#'*A0P M)2EY,L#YF^EZSKW]=U/.%U&_ M^D>QV.2T_>?^$Y&VOAD,1)8B##1%EA$9T19RBS'S%_>T2:-*;M_$\^JG0'6% M:/8@TS,\Q[QXL2,!&H\9$AKI"+V-:Y+PI)(&=?A";KF_ULG2A,QZ866VF5?7 M<@6C$AK%!;EB!"N *S0<]3DJ4$_?:FB%PZVB?HX,;BN%Z^E5EP/IW![5"8X3 MS:'B<Z;ZG]7D? M?5XL'P1G2"%%&;1.&8XXUELEQP*5DRBR1Y?V6Z9.$]">Z_SCS+$/;1U_0.24 MA5XC"*+AZJ7V%#NOC0$8< ]JJ8LYQQ^?RO?+V?!+Y,6#[!\'(QNRV@N:. "T MU$XC0ZVD"J=@'R7C'[UW..N6[*N;R[4)Q MA>G-.'99S>?%XGS3?4^?[H^0:\S^H]H)P$H1MW!N&/;4*"BXQ#3%G6C@A4)G M#(JJ-8XZ<1#'-12<@\0H0;R"D@KIA :6"&IQM,J,-5FYQ?NW5+3$EK)#$9Q] MR3AWG,1Y5@XO,0=.(8L0!HP0[_3F$I/54)):EE7;X91^/!TOBK?CK\6S$:UV MJ5H1E(<:"=PK;C5A.NZB/'*5 MX@E$O>1!%\&T/!:4;2'>&;-B)Q>SYE0N>,@LT'7 M&1<&W^MQX6&Y(#D1AF"--(1 8 @8K7938[S),7=ZN&TTPH4,_'K@.GY;/0EZ MFK]X6SU(S3@0$DIJ@5/I\IGE6R/.@IS+?CTTE,][8G$JZN?GV^_SXGHY>3N^ MWG=<6Z=Z<%0:*^/2*[WDVD0C\-YI@)#/R3/9PUVK63+49MK)>)^?:?/5:_>G MK6JKJ@%Q#KS"*"J*%@-LJ4&J&C'364^)]W O/!/#3L*Z!^Q2P^'R=CD9I/M# MM^5L,?[GH\>EC^/;CL8"LEH;[16DD%+"N1)RZXB@C.0<7-3?4^6:@=/B)O7O M(CG8#/X]8.6[8E],V/Z*P:.HC7 I,9"$""FPUFQK%S.=DR^NAYF;S\6UXY'N M+-_I ^I?7>^*I7XID>G>B@%0A92A !#%27JTC]_/(NBR0NI>E_\ZGU>-(MT5 MKZH@P_4%QE6N_<&\L,7Z]QHQK"]7#-Y#JZBF7%)J).2"F&JTUBF08P'T\$Y7 MJ[QJ%.D>[(-^N5BN4O-N9\OFMEJ-R.F<9@-W7GL'0=1?H8)$ ,M A92G6<[KO2T&PY"4&J0S F2,8A#JK30DS$J7V,,3E-=" MW!-$TU_J^G+9G 91-1B8U,XE4U, H)PS3BF]W8T$R\EB_+JB'?M$W!,DTV/> MQK+-\C:6#1%["KUU D$D+8+IO>$*'2KEA>43>BV\/5XR_>2MNHXR;9R\CUH- M7$>(A),$N4@(ZC#16YP(X#G71%^7"ZPO#,X1SW,:-^8).N=IREE$DW/*Q!-<6$4A-Q@;3HF@TGH 5J8ABX2H]WQG.WC4C_ Z[@VOVJT%1:0Q M3"F%F:.6:$DD$DQ@I:PW4%S89=B6>'-R*HI3Y=!9:LW-2,I](]FY]AY-W"8^ M$X!GU'#K/3:>6L$4D%[1=/DXO=MH5NSH]S-N MCML^'+45[JD5".3Q/Y00#PD5"@C"''8$0L(9$O42O'0VUCH+Q;YJD5=0> R, MP##2R7A-%0#&,P^I8ESDN#9[^2A=(Y(O6P.X\XE[[JQJ+;8S5G=]70S38\;;[G\8+ I33A?CZ7(\O;FZ*V;K-"![ MAEZ_D< CT81#6FBH"%1:*\PK)(ST_++4U$8X\?2Y@K; [LPQ5D1Q#2;;[F^4 M"UU,B^OQXDCJ'=]8 $0H[0 E)EVN$0Y3#"M4&((Y!Q#U]^ M,^LH"C*E*G\;9=T0+T]M,D H%.'0IF=!- 1*"V,KA)R4.79\#\]UVZ!E1]!W M15 ME?]^5GX=SZ,4=\Z1%QC6>1\"=S).0H0H,"F6PD"MQ097:QF^L'0V33*V[[+J MRJS\&FN6LQ]GM"8W/3C2FMQ9*Q@M+1?00A&9A@8ZPHW4.MKRK):*T-E8 MZWF#=E<+#%/-N/+:6TD=58II39/S(M+>,7YA^60;D?NS/:LQ>#N>M.?W!#4] M=Z/,K(G_\TPR:A@5"!H,&!">$TSY&7/G;WO]KEBL[F+$WZ^N/T0ASKX6:A*I M/QTDM\,Q -1L*F#.@:0D*E&>4H&-2(X*#S23$ DL+BR!>2/\V#7'VX&\.V-G M,XP/@V^_12UD-AY,'@UEG\U]N') '%.L6>>4>JLD$QI A&!D$;%"N0$\?69 M:(V38A?[FD*^<[ZEX]#YEV*4CF&/)]SNVH$9Y(PCC*=DDTP 306E$#IF$=%$ MYMR3[^$I=O>,:PSZSBFW/_W"PV(!4$M@1 9+0"BU5H X*FB-HXAJ)+M)[=%9 M>&#W)#H>XXX5X3.'^S6O!PLFD"" $L5(M&60!!Y0Z01)SX!J6\NOTW8HW[;_ M9CE+O#TA?F]_$T%2%JTND)+_*:H]4]&4(T9$/"R(B]:EJB,Y?-@9HMK 8GKSJ9C=VN+SXFQ3/7W\J%G^:9SSMJ! "<]P)80[VG!""-*2*60H:(BE9;SCP,L+SPL%S* 5Q%F*M''?6(UP%!R"NNEWK MVR=+ ])]8;'/@O0\1*GU1.*N*L%8QHU/+X-P2Y@T\>_5B2AB7%[@"G.JB/>R MY61$3XZS6#-_^];+SKSXNPL'2[5@6G+")<-24T!Y=5Z/:31O+EGVIPBL;!C1 MKM:+_QS,QFEE3$$3![:5IT5#NB<&/&/:4025PCPB7XW(87%A#R@TOZED GH. MBAS<3)X7#MQR(YD0A'K.HXGEB<75J* 6.>[?'BXEIPMU#SM.0K(K?D1K'.$_-75:@+;0_L3\\+!ZDQT=H@RP653"I&3+5]8Q;UNYER4EHGFSJ M_+V<_9'"?P=WX\5@LM_2>:EL4%8000Q,RUWL%C&*5*'O6"/1Z2%6%U[P/&&5 MS<+9F8I2+!8IK>QZ\(*!RM2XAXJM1':0J^L(J@:F8+NPA(Z-$*3!O'L M[#)=,1L7\W0>.QI_'8^6@\GDQYO;VTU4F%[.XQX[GZOA_RS'\_'JXM5!-IW: M9$!$,68P2%G%C:/0* M!Q]50$$-4,!)X:US&LJM)2KJ'6J_GMRES6O##8!Z+KH>^(P,=(A M>7^;$SN4]71&#W7AAH2=#V17J\'V_?@]:\#]&_,**BB(]4@1K1R0\<];A4D9 MFJ-6]/"2<_-JQ:E(=LJ&@WO"P_?%L4HOYSH8ERTB'".:8%6-(RYH%Q88?(+\ M7F+ 2=AUQ8'?QM/[E]_WL.!1N0 =UP!2"A7W(DX(0$BUNA&-_(7I!"=)L6P. MO\ZX,/A>CPL/RP7BO862:T(XDHKRE*.F&@L7]L)NDC7"A0S\NN+"WY:#V6"Z M*(JKSY/QS3H3D?[Q;K!*P;I?@3A4-2"(+KG M9-)&L=/E;%9^6Y^@QW]9_#B26+N:"9I;B;STRE+FH]6@@;#W9D/6P\P]7*L: M8D4-KC4$^,FNVO?%;)AD M"/%J-!<$$,B(.-F4 HP)#^@V%)9(+G..'UY)6&<+?&L>^)-I]NBCOY738C&8 M_=#%=/CE=C#[(_9JWWS91;:L1H,T2$B/"38J97VR6FSCHPFE6EQ^[$0FY;J$ MO\LHBZ0HY8DQ[I2Q1JY$HRX6G@N;D[W\EIV4-*&>G ]K( MUO<^O2T5H9^LQ%.,/I4/XLC>+V?#+Y'C[V?C8:V=KWYK 7OC71P395I)BS!" MVR-G(HW+V?B.=HEV$1'8\M;7&O+GN>V=IL2>9>AYX< 5=D0Y*KS6)FJ-@EFQ M];[XIV^]7Z)'(G\QRH;U/&2)V_!X_C&*:#"ZFCZ\;@9K4VAW$P% XAB"E!AK ML<31)#';TRHL2,Y=&G'Y"U7+<)^\!SZG^M7UPX[LVNT.U0L.1.-!I^1F4L>N M*YH>H:CK*]2+N&&/RY&;CO9IV/5;"=!$ M>X$#Q)S62#)F)-WB0"/<.=Y1\&?9]-H#_)S$^WVZG!>CRJUKRMO;\2+-)E\4 M]VKCD32LU6:P%#$A>9R7'G)%##+W&$$$L^+L_]0^^S;@/R=%/Q3I_#6Y43)/ MCW8W%+QQ $HL)5!6<&T!@VB[4U"6D]<%7KP_OQ/,LS0X,YA_\9/RV]LBJCJ1 M_1^2D/:I;B]6"%AK*B$3*J6B,%01R:O["50)EN/(@G\.+WQ3V&:QX6,Q^SH> M%J:L28:7R@>$O2!,&*&]@LIB!E!UZYL:FA?HV\O'^5IB0P/@GF-SJKGU!"N= M!4 X9"1#<23*-HK%#@L'(*<2L 5SBJC*163HA.SB(.Y+5^H72@D#D/L%-2:,HXE]H3 M# B'P@/'44Z^BQ[:P+D"WG\,<0*@KRF5!;3 $^>X)LQ2J9T&RG /L21*Z(C= MY5'E9-G626)Q')RO+8D%IR)N78IS8RQ5((Y'*& XCU:5D-)D6:K](TN>@.LE ML3@.T=>3Q(*A]!A('(#5C'JI)?46>AG!\UYB<6$I '.%6R.)Q7& =IO$@CKH MA2$:6J,ICO, >X,141@#%PVJ"TOHUI"P\X$\3[C#UEJJK9/>VU>:0F&UE@Q0 M19E'*3^82[XY(M++\#FIAWM(E":5C680/4".EYEI?U:?=X^'[P(_VU]B+SI%Z BD#-@(ES MC5&%A8">*:H1B^,FREP8??+$O7>MR0/V@ZBO"NGPZ.X MG=%ME+.Y7197TX=%+N6TCL7UW4*-15SD'>#>\Z@26&L]2FHGJ^4Y:'\^ZQ^_ MI=PNZ1F0XZS>YQ6#$%A" B5V"D-+&;?$52,V-.MJ=@\-F%RQ[YG?V=B>8V?8 M='ELU;<>;C MVJJT!1QR3#:(26SP!:8O;X(^>UC9@11ZR-LWTS2.3]]>"HS,:2Y$#4!'>U ) MJ!ERSCN&984,4?*"K?'S\/-4Y/O+R?CUO3=23FHP6* =8DY(RUS4(!V20%7H MQ'E\:>_F]867)V#?6V;ZZ>.]I9(="2B9_>+K4(M7K_/2SK% M-?)<>9J\V%12'V=HE(%%U&A3*Z=,.R/<>3G@4X19QV_^L6>TARN':-:F.+>4 M53N.FVJ!G:4&.&TH4,!DW9OMWS:0*_ZGF:&;QK>KM=Z4T]7(EX/)_3V:>^]' MM;15XUO-\CJ$RVHW<,MB=RF0@$&JB9#.:A82YV"7TW MV\[5[&8P'?]S+M]@\C'^I%BM"35VIT;:#\Q9X!AW'C)$F?'1%G<4,1)M<^:4J:79MX/?.AW_ MU?7573%;7]W; \;SPB'.!$RE! )1#4$VD!,F;*0XSAG1*<'-5TSK6"WB*L\$$M%F(8P"#E742B0&B%K(L*2U-MV:-Q[>+5/H_=7U MAW*Y*%)*W='[\?"/W^\V&03>3%?=^U#<[%@9CF\D$!Z'1XVA&,7]U#+E@59* M*PV@U=!=V&%:QXPH.Q)+-^M(RED_74Q^O)G/E\5HD\5Y/+V)'9^.!K/1^1:2 M=\6W^^Z\GY73^,?A1FC3D?F2WFV;OYD^++-R.D7+O,8RTD#K :<-AB+@G(Q; MB^&1.E1YC21FP'%7*Y=*6QZ"^7 VOENS?L]0WY6+?Q0+-2KO%L6^N.63V@L$ M>T(4IIR(J&1C*4S:1HG2FBOBS86]X=4IHYY%U+2U?V^':<6=U1'(5E66.*;4F;74($L$XC(JXO+!+W?D4>.IN:QSB M<\WDEW.;E>R MC$)9_^.A["\GM!8D@]9RZ0B+=K,A7MJHY#I"#"-2Q8WF3S+A:U-DIW^]+K7) MAJ?,:Q#WSCBV[N+!C#./R@4L(QY4$<( IU9YI86GCF(8MV:,U84]O-B07%]6 M3$Y"].3\(;]%#>+S8/C'?'\"D2?% O/1K#'4IIP(5 (G$?9.$(PQD/%'%W9; M^T3)E(T!>+)X'SO2EI4C[8"T]]<*2'GF$18< 4JC5JP%1<@B'5=$GIXHNZP3 MU@:$WRB>)W-AG1#^MV(T'FXR7NXEP8[B@:>'5;S L?E#0BD"?<:Q-4NFDD> M9B4/ZF&$= /2;P;(TS-$?1G/1N\'L\6/3[-BL'H"H-XJ<+!BB$ 8++5$-!*7 M1M.8!B4W0(6F(>U**523R=7B2S&K])R#*>9>KI!>XJ$* M\G1( RAR7($X 332 /B47"GGU;4>A@OG$:91*#NV'EZRJ=[6R$-6IWI@C#*+ M,5/ 1^TZ/>HDI';&"(FM@SS''=)']:-+>[5Y^#LCWF"20N97+M)WQ5X7Y..2 M@5(,@%*,86AHM-TD@,8K+CG7QE"3]8)#'\.!FA7R4P9E@=MAX&HZI5_'(WT8 MS_^X?Q!IWQN0^ZH%Q7$<:%3,ROA0#"-3QI/Q)AQIK2:- M;Z;CZVAJI;%L_CWR,Q'21QI76M2G\CZTJ1C5.9IMX6L!"2:RB<123R+9+9"F2948@J2S 1ZL*. MRIH0^;-=OB%L3S]%N__TU;4>3R9J.OH_Y62TZ=G.8[3]U0)!4<.@V%O %%72 M*&FE]YI*%!4?;W*RZ_>0&4V(L6P-W9.Y\>#+;Z;QRU%$+SU(O+-L8,YI !14 MZ4(5\5@JKR4@3D.K#;FT3%A-LZ !2'NPNU^<+N\$L$P3:PTEU#@15WV/*$'* M,BXU/&,JA.<$7'7^1ST7P(&Z(66ZYLIAY+2B2!#I(,'IQA-3S+I+6]*;(,#! MS3X/XJYR MTK)Z)OUF= MX(V_%N\G@^EF2/O\H\>W%J!74;N'BF,=9Y9$"A FE95,IS?;9*?O*;Q*SK4/ M>E=D](/Q[#\'DV7Q("7!@SQ:!^E7JWZ@ $-CF9<@3L1T"HT@Q=%>11AIH[/N MR1R?IO U$JX-F+NBV)Y+X.M^U]]'CVTJ8*2P-2#N RGW&Z>*QUD(K 76.XQ! M3KP]_U,0KV7$.W(@+6+/GBW79_,8W5^;OKI^V*$/Q20=J)MROIBO=IC/JWL/ MFU2V=9)K9C4<9(H>()RF).(T:MC2&"5Y.CSD*G+DC'G+:@],/QQ8G14EL^4@ ML 3$$P,-B3,+.\U4-%@\IPQB#V"G82A=G#MW1;&G644Z%=,Y5Z5SGU;W=7&B M1*6;H%K"J# [SZ6B*;USE*6-EER]F_PMV7/;,'-W>S_]=C.2 _D6]M0* $B%);5:1/.&"J$XT\P+BU4TI[') MN3/70XJ>F2LOG@LT(9[6R_SQ=7UZH;.P?N;S\H&QK5AUM$XMKA; "*\\2!=8300 M"*USKGV_'LX<*]]G%UOR4.WN%N=KX;ZG M!;L&BXYJ)S"@+2.66.5]U$2@!"@B@1"R4F#NWCLW0[#VD2\*_8UHRF\ MK7'=N.$O!< 5)00;IP2F/NK7&$,,-602DBC.G".I'C*X7[K=>65YWF/7HT]6 M@R/6&:) 1!M0B(544?6!QA!,I8.NTWQ=77C\SL:.6F>N1XKCG)Z]42^&-?S-$+4?AXA$EHIHKW&IHII, M-"%.<4Z0S0DTZJ$5TA4IVW;PG2B^&NO&UL4$L! A0#% @ 75VC3"^@VX:%&P +#4! !4 ( ! M3-, '-M960M,C Q.# S,S%?9&5F+GAM;%!+ 0(4 Q0 ( %U=HTQ$+H0B M!GD %J !0 5 " 03O !S;65D+3(P,3@P,S,Q7VQA8BYX M;6Q02P$"% ,4 " !=7:-,K=,.$Z\_ "N^0( %0 @ $] M: $ &UL4$L%!@ & 8 B@$ !^H 0 ! $! end